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ABSTRACT 
Background 
The flaws of current methods of assessing disease severity in patients with COPD and emphysema are 
increasingly recognised, and new methods of assessing disease activity are urgently required. 
Although many potential biomarkers have been suggested to fulfil this role, few have been effectively 
validated, and furthermore any biomarker should be based on our current understanding of the 
pathophysiology the disease process. This is poorly understood, however it is apparent that neutrophil 
proteases (particularly neutrophil elastase (NE) and proteinase 3 (Pr3)) may represent a final common 
pathway leading to tissue destruction. The current thesis describes the development and validation of 
a new marker of NE activity (Aα-Val360), and the identification of a marker of Pr3 activity, as 
potential biomarkers of COPD and emphysema disease activity. 
Methods 
Following in vitro validation, the performance of Aα-Val360 was assessed in a series of patient 
populations. Mass spectrometry was used to identify a specific marker of Pr3 activity. 
Results and Conclusion 
Aα-Val360 demonstrated acceptable in vitro and in vivo variability; related to physiological, 
radiological and patient reported outcomes in subjects with (or at risk of developing) COPD and 
emphysema (both with and without A1AT deficiency); increased during acute exacerbations; 
decreased in response to treatment; and partly related to disease progression in some populations. 
Also, a Pr3 specific cleavage product was identified which could be used to develop a new specific 
assay of Pr3 activity. These potential biomarkers of disease activity may be important in the 
assessment of patients with COPD and emphysema (or who are at risk of developing these 
conditions), particularly in early phase clinical trials.  
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CHAPTER 1.  INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is a group of conditions that includes chronic 
bronchitis, airflow obstruction and emphysema and, despite the heterogeneity of this syndrome, 
guidelines suggest a diagnosis is only made in the presence of airflow obstruction [1, 2]. The 
airflow obstruction in patients with COPD is largely irreversible and defined by spirometric 
criteria, generally with a ratio of the Forced Expiratory Volume in 1 second (FEV1) and Forced 
Vital Capacity (FVC) of  less than 0.7 [2].  
 
The risk factors for the development of COPD are well known and include exposure to tobacco 
smoke (the most common risk factor in Western countries) and smoke from the combustion of 
biomass fuels within houses for heating or cooking (the most common risk factor worldwide) [3]. 
At present, alpha-1-antitrypsin (A1AT) deficiency is the only widely recognised genetic risk 
factor (see 1.2.4), however genetic factors are likely to be important since there is a greater 
prevalence of airflow obstruction amongst first degree relatives of patients with COPD [4], and 
they may partly account for the dramatic variation in clinical phenotype which is observed in 
patients with similar risk factors. Historically, it was thought there was a genetically ‘susceptible 
minority’ of tobacco smokers who develop COPD, based on the initial description of 13% of 
smokers who developed ‘airflow obstruction’ (with an FEV1 below 2.5 litres) [5]. However, more 
recent studies demonstrate that this is a significant underestimate and the true figure is closer to 
50% [6], when COPD is defined using the Global Initiative for chronic Obstructive Lung Disease 
(GOLD) criteria [1]. These data are consistent with the prediction that COPD will become the 3
rd
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leading cause of death worldwide by 2030 [3], however it is also clear that the use of different 
diagnostic criteria to define COPD will predictably lead to variation in both its prevalence and 
incidence. 
  
1.1 DIAGNOSTIC CRITERIA FOR COPD 
 
Chronic bronchitis and emphysema were first described in the 19
th
 century and a formal symptom 
based definition agreed by the American Thoracic Society (ATS) in 1962 [7]. However more 
recently, COPD has become the ‘preferred term’ for patients with airflow obstruction who were 
previously diagnosed with chronic bronchitis or emphysema [2]. Current guidelines from the UK 
National Institute for Clinical Excellence (NICE) [2], European Respiratory Society (ERS)/ATS 
[8] and GOLD [1] recommend that COPD is only diagnosed in the presence of symptoms with a 
post-bronchodilator FEV1/FVC<0.7. The key defining symptoms of COPD include 
breathlessness, a persistent cough, sputum production and wheeze, however patients may also 
experience ankle swelling, fatigue, and chest pain [2].  
 
Emphysema is defined by pathological criteria, although it is increasingly recognised that the 
optimum method for the in vivo diagnosis of emphysema is computed tomography (CT) (see 
1.3.3) [9]. However, CT methodology has yet to be standardised with a normal range of lung 
density defined, and therefore the diagnosis or quantification of emphysema is not encompassed 
in current diagnostic criteria for COPD. Both GOLD and NICE only recommend performing CT 
scans or measuring gas transfer when surgical intervention is indicated or in patients with 
13 
 
symptoms disproportionate to the degree of airflow obstruction [1, 2]. However, emphysema may 
occur in the absence of airflow obstruction and the FEV1 relates poorly to the severity of 
emphysema quantified by CT densitometry [10], and therefore it should be recognised that 
diagnostic criteria based on spirometry alone will exclude a number of patients with clinically 
important disease. The implications of this are discussed later in the current thesis. 
 
1.1.1 Using The ‘Fixed-Threshold’ to Define Airflow Obstruction 
 
The FEV1/FVC threshold of 0.7, to be used regardless of age, was recommended in the GOLD 
document for ‘simplicity’ [11], however, this has been increasingly questioned as it lacks 
supportive clinical evidence, statistical validity, and misclassifies some subjects at the extremes 
of age [12-14]. Lung function was originally accepted as impaired when below the ‘lower limit of 
normal’ (LLN), which is usually defined as the lower 5th percentile of a reference population 
(stratified by age and gender [15, 16]), a definition which is therefore used in the current thesis. 
More recently an ERS/ATS guideline has supported the use of these limits [17], endorsed in an 
editorial [18]. Reference ranges are widely used for the interpretation of clinical laboratory tests, 
and cross-sectional studies demonstrate that using the LLN to diagnose COPD is associated with 
less age and gender-related bias [19]. However, the lack of well validated post-bronchodilator 
reference ranges (particularly for certain ethnic groups) currently limits the widespread adoption 
of LLN [1], and therefore the threshold to define airflow obstruction has yet to be established. In 
light of this controversy, the fixed threshold is used in the current thesis, however the influence of 
the LLN is also considered in some of the studies.  
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1.1.2 GOLD Stage 0 
 
There is disagreement over the importance of chronic cough and sputum production in the 
presence of ‘normal’ spirometry, particularly since some of these subjects will have visible 
emphysema on high resolution CT (HRCT) scans of the thorax [10]. Patients with symptoms 
suggestive of COPD but with an FEV1/FVC above 0.7 were initially classified as ‘at risk’ 
(GOLD stage 0) [20] and then excluded by subsequent documents [1]. Nevertheless, some 
patients classified into GOLD stage 0 demonstrate progression with time [21] and have an 
increased mortality [22] suggesting that this is not a benign state, although this has not been a 
universal finding [23, 24]. However, no similar longitudinal studies have included symptomatic 
patients with spirometry above the LLN. Further work is therefore required in this group of 
patients who may have an early disease process which may be more sensitive to therapeutic 
intervention [25] and this is discussed in more detail in section 6.2.5. 
 
1.2 THE PATHOPHYSIOLOGY OF COPD AND EMPHYSEMA 
 
COPD is a heterogeneous disease with individuals demonstrating a range of pathology within the 
large airways, small airways and parenchyma, and it is therefore unsurprising that its 
pathophysiology is complex and remains relatively poorly understood. Nevertheless, it is known 
that there are several key mechanisms related to inflammation that have been implicated in the 
development of COPD including oxidative stress, alveolar cell apoptosis, accelerated ageing and 
antiprotease-protease imbalance [26]. 
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1.2.1 Oxidative Stress 
 
A number of studies have demonstrated evidence of greater oxidative stress in patients with 
COPD compared to healthy controls [27-29], indicating an association with the pathogenesis of 
COPD. Oxidative stress may lead directly to lung damage, and interfere with elastin synthesis 
and repair [26] but its detrimental effects are also potentially mediated via inactivation of anti-
proteases (A1AT and secretory leucoprotease inhibitor) [30] or activation of metalloproteases 
[31], which is considered in more detail below (see 1.2.4). Also, patients with COPD have 
reduced levels of nuclear erythroid-related factor (Nrf2) which influences the expression of a 
number of genes, including those encoding several important antioxidants [32]. Nrf2 deficient 
mice have high levels of neutrophilic inflammation and are also very susceptible to the 
development of emphysema following exposure to cigarette smoke [33] or neutrophil elastase 
(NE) [34] demonstrating the pathophysiological plausibility of both oxidative stress and protease 
imbalance in COPD. 
 
1.2.2 Alveolar Cell Apoptosis 
 
Apoptosis, particularly of the endothelial cells of the alveolar walls, is enhanced in patients with 
emphysema and may be mediated directly by proteases, including Proteinase 3 (Pr3) released by 
neutrophils [35].  Apoptosis is also associated with decreased expression of vascular endothelial 
growth factor (VEGF), a protein important in cell maintenance [36], and animal models 
demonstrate inactivation of VEGF leads to the early development of emphysema [37]. However, 
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despite VEGF inactivation, smoking induced emphysema does not occur either in the presence of 
antioxidant or in cathepsin-S knockout mice suggesting a complex interaction between oxidative 
damage, apoptosis and protease-antiprotease imbalance [38].  
 
1.2.3 The Ageing Lung 
 
Even in the absence of pathological disease states, ageing is associated with a decline in lung 
function, increased pulmonary inflammation and emphysematous changes leading to the 
hypothesis that COPD and emphysema may represent an abnormal or premature ageing process 
[39]. However, the process of ageing is complex and involves a number of mechanisms which are 
poorly understood. Nevertheless, it is known that deoxyribonucleic acid (DNA) damage and 
somatic mutation increase with age, and also a relationship exists between longevity and DNA 
repair, suggesting this repair capacity is an important factor in ageing [40]. Also, somatic cells 
enter senescence after a limited number of cellular divisions due to the gradual attrition of the 
telomeres which protect the ends of chromosomes [41] and this may be important in subjects with 
COPD since telomere shortening is enhanced by oxidative stress [42]. Also, telomere length 
relates to pack years of tobacco smoking [43] and is reduced in subjects with COPD compared to 
controls [44]. Additionally, tobacco smoke, COPD and ageing (Figure 1) are associated with 
persistent increases in the levels of the plasma cytokines interleukin 6 (IL-6) and IL-8 which may 
themselves trigger inflammation, protease-antiprotease imbalance and cellular senescence [26]. 
Other important mechanisms in the process of ageing, which are also highly relevant to the 
17 
 
pathogenesis of COPD, include altered protein turnover and the accumulation of mitochondrial 
DNA mutations, with a corresponding increase in the production of reactive oxygen species [45].  
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Figure 1: The complex inter-relationship of the ageing lung, antiprotease-protease imbalance, tobacco 
smoke and COPD which occurs over time [26]. 
 
1.2.4 Antiprotease-protease Imbalance 
 
Some work pertaining to the following sections has previously been published in Carter, R.I., 
Stockley, R.A. A1AT Pathophysiology in the Lung; in Alpha-1-antitrypsin deficiency. 
Pathophysiology, Diagnosis and Treatment. (eds. Bals, R. & Kohnlein, T.)  18 – 24 (Thieme, 
Stuttgart, 2009). 
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1.2.4.1 Alpha-1-Antitrypsin (A1AT) 
 
A1AT is the dominant human antiprotease which is synthesised by hepatocytes [46] and in 
smaller quantities by alveolar macrophages, circulating monocytes [47] and lung epithelial cells 
[48]. There are around 125 documented variants of the A1AT protein, and several are associated 
with deficient plasma levels. The most common variant associated with a severe A1AT 
deficiency occurs because of a point mutation around the mobile domain in the Z protein causing 
the formation of polymers which accumulate within the liver, rather than being secreted [49], and 
which are also less effective at inhibiting NE [50].  
 
A1AT is the main inhibitor of free or neutrophil membrane bound NE, with which it binds 
irreversibly on an equimolar basis. Although NE bound to the neutrophil membrane was initially 
reported to be relatively resistant to inhibition, this was probably technique associated rather than 
a true finding [51]. A1AT is generally present in excess (even in ‘deficient’ states), however the 
elegant mathematical and in vitro modelling of Campbell et al [52-54] demonstrated quantum 
proteolytic damage occurs at the point of neutrophil degranulation even in a healthy individual, 
due to the relative excess of NE. Nevertheless, in healthy subjects, the destructive potential of NE 
is usually limited since molar equality between enzyme and inhibitor rapidly occurs as the 
enzyme diffuses from its point of release. However, in subjects with an A1AT concentration less 
than 11 μmol (such as the homozygous Z phenotype), there is an exponential increase in the time 
and distance of diffusion until molar equality is reached with a corresponding increase in the 
potential area of proteolytic damage (Figure 2).   
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1      3                                     5
2          4
AZUROPHIL
GRANULE
Position Elastase 
Concentration 
1 5 millimolar
2 30 µmolar
3 10 µmolar
4 5 µmolar
5 2 µmolar
Neutrophil
 
Figure 2: The relationship between the distance from the azurophil granule, the A1AT concentration and 
NE concentration based on the mathematical and in vitro modelling of Campbell et al [52-54]. The mean 
concentration of A1AT in the PiZ deficient patient is around 5 μM compared to a mean concentration of 
30 μM in a healthy PiM individual. There is therefore an exponential increase in the distance until molar 
equality with NE is achieved in the PiZ subject, and hence the volume of potential proteolytic damage, 
compared to the PiM subject. 
 
 
The concept of quantum proteolysis, demonstrated by mathematical and in vitro modelling [52-
54], is also supported by the clinical observation that subjects with PiSZ A1AT deficiency (with a 
mean A1AT concentration of 11 μmol) are not particularly susceptible to emphysema [55], 
although this remains controversial [56]. Also, there is currently no direct evidence of this excess 
local NE activity in PiZ patients owing to the eventual inhibition of this enzyme by the remaining 
A1AT, even in the deficiency state, within the neutrophil micro-environment. 
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1.2.4.2 The Neutrophil 
 
 
Activated neutrophils with an enhanced chemotactic response are found in the circulation of 
individuals with COPD [57] and these cells also demonstrate abnormal destructive potential [58] 
and increased adhesion and spontaneous migration under flow [59]. Neutrophils migrate into the 
bronchial submucosa under the influence of a variety of chemokines and chemoattractants 
including tumour necrosis factor alpha (TNF-α), IL-8, leukotriene B4 (LTB4), NF-κβ and matrix 
metalloproteinase 12 (MMP-12) [60, 61] via post-capillary venules of the bronchial circulation 
[59], while (uniquely) neutrophils enter the lung parenchyma via the pulmonary circulation at the 
capillary level [62]. Integrins are crucial for neutrophil passage through the endothelium [63], 
however, NE is localised to the leading edge of migrating neutrophils [64] and inhibition of NE 
prevents migration [65] suggesting the importance of this enzyme for transmigration, particularly 
through the perivascular basement membrane.  
 
Upon activation, neutrophils generate reactive oxygen species and degranulate releasing 
proteases, particularly NE and Pr3, which are capable of damaging or degrading a wide range of 
proteins including elastin, collagen, fibronectin and Tissue Inhibitor of Metalloproteinases 
(TIMP). Neutrophil degranulation may therefore lead to damage to the airway epithelium and 
cilia [66] and increased mucosal permeability [67].  
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1.2.4.3 NE and the implications of antiprotease-protease imbalance 
 
It is increasingly accepted that inflammation is central to the development of COPD and an 
antiprotease-protease imbalance may represent a final common pathophysiological pathway, 
although there may be a number of underlying mechanisms. Our understanding of this process 
has been greatly enhanced by the observation in the 1960s that severe early onset emphysema 
was associated with A1AT deficiency [68], with subsequent animal models demonstrating human 
NE could induce emphysematous changes [69]. Other serine proteinases, known to be co-
localised within the azurophil granule, are also important since cathepsin G may produce mucous 
gland hyperplasia [69] while Pr3 is also capable of inducing  emphysematous changes [70] 
(which is discussed further in section 1.2.4.4). Since A1AT is the main inhibitor of all these 
enzymes it was hypothesised that emphysema and COPD developed from a relative excess of 
enzyme versus inhibitor at the site of disease. However, in the absence of an acute exacerbation 
[71], enzyme activity has not been demonstrated in the airways of patients with COPD and even 
in A1AT deficiency, only low levels of enzyme activity are found in sputum in the stable clinical 
state [71] and therefore conclusive support of this mechanism is currently lacking.  
 
Studies have subsequently shown that enzymes belonging to 2 other groups (the cysteine 
proteases [72] and the MMPs [73]) are also capable of elastin degradation, while MMP-12 
knockout mice are protected against emphysema [74] which raised the possibility that MMP-12 
could also cause emphysema directly. However, it is far more complex than this and Churg and 
colleagues have demonstrated that MMP-12 is required for TNF-α receptor processing, and in 
TNF-α and TNF-α receptor knockout mice, emphysema also does not occur on exposure to 
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cigarette smoke [75]. Furthermore, A1AT treatment prevents TNF-α release in smoking animals 
[76] and thus also prevents the development of emphysema [55]. In addition, NE can activate 
cathepsin B [77] (a cysteine protease which can also produce emphysema [72]) and MMPs [78], 
and is capable of inhibiting TIMP, the main inhibitor of MMPs [79]. Also, in A1AT deficient 
subjects, A1AT augmentation therapy decreases cathepsin B and MMP-2 activity, even though 
these enzymes are not inhibited by A1AT [80]. Furthermore ageing, cell senescence, tobacco 
smoke and COPD are also linked via a complex interaction with antiprotease-protease imbalance 
(Figure 1) [26]; in the absence of proteases, alveolar cell apoptosis does not lead to emphysema 
[38]; and oxidative stress may particularly lead to local inactivation of A1AT [30] or activation of 
MMPs [31]. These data support the theory of the central role of proteases, particularly NE, in the 
pathogenesis of COPD (Figure 3), indicating that a marker of NE activity may be an effective 
marker of COPD disease activity (see 1.5.2) 
MMP Cathepsin B
Cystatin CTIMP
Tissue 
Damage
SLPIα-1
antitrypsin
ActivationActivation
Inactivation Inactivation
Inactivation
Inactivation
InactivationInactivation
NEUTROPHIL 
ELASTASE
 
Figure 3: The complex relationships between cysteine, serine and metalloproteases. SLPI is secretory 
Leucocyte peptidase inhibitor.   
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1.2.4.4 Pr3 and the implications of antiprotease-protease imbalance 
 
Although NE is central to the pathogenesis of COPD and emphysema, Pr3 may be of equal or 
even greater importance since it is co-localised with NE within the azurophil granule of the 
neutrophil, and it is also capable of cleaving the matrix proteins elastin, fibronectin and type IV 
collagen [70, 81] and instillation into the lungs of hamsters induces an emphysematous like 
process [70]. Pr3 is potentially of greater importance than NE in the pathogenesis of COPD, since 
the concentration of Pr3 within each neutrophil is about 3 times higher than the concentration of 
NE [82] and thus upon activation greater quantities of Pr3 are released [83]. Furthermore, 
although Pr3 is inhibited by both the local lung inhibitor elafin [84] and A1AT (though not 
oxidised A1AT) [85], there is disagreement over the efficacy of A1AT inhibition when Pr3 is 
bound to elastin [85, 86] and, in contrast to NE, Pr3 is not inhibited by the major local serine 
proteinase inhibitor (SLPI) [81] which is found primarily within airway secretions. Also, the 
association rate constants for A1AT and elafin (the mutual inhibitors of these enzymes) are 
greater for NE than for Pr3 and the inhibitors will therefore preferentially bind NE. This is 
primarily of importance at the point of degranulation when the enzymes are present in a relative 
excess over their inhibitors, and Pr3 may therefore contribute disproportionately to the area of 
quantum proteolysis observed around neutrophils even in healthy individuals, which would still 
be exponentially greater in those with A1AT deficiency [54]. 
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Pr3 is one of the less well studied of the serine proteases because of difficulties in isolating the 
protein and the absence of specific substrates and inhibitors [82]. Also, N-terminal sequencing of 
Pr3 was initially difficult [87] leading to the early description of 4 independent proteins, all 
located within the azurophil granule but associated with separate pathological and physiological 
processes [85] namely:  
 Pr3 
 p29b (with microbiocidal properties) 
 myeloblastin (a regulator of growth and differentiation in leukaemic cells) 
 the target antigen for cytoplasmic anti-neutrophil cytoplasmic antibody (cANCA) in 
people with granulomatosis with polyangitis (formerly Wegener’s Granulomatosis)).  
However rather than 4 separate entities, DNA sequencing confirmed a single hybridising gene 
and therefore a single protein with a high sequence homology to the other serine proteases [87]. 
Initial research focussed on the role of Pr3 as the target for auto-antibodies in the pathogenesis of 
granulomatosis with polyangitis, however since it is likely to be central to the pathophysiology of 
COPD and emphysema, the current thesis also describes the identification of Pr3 cleavage 
products which could be used to generate a specific assay of pre-inhibition Pr3 activity (2.11 and 
Chapter 8). 
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1.3 MARKERS OF DISEASE ACTIVITY, SEVERITY AND 
PROGRESSION IN COPD AND EMPHYSEMA 
 
The pathophysiology of COPD and emphysema is complex however, it is important that 
biomarkers of progression and response to treatment measure processes which are central to this 
disease. At present, in the absence of an effective marker of disease activity, markers of end-
organ damage (disease severity) are widely used although it is increasingly recognised that they 
are insensitive to change and cannot predict future progression, since an initial assumption that 
those with the most severe disease progress at the greatest rate is flawed [88]. There is therefore 
renewed interest in identifying biomarkers of disease activity [89] which may allow the 
identification of patients who are at risk of disease progression, before the development of 
irreversible lung disease, and which could also be used as early measures of treatment efficacy, 
particularly in stage II and III clinical trials. This section reviews the important measures of 
disease severity and also explores other potential biomarkers of disease severity and activity in 
COPD. 
 
1.3.1 Spirometry 
 
The FEV1 is a widely used measure of outcome in clinical trials and disease severity in routine 
clinical practice, and relates to all cause, respiratory and cardiovascular mortality [90]. The 
relationship to all cause mortality is interesting and is probably explained by either a common 
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inflammatory phenotype linking a number of distinct disease processes, or indicates the role of 
FEV1 as a surrogate for overall health status.  
 
GOLD Grade Severity of Airflow Obstruction FEV1 (% predicted) 
1 Mild ≥ 80 
2 Moderate 50 to 80 
3 Severe 30 to 50 
4 Very Severe <30 
Table 1: The GOLD spirometric severity classification of COPD (in subjects with an FEV1/FVC<0.7) [1]. 
The 2010 NICE classification is similar, although patients with an FEV1<50% and respiratory failure are 
also considered to have very severe disease [2]. 
 
Clinical guidelines suggest the use of spirometry to classify disease severity in patients with 
COPD (Table 1), although it is increasingly recognised that a multidimensional approach or test  
is required to assess patients accurately [1]. Additionally, although short term improvements in 
FEV1 may relate to improvements in patient symptomatology, this physiological measure also has 
important flaws. Firstly although there is a highly significant relationship between health care 
status and FEV1, this relationship is relatively weak (Figure 4) [91], and a similarly weak 
relationship between spirometry and exercise capacity has also been reported [92]. Secondly 
there is significant day-to-day variability of FEV1 which may be greater than the progression 
observed in patients with COPD over many years [93], and therefore prolonged follow-up is 
required to determine whether deterioration has truly occurred. For these reasons, FEV1 is a poor 
surrogate marker for early phase studies of potential disease modifying agents. Thirdly, around 
half of patients with COPD have significant increases in FEV1 following the administration of a 
bronchodilator [94], although there is considerable intra-individual variability of this measure 
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with repeated testing, and furthermore the degree of reversibility does not relate to response to 
current treatments [95]. Nevertheless, bronchodilator reversibility may relate to disease 
progression [96-99], although this has not been demonstrated in all studies [95, 100].  Fourthly, 
pharmacological interventions may significantly increase FEV1 yet fail to influence mortality 
[101]. Finally and importantly, it is recognised that COPD is a group of distinct pathological 
processes and the FEV1 relates poorly to the presence of emphysema and its severity as 
quantified by CT densitometry [10] indicating that assessment using FEV1 alone will not provide 
sufficient information about overall disease severity. 
 
 
 
Figure 4: The relationship between FEV1 (% predicted) and the baseline St George’s Respiratory 
Questionnaire (SGRQ) (section 1.3.4.2) is highly significant, however there is a wide spread of values 
within this population. Reprinted with permission from British Medical Journal publishing group limited 
[91].  
Post-bronchodilator FEV1 (% predicted) 
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1.3.2 Gas Transfer 
 
The measurement of the transfer factor of the lung for carbon monoxide (TLCO) or the carbon 
monoxide transfer co-efficient (KCO) are well established measures of alveolar function [102], 
and cross-sectional studies demonstrate that abnormalities of KCO relate better to upper zone 
emphysema while FEV1 relates better to lower zone predominant emphysema [103]. Also, KCO 
relates to pathological measures of emphysema severity [104] and even isolated KCO 
abnormalities are associated with a worse SGRQ (see 2.1.5.1) [103]. Few longitudinal studies 
have validated KCO, although one small study conducted in subjects with spirometry 
predominantly in the normal range, demonstrated there was no significant progression of KCO 
over a 22 year period and no difference in the rate of progression of KCO in smokers versus ex-
smokers, indicating the stability of this marker in ‘healthy’ controls. In contrast, studies in 
subjects with COPD [21] and with PiZ A1AT deficiency [9] demonstrated a decline in KCO, 
although this did not achieve conventional statistical significance in the PiZ population in whom 
CT densitometry was a more sensitive measure of progression [9]. Gas transfer alone is also 
therefore not an effective measure of overall COPD/emphysema disease severity and progression.  
 
1.3.3 HRCT Scans of the Thorax 
 
The use of HRCT now enables in vivo assessment of the amount and distribution of emphysema 
and may detect disease prior to physiological abnormalities [10], which previously could only be 
achieved by pathological analysis of lung resection or post-mortem specimens [104]. Quantitative 
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measures of lung density on HRCT (Figure 5) have advantages over visual severity scales since 
they are objective and relate well to exercise tolerance and health status [105], and are more 
sensitive measures of emphysema progression and better predictors of mortality than FEV1 [106]. 
Also, low dose, multi-slice CT protocols enable multiple scan repetition with radiation exposures 
below the annual background radiation dose [107]. CT densitometry has therefore been approved 
by the United States Federal Drug Administration for use as a clinically meaningful endpoint in 
pharmaceutical trials [108].  
 
 
 
Figure 5: CT densitometry, demonstrating areas of low attenuation which are highlighted by automated 
software.  
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The voxel index and the 15
th
 percentile point are the two most widely used and validated 
densitometric scores, and may be calculated using semi-automated or automated computer 
protocols (Figure 5). The voxel index refers to the percentage of the lung which is below a set 
density threshold (in Hounsfield Units) while the 15
th
 percentile point is a density threshold in 
Hounsfield Units which encompasses the least dense 15% of the lung (similarly the 5
th
 percentile 
point refers to a 5% density threshold). Although the voxel index correlates well with the severity 
of emphysema in pathological specimens [109], it is threshold dependent and progression varies 
with disease severity [110]. Conversely, while the 15
th
 percentile point is threshold independent 
[110], studies are yet to correlate this densitometric measure with pathological specimens, and to 
date this analysis has been restricted to the 5
th
 percentile point. Furthermore, while the voxel 
index may correlate well with pathological severity of emphysema [109], a normal range for lung 
densitometry has yet to be defined and therefore densitometry cannot yet be reliably used to 
discriminate between normal and emphysematous lung. 
 
Scan reproducibility is also difficult to assure, particularly in longitudinal studies, due to a 
number of factors including ageing or replacement of x-ray tubes [110]. Although these can 
partly be controlled for, the level of inspiration of the study subject also influences the results 
[111] and further mathematical adjustment is required to account for this. Finally, particularly in 
multi-centre studies, differences in scanners and acquisition protocols influence densitometric 
readings and therefore it is recommended that serial examinations of a single study subject be 
performed on the same scanner [107]. Although the use of techniques that enable adjustment for 
variation in the level of inspiration and calibration protocols (using materials of a known density 
such as water, air or lung “phantoms”) reduce longitudinal variation, uncertainty remains over the 
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most appropriate methodology [111]. Consequently, further research is required before CT 
densitometry is considered a universally accepted method of severity assessment and for long 
term monitoring of patients in trials or routine clinical practice. Nevertheless, and despite its 
current flaws, it remains the best current measure of emphysema in vivo and therefore new 
biomarkers for COPD should relate (at least in part) to CT densitometry. 
 
1.3.4 Patient Reported Outcomes 
1.3.4.1 Medical Research Council Breathlessness Scale 
 
Dyspnoea, related to exertion or exacerbations, is both common and distressing in patients with 
COPD and can impact on social and recreational activities and, in those with more severe 
symptoms, can limit the performance of activities of daily living [112]. Although the principle 
physiological process leading to the perception of dyspnoea is likely to relate to changes in lung 
mechanics, volumes and activation of respiratory muscles, there are also important psychological 
and social influences on this complex symptom [112]. The degree of dyspnoea can be assessed 
using the Medical Research Council (MRC) dyspnoea scale (Table 2) which was first described 
in 1960 [113] and is widely used because it relates to important clinical outcomes, including 5 
year mortality [114]. A modified version of the scale also exists (mMRC) which includes 
comparable descriptors, but has a scale which ranges from 0 to 4 rather than one to 5 [1]. There is 
a partial correlation between the MRC scale and more objective shuttle walk testing [115], 
however there is a poor relationship between MRC and FEV1 which indicates the inadequacy of 
FEV1 as a measure of symptomatology in patients with COPD. However, while the MRC scale is 
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helpful in assessing dyspnoea, it remains subjective and this is particularly important in 
longitudinal studies where half of patients reporting an improvement, have actually deteriorated 
using objective assessment [116]. The MRC and mMRC can therefore only form part of a global 
assessment of patients with COPD.  
 
Grade Degree of Breathlessness 
1 Not troubled by breathlessness except on strenuous exercise 
2 Short of breath when hurrying or walking up a slight hill 
3 
Walks slower than contemporaries on level ground because of breathlessness, or has to stop for breath when 
walking at own pace 
 
4 
Stops for breath after walking about 100 metres or after a few minutes on level ground 
 
5 
Too breathless to leave the house, or breathless when dressing or undressing 
 
Table 2: The MRC dyspnoea scale has been widely used since 1960 to assess patients with COPD [2]. 
 
1.3.4.2 SGRQ  
 
The SGRQ is a subjective quality of life score which measures the influence of health on an 
individual’s overall satisfaction with life. The score is therefore a measure of both disease 
severity and impact on everyday social, occupational and domestic activities.  
 
The SGRQ questionnaire comprises 50 items and is divided into 2 parts; part one encompasses 
the symptoms score, and part 2 the activity and impacts (psychosocial) scores. A total weighted 
score is also calculated and each score ranges from 0 (no impairment) to 100 (maximum 
impairment). Although patients with a lower FEV1 have a worse SGRQ, the overall relationship 
33 
 
between FEV1 and SGRQ is not strong (Figure 4) [91]. SGRQ scores are also worse in subjects 
with COPD who experience greater numbers of exacerbations [117], which is consistent with the 
greater rate of disease progression in those patients [118], and relates to other measures of disease 
severity including the 6 minute walk test, and the short form 36 [119].  
 
The SGRQ is frequently used as an outcome measure in clinical trials and the TORCH study, for 
example, demonstrated a mean reduction of 3.0 units in subjects receiving combination therapy 
over the 3 year study [120]. Although this may not be clinically significant for the group, since 
the suggested minimum clinically important difference (MCID) is 4.0 units [91], it still suggests 
many individual patients had a significant improvement. Furthermore, determining the MCID is 
complex since there is no gold standard measure of health status, and also there is controversy 
over the meaning of clinical significance. Most studies consider the MCID should relate to a 
threshold that is ‘just-noticeable’ to a patient, or is considered to be important to a clinician 
(although there is clear disparity between what is considered important by a patient or by a 
clinician) [121]. Alternatively, the MCID may be determined by exploring the relationship 
between the score and a major health event (e.g. admission to hospital, or death) [122], although 
this may set too great a threshold.  
 
The SGRQ is however well validated and its clinical significance is reasonably accepted, 
although its sensitivity for detecting improvement (treatment effect) or deterioration (disease 
progression) in a longitudinal trial is more questionable. However, while the SGRQ is self-
administered, its analysis is labour intensive and it is therefore not suitable for routine clinical 
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practice. Consequently the COPD Assessment Test (CAT) has been developed with the 
expectation that it will be applied in more routine practice.  
 
1.3.4.3 The COPD Assessment Tool (CAT) 
 
The CAT (see 2.1.5.2) is a validated measure of quality of life in patients with COPD which has 
been shown to be higher (i.e. a more symptomatic patient) in a population of subjects 
experiencing an acute exacerbation of COPD compared to a population in the stable state [123]. 
Additionally, the CAT correlates with SGRQ, MRC score, age and FEV1 when performed in the 
stable state [119]. The tool consists of 8 questions, rated on a severity scale from 1 to 5, giving a 
maximum severity (worse symptoms) of 40. A statistically significant decrease in the CAT score 
(from baseline) is described in subjects following pulmonary rehabilitation, and the improvement 
was greatest (-3.8 points) in subjects who felt ‘much better’ compared to those who only felt a 
‘little better’ (-1.3 points) or no different (-2.3 points) [119]. If it is assumed that the MCID for 
the CAT score can be interpolated from the SGRQ, then the MCID for CAT is 1.6 
(corresponding to 4 units on the SGRQ) [123] which is therefore of a similar magnitude to the 
change in the group who felt a little better following pulmonary rehabilitation [119]. Although 
‘feeling a little better’ could be considered a ‘just-noticeable’ difference [121], it should be noted 
that in the study of Dodd et al [119], 96% of subjects felt a little or much better, while only 4% 
felt the same or worse which would question the validity of this conclusion. Further work is 
therefore required to demonstrate whether or not CAT is an effective and sensitive measure in 
longitudinal studies. 
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1.3.5 Measures of Exercise Capacity 
1.3.5.1 6 Minute Walk Test (6MWT) 
 
The 6MWT measures the distance that a patient can walk in a period of 6 minutes (i.e. the 6 
minute walk distance (6MWD)), and guidelines (United States) recommend the use of standard 
instructions to improve repeatability [124], although this may require some modification to 
account for different populations: 
 
‘The object of this test is to walk as far as possible for 6 minutes. You will walk back and forth in this 
hallway. Six minutes is a long time to walk, so you will be exerting yourself. You will probably get out 
of breath or become exhausted. You are permitted to slow down, to stop, and to rest as necessary. 
You may lean against the wall while resting, but resume walking as soon as you are able.  
You will be walking back and forth around the cones. You should pivot briskly around the cones and 
continue back the other way without hesitation. Now I'm going to show you. Please watch the way I 
turn without hesitation.’ [124] 
 
A multicentre study conducted in 7 countries [125] demonstrated the mean 6MWD in healthy 
controls was 571 metres (Standard Error (SE) 90), with a range of 380 to 782 metres. 
Importantly, there were significant differences between countries which may be explained by 
cultural factors (usual speed of walking, lifestyle etc), and this should be considered when 
conducting the 6MWT in subjects from a variety of ethnic backgrounds. Additionally, there was 
a significant increase in the 6MWD on repeat testing, demonstrating there is a learning effect 
within this test [125], which must be accounted for, particularly in longitudinal studies. 
 
36 
 
The 6MWT test offers advantages over other forms of exercise testing. Firstly, there are 
ventilatory and metabolic differences between assessments of walking (such as the 6MWT) and 
cycle ergometry [126], and since the 6MWT measures an activity central to daily living this is 
probably the more useful assessment. Secondly, the test has been evaluated in patients with 
COPD and relates well to self-ranking of symptom severity (compared to their peers with 
COPD), with differences of more than 54 metres considered to be the MCID [116]. Finally, it is a 
simple, safe assessment that requires little equipment and although there is a learning effect, this 
is only modest.  
 
1.3.5.2 Incremental Shuttle Walk Test (ISWT) 
 
Although the 6MWT is partly an objective assessment, the test may be influenced by motivation, 
cultural norms and repeated testing [125]. The ISWT protocol was an attempt to overcome these 
issues and requires the subject to walk up and down a 10 metre course, at a speed dictated by a 
pre-recorded audio signal (a beep) [127]. The time between the ‘beeps’ decreases as the test 
progresses and the test ends when the subject can no longer keep up with the beeps or they are 
too breathless to continue. The test relates well to maximal heart rate, and since subjects do not 
have to pace themselves the test will theoretically provide a better measure of their true disability 
[127]. However, a study comparing 6MWT, with ISWT and cycle ergometry showed that 
subjects performing the 6MWT were able to match exertion and dyspnoea to reach a more 
sustainable (and natural) maximum intensity, although there was no difference between peak 
heart rate or dyspnoea between the 3 tests [128] which indicates that effort was also similar. The 
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theoretical advantages of the ISWT have therefore not been proven and hence the more 
straightforward 6MWT is probably the more appropriate form of assessment. 
 
1.3.6 Composite Scores: BODE 
 
The BODE score is a multidimensional score of COPD severity comprising the Body mass index 
(BMI), airflow Obstruction (FEV1 % predicted), Dyspnoea (modified MRC score) and Exercise 
capacity (6 minute walking test) [129]. When compared to FEV1, this assessment tool has a 
stronger relationship with the need for hospital admission [130], exacerbations [131] and 
mortality [130, 132]. The BODE index is expressed as the sum of the individual component 
scores (Table 3) and therefore ranges from 0 to 10. BODE is a good measure of cross-sectional 
disease severity, however, there is stronger evidence for the use of the index expressed as 
quartiles (usually scores of 0 – 2, 3 – 4, 5 – 6 and 7 – 10) due to small numbers included in 
subsequent follow-up studies and this allows for less discrimination between individuals. This is 
particularly important in longitudinal studies where sensitive measures of disease progression or 
treatment efficacy are required, and may partly explain why there is a statistically significant 
increase in BODE in only 14% of patients with moderate to severe COPD over a median study 
period of 64 months [88], although this may also relate to heterogeneous disease progression. 
Also even within those whose physiology declined, the average increase in BODE score was only 
0.5 points per year, which is of doubtful clinical significance, and there was no relationship 
between decline in BODE and FEV1 progression. However and importantly, FEV1 progression 
within this study was also non-linear and variable [88], which indicates both the heterogeneity of 
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disease progression in subjects with COPD and the need for markers of disease activity rather 
than severity (discussed later in this thesis). Finally, all the components of BODE are simple to 
perform but in combination are labour intensive and therefore this score may not be suitable for 
widespread use in the assessment of this prevalent disease.  
 
Parameter BODE Index Score 
0 1 2 3 
Body mass index >21 <21   
Airflow obstruction (FEV1 % predicted) ≥65 50 – 64 36 – 49 ≤35 
Modified MRC dyspnoea scale 0 – 1 2 3 4 
Exercise Tolerance (Distance walked in 6 minutes (metres)) ≥350 250 – 349 150 – 249 ≤149 
Table 3 The BODE index. This multidimensional assessment tool of COPD disease severity also relates to 
mortality [129]. 
 
1.3.7 Biomarkers 
 
A biomarker is ‘a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic 
intervention’ [133]. While this term may include any clinical endpoint, it is generally considered 
that a biomarker is something (usually a protein) that can be measured [134] whether in sputum 
(induced or spontaneous), exhaled breath, bronchoalveolar lavage (BAL), bronchial biopsies, 
blood (serum or plasma), or urine. In contrast to markers of disease severity, the biomarkers have 
the potential to be markers of disease activity (which may therefore predict future disease 
progression) and may also allow a more sensitive assessment of treatment effects.  
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1.3.7.1 Sputum Markers 
 
Up to 60% of current smokers with COPD have chronic bronchitis and therefore regularly 
produce sputum spontaneously [135], however sputum production may also be induced by the 
inhalation of an induction agent (often hypertonic saline). In those who are ‘producers’, 
spontaneous sputum is generally easy to obtain at minimal cost and without discomfort. 
However, sputum induction may not be acceptable to all patients and furthermore in subjects with 
COPD it may be associated with a temporary but significant worsening of FEV1, FVC and 
oxygen saturations [136], which could be temporarily detrimental in those with the most severe 
lung disease. Also biomarker concentrations in spontaneous sputum are not influenced by the 
dilutional or inflammatory effects of sputum induction agents, although they may both be diluted 
by physiological secretions from the oropharynx. In addition, processing methods [137, 138] and 
the dilutional effect of the inhalation and eventual expectoration of the induction agent (usually 
saline) may also affect the results [139]. Furthermore, inflammation is only detectable in induced 
sputum samples obtained from those who also spontaneously expectorate, however, the induction 
process adds a further dilutional error [140]. Although analysis (in the stable state) of 
spontaneous sputum is limited to those with chronic bronchitis, importantly (if patients 
expectorate) the cellular results and validity are the same in expectorated and induced sputum 
[141], however this is not a universal finding [136]. Additionally, the accuracy of spontaneous 
sputum analysis may be increased by repeated testing [141], however sputum induction may 
itself trigger inflammation with raised neutrophils that persist for 24 hours which precludes 
repeated testing, at least within a short timeframe [142].   
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A number of inflammatory mediators are raised in the sputum of patients with COPD, 
particularly during exacerbations, although few have been fully validated in longitudinal studies. 
Of these markers, sputum IL-8 has been more extensively studied and is present in higher 
concentrations in subjects with COPD, and relates to FEV1/FVC in cross-sectional studies [143] 
and to disease progression measured by CT densitometry, but not lung function, in longitudinal 
studies [21]. Also sputum myeloperoxidase (MPO) and LTB4 correlate with FEV1 and TLCO 
decline respectively [21]. However, at present, limited data exists regarding the long-term 
variability of markers in induced sputum [144], which currently restricts their use as biomarkers. 
 
1.3.7.2 Exhaled Breath Condensates (EBC) 
 
Exhaled air contains aerosolised particles from airways’ lining fluid as well as water vapour and, 
when cooled, the water vapour condenses trapping non-volatile substances in the EBC [145]. 
Guidelines for the use of EBC were produced by the ERS in 2005 [146], however there are still 
outstanding concerns regarding the variability in both sample collection and analysis [145]. For 
example, the dilution of exhaled biomarkers (and therefore their concentration) may be 
influenced by either the water content of the airways’ lining fluid or exhaled breath, however 
there is no accepted endogenous factor to compensate for this [145]. Intra-patient variability has 
also been shown to be greater in patients with COPD than healthy controls, largely due to 
changes in airway pH of uncertain aetiology [147]. 
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 LTB4 is raised in the EBC from patients with COPD [148], increases during exacerbations [149] 
and correlates with sputum neutrophils [148]. However, studies reveal a wide range of absolute 
values (despite the use of the same ELISA and similar methodology) and this variability currently 
precludes the routine use of EBC in COPD [145]. Airway cytokines are also raised in EBC from 
patients in COPD relative to controls, although at concentrations that are below or close to the 
lower limit of detection and quantification for many assays, which again may lead to 
unacceptable variability or interpretation [145, 150]. Nevertheless, the EBC IL-6 concentration 
correlates with FEV1 in current smokers in cross-sectional studies [151], although no longitudinal 
data are available.  
 
The nitrogen oxides nitrite (NO2
-
) and nitrate (NO3
-
) may also be measured in EBC and while 
nitrite
 
is raised in COPD relative to healthy controls [152], nitrate
 
is not [153], and it has been 
suggested that exhaled nitric oxide relates more to concomitant asthma than COPD [154]. 
Although certain EBC markers may relate to physiological markers of COPD, and proteomic 
analysis of EBC has established that several proteins are elevated in subjects with A1AT 
deficiency compared to controls [155], further studies are required to prove the validity of the 
methodology, reproducibility, predictive value and response to treatment.  
 
1.3.7.3 Bronchial Biopsies and BAL 
 
Bronchial biopsies demonstrate an inverse relationship between FEV1 and the number of 
neutrophils, macrophages and NK-lymphocytes in the subepithelium in smokers, both with and 
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without airflow limitation [156]. Also, in situ NF-κβ activation is greater in subjects with COPD, 
and increases with disease severity [157]. However, bronchial biopsies are performed via 
bronchoscopy and therefore they are not without risk, particularly in those with more severe 
disease or co-morbidities [158]. Furthermore, they provide only a limited anatomical and 
pathological ‘snapshot’ and the reproducibility of measurements of inflammatory cells is poor 
requiring multiple biopsies [159]. 
 
Betsuyaku et al demonstrated that subjects with a high level of A1AT/NE (A1AT/NE) complex 
in BAL have a greater rate of decline in FEV1 than those with a low level, although the high 
group included only six subjects and there was no correlation between FEV1 decline and 
A1AT/NE complex when expressed as continuous variables [160]. Also, BAL from current 
smokers with COPD contains the greatest proportion of neutrophils, while ex-smokers with 
COPD still have a greater proportion of these inflammatory cells than ‘healthy’ smokers. 
Moreover, the absolute number of neutrophils correlates with pack years of smoking, and there is 
greater macrophage expression of MMP-12 [161] and MMP-9 but less TIMP-1 [162] in those 
with COPD compared to non-smokers (the role of these inflammatory mediators was discussed in 
1.2.4 and Figure 3). However, BAL is invasive and may lead to a transient fever and also carries 
the associated risks of bronchoscopy (albeit small), such as haemorrhage and respiratory failure, 
which increase with disease severity [158]. Also BAL recovery decreases with greater 
emphysema severity [163], and again there is no accepted measure of the dilutional effect of the 
saline lavage, hence interpretation of biomarker concentrations in the recovered fluid presents a 
major challenge [164].   
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1.3.7.4 Circulating Markers 
 
There has been increasing interest in peripheral blood biomarkers for use in patients with COPD, 
since they have many advantages in terms of collection (reproducible methodology of collection; 
minimal staff training; limited equipment required at the point of collection) and patient 
acceptability, even for repeated measures. A number of plasma or serum markers have been 
evaluated in many studies of patients with COPD: 
 
(a) Circulating Cytokines 
 
Raised levels of TNF-α and its receptor have been observed in patients with COPD associated 
with hypoxaemia [165], cachexia, skeletal muscle wasting and weakness [166], however, this 
may reflect association rather than causation (see 7.3.4). Also, elevated levels of the pro-
inflammatory cytokine IL-8 (and other similar chemokines) have also been associated with 
muscle weakness in patients with COPD [167]. IL-8 is produced by leucocytes, as well as airway 
epithelial cells, in response to cigarette smoke [168], TNF-α, IL-1β [169] or bacteria [170] and 
these potential stimuli are either present or increased in subjects with COPD or have an 
associated gene polymorphism [171]. Additionally, the adipokine leptin, which is important in 
the regulation of energy balance, is found in lower concentrations in plasma from subjects with 
COPD [165], and its potential role in inflammation is summarised in Figure 6.  
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Figure 6: The inflammatory role of the adipocyte [172]. Leptin and adiponectin appear to be important in 
systemic inflammatory processes such as COPD, particularly during acute exacerbations. The primary 
role of LEPTIN is to influence energy balance via the hypothalamus by decreasing food intake and 
metabolic efficiency while increasing energy expenditure, however leptin may also be important in 
systemic inflammation since it can stimulate neutrophil and macrophage chemotaxis and activation, and 
influence T lymphocytes. Leptin therefore stimulates both inflammation and weight loss, while 
ADIPONECTIN inhibits production of TNF-α, IL6 and ICAM-1, and may also inhibit the pro-
inflammatory activities of these cytokines, and is therefore anti-inflammatory. However, disorders 
associated with increased NE activity (including COPD) may be associated with reduced adiponectin 
anti-inflammatory activity since NE can cleave adiponectin. This dysregulated leptin/adiponectin cycle 
may therefore be self-perpetuating in subjects with COPD [172]. 
 
 
Levels of circulating cytokines may be increased through a ‘systemic overspill’ of mediators 
originally released within the lung [173]. However, it appears more complex since the levels of 
circulating cytokines do not necessarily relate to their concentration within the airways, a 
relationship which would be expected if overspill occurs. However, there may be a number of 
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explanations for this disparity including the variability of the biomarkers within sputum [141], 
facilitated protein transport from (or to) the lung, local autocrine and paracrine effects and 
systemic uptake [173]. Also, it is questionable whether these cytokines are central to the 
pathology of COPD or are secondary phenomena which relate to other features of COPD (such as 
bacterial colonisation) and therefore do not truly reflect concomitant COPD disease activity. 
Further longitudinal studies are therefore required to explore the relationship (if any) of these 
systemic cytokines to the disease process in subjects with COPD. 
 
(b) Circulating Acute Phase Proteins 
 
In comparison to healthy controls, subjects with COPD have higher average plasma IL-6, an 
inflammatory mediator which increases the expression of acute phase proteins (such as C-
Reactive Protein (CRP)) and is associated with both reduced muscle strength and exercise 
capacity [174]. Also, the concentration of CRP relates to mortality in people with mild-to-
moderate (but not severe) COPD [132]; health status; exercise capacity [175]; and risk of 
cardiovascular disease [176]. Elevated levels of CRP occur in some patients during acute 
exacerbations of COPD, and it has been shown to be a sensitive marker of exacerbations in the 
presence of one or more symptoms [177], although the diagnostic sensitivity was found to be less 
in other studies [178]. Additionally, CRP relates cross-sectionally to FEV1, however does not 
predict a more rapid subsequent FEV1 decline [179].  
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Fibrinogen is also an acute phase protein which is elevated during exacerbations and is associated 
with an increased risk of hospitalisation, frequent exacerbations and inversely with FEV1 [180]. 
However, studies have not shown a relationship between fibrinogen and disease progression 
[181] nor is it a sensitive marker of therapeutic intervention [182]. 
 
Surfactant protein D (SPD) is a large hydrophilic protein found within the endoplasmic reticulum 
of type II pneumocytes and secretory granules of Clara cells and has been suggested as a lung 
specific biomarker. Lomas et al [183] demonstrated that this marker is slightly, though 
significantly higher in subjects with COPD relative to controls (121.1 vs. 114.3 ng/ml) and higher 
levels were associated with increased risk of exacerbations. However, the greatest difference was 
seen between non-smokers and current smokers and the marker did not correlate with FEV1, 
visual emphysema or objective emphysema scores. Although values decreased in subjects 
receiving steroid therapy, it was not certain whether this reflects reduced leakage from the lung, 
reduced production or molecular and hence immunological change [184]. Additionally, while 
reasonable short term reproducibility has been demonstrated, there are no long term data. 
 
More recently, the ECLIPSE study demonstrated an association between disease progression 
measured by FEV1 decline over a 3 year period and Clara Cell Secretory Protein 16 (CC-16), but 
not fibrinogen, IL-6, IL-8, TNF-α, CRP or SPD [181]. However, the association was weak, the 
statistical testing did not account for multiple analyses, and furthermore, there was no 
relationship between CC-16 and emphysema severity measured by CT densitometry [185]. CC-
16 is produced by a number of tissues, although serum levels are primarily influenced by 
secretion from cells of the lower respiratory tract [186], and it has immunomodulatory effects 
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including protection against oxidative stress. Although CC-16  may be relatively specific to the 
lung, any pathological process within the lung has the potential to cause depleted concentrations 
[185], and its relationship to disease activity in subjects with COPD is questionable since it may 
simply be a measure of general inflammation or reflect past events causing airway damage.  
 
(c) Circulating Cells  
 
A number of abnormalities may occur within circulating leucocytes, which relate to overall 
mortality in subjects with COPD [187]. Also, an inverse relationship exists between FEV1 and 
circulating neutrophil numbers [188]. In addition, neutrophils from subjects with COPD exhibit 
both abnormal chemotactic responses [58] and enhanced production of reactive oxygen species 
[189] compared to those from ‘healthy’ smokers and non-smokers. Monocytes also accumulate in 
the lungs of patients with COPD owing to an enhanced chemotactic response to CXCL-1 and 
CXCL-7, which may be explained by an abnormally high turnover of the monocyte receptor 
CXCR-2 [190]. Circulating [191] and alveolar macrophages [192] from patients with COPD also 
show greater spontaneous production of MMP-9 compared to healthy controls indicating a degree 
of activation and/or the production of potentially damaging proteases [162]. However, while 
these cells are important in the pathogenesis of COPD (see 1.2.4), their absolute numbers do not 
relate well to COPD severity or progression and therefore cannot be considered as biomarkers. 
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1.3.7.5 Biomarkers of NE Activity 
 
(a) Connective Tissue Destruction 
 
Elastin monomers are cross-linked by 2 amino acids (isodesmosine and desmosine) to form 
insoluble elastic fibres which are a key component of the skin, blood vessels and lung [193]. 
Elastin is degraded even in healthy individuals by NE and other proteases (although this is 
increased in pathological processes such as COPD) releasing isodesmosine and desmosine which 
may be detected in plasma, urine and sputum [194]. Although these amino acids are elastin 
specific, and have therefore been considered potential biomarkers of COPD, they are not specific 
to a pathological process and therefore urinary desmosine may be influenced by diet [195], renal 
function [196] or reflect tissue breakdown in other organs [197]. Urinary desmosine differs 
between healthy non-smokers, smokers with normal lung function and subjects with COPD 
[198], however it demonstrates poor stability in individuals over a 2 week period [199] (although 
this accuracy has been improved more recently using mass spectrometry (MS) technology [200]). 
Also, while urinary desmosine is higher in PiZ individuals than ‘healthy’ smokers [138], it is not 
influenced by A1AT augmentation therapy [140, 150]. Early studies did not show a correlation 
between  desmosine and  FEV1 [35, 155, 198], although more recently a relationship was shown 
in subjects with COPD, but not healthy controls [201]. However, the relationships in this more 
recent study, while statistically significant, were relatively weak and also desmosine related to 
age, sex and weight (even in the healthy controls), demonstrating that this marker is not specific 
to disease states but may also reflect physiological processes.  
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Elastin peptides may also be useful biomarkers since some are found in subjects with COPD but 
not in healthy controls [202]. However, the studies are relatively small and further work would be 
required to validate these markers prospectively.  
 
(b) Alpha-1-antitrypsin/neutrophil elastase complex (A1AT/NE complex) 
 
When A1AT and NE interact, they bind (largely) irreversibly on an equimolar basis to form the 
A1AT/NE complex which can be measured in plasma or other bodily fluids. Although the 
complex concentration will be a surrogate measure of the total amount of NE released, it will not 
provide information about the duration of exposure of proteins to NE (and hence potential tissue 
damage) prior to its inhibition by A1AT. A1AT/NE complexes have previously been shown to be 
higher in subjects with an infective exacerbation of COPD compared to those in the stable state, 
however, there was no difference in A1AT/NE complex between subjects with COPD and 
healthy controls [203] which suggests that a measure of total NE release is an inadequate measure 
of the destructive potential of NE in the stable state. The A1AT/NE complex assay and the 
distinction between a measure of total NE release and pre-inhibition NE activity is considered 
later in the current thesis.  
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1.4 VALIDATION OF BIOMARKERS 
 
1.4.1 Markers of Disease Activity, Severity and Impact 
 
The markers used in COPD and emphysema (many of which are outlined above), could be 
categorised into 3 separate groups (disease activity, severity and impact) which provide differing 
information about the patient with COPD [204]. Disease activity describes the underlying 
pathophysiological process leading to end-organ damage (measured by a marker of disease 
severity) leading to an impact producing an adverse influence on the quality of life of a patient.  
 
Disease activity is recognised to be distinct from disease severity since subjects with only limited 
impairment of a marker of disease severity (e.g. FEV1) may have very active disease and may or 
may not progress at a greater rate than those with ‘severe’ disease [89, 204], although true disease 
activity remains unclear in the absence of an effective marker. An ideal marker of disease activity 
would be a measure (biomarker) of the underlying pathophysiological process which leads to 
end-organ damage, with the associated development of symptoms and changes in a marker of 
disease severity such as FEV1, gas transfer or CT densitometry. The rate of change of markers of 
disease severity (e.g. change in FEV1) have also been considered to be markers of disease 
activity [204], with the caveat that they measure a single aspect of disease activity in COPD 
(namely disease activity leading to increased airflow obstruction for FEV1) rather than measuring 
overall disease activity. Furthermore, the rate of change of FEV1 could not be considered a gold 
standard marker of the activity of the disease leading to emphysema development, nor could it be 
51 
 
considered a direct marker of underlying pathophysiological disease activity. An assessment of 
overall disease activity would therefore require a composite score, which as a minimum should 
include measures of emphysema progression and airflow obstruction. The current thesis therefore 
considers the rate of change of FEV1 as well as gas transfer in an attempt to overcome some of 
these issues. 
 
There is also controversy regarding the most appropriate methods to measure the rates of change 
of markers of disease severity such as CT densitometry (see 1.3.3) and FEV1 since the change of 
an absolute value of FEV1 is dependent on the baseline value [95]. For example, a 60 ml change 
in FEV1 is a relatively lesser change in someone with mild airflow obstruction compared to an 
individual with severe airflow obstruction. The use of change in % predicted or standardised 
residual values partly (but not completely [205]) compensates for this differential and is therefore 
used in the current thesis, however, this anomaly requires careful consideration when discussing 
disease activity. With this in mind, and in the absence of sensitive markers, the description of 
different rates of disease activity at different disease severity stages should be considered with 
caution. Furthermore, the rate of change of FEV1 is essentially a surrogate, rather than direct, 
marker of a single aspect of the underlying pathophysiological disease activity in patients with 
COPD since a change in FEV1 will only occur in situations where the underlying disease process 
specifically alters airflow obstruction rather than being a direct measure of other underlying 
processes. Additionally, FEV1 relates to overall mortality and is therefore at least partly a 
surrogate marker of overall health, rather than a specific marker of disease severity (or activity in 
the case of rate of change of FEV1) [206]. All these factors further support the need for new 
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biomarkers of disease activity for use in highly characterised patients who have or are at risk of 
developing COPD and emphysema. 
 
Measures of disease severity would include spirometry, gas transfer and HRCT thorax scans, 
while it has been suggested that measures of disease impact would include the mMRC, daily 
activity score and COPD assessment test [204]. However, the 6 minute walk test (and equivalent 
tests) could arguably be described as either a measure of disease severity (since those with more 
severe disease may be expected to walk a shorter distance in 6 minutes) or a measure of impact 
since it is a measure of the influence of the severity of the disease (muscular dysfunction, 
breathlessness, fatigability) on an everyday activity. Additionally, the impact of a disease relates 
to the complex interaction between the individual’s disease severity, their perception of 
symptoms and the influence of the disease on their everyday life (which may also vary depending 
on lifestyle choices). This may differ considerably between people who otherwise have similar 
disease severity or even similar symptoms, and could also be considered in terms of disability 
(symptoms) and handicap (impact). Therefore the ‘impact’ of a disease may only be truly 
measured by a marker of quality of life, while a 4
th
 group of tests may be required to measure the 
symptoms of the disease, since moderate symptoms may have little impact on the quality of life 
experienced by some subjects yet warrant inclusion in any composite measure of COPD.  
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1.4.2 Validation of the Ideal Biomarker of Disease Activity 
 
A large number of studies have now reported data demonstrating a relationship between a range 
of proteins and inflammatory mediators and disease activity or severity in patients with COPD, 
and also allude to their potential as biomarkers, however few have been effectively validated. 
This validation step is critical, and although less validation may be required depending on the 
purpose of the biomarker, an ideal biomarker of COPD disease activity that will serve all 
purposes must [207]: 
1. be central to the pathophysiological disease process 
2. be either a direct measure of that disease process (or a close surrogate) 
3. be stable and reproducible, but vary with events associated with disease progression 
4. relate to disease severity 
5. be responsive to therapies known to modify disease progression 
6. predict individuals who will progress more quickly 
 
It should be recognised that the relationship between a marker of disease severity and disease 
activity will be complex, since there is likely to be a relationship between a marker of current 
disease activity and future disease severity (assuming relative stability of disease activity between 
the point of measurement of the marker of activity and marker of future severity). Additionally, 
there will be at least a partial relationship between disease activity and contemporary disease 
severity in a cross-sectional study if disease activity is stable over a more prolonged period of 
time. These concepts are discussed further in subsequent sections of the current thesis. 
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Alternate criteria have also been suggested for the validation of biomarkers. Bucher et al [208] 
proposed that the biomarker concentration must firstly relate to the clinical endpoint and secondly 
would demonstrate a treatment effect allied with evidence of clinical improvement in an RCT. If 
applied to biomarkers of disease activity in COPD, the use of these criteria must therefore also 
assume stability of the disease activity and the marker over time (since a change in a clinical 
outcome marker such as FEV1 or mortality may only be measured after observation of the 
patients for several years). Also, since no therapies have been conclusively shown to influence 
disease activity and survival in patients with COPD these criteria are of limited use to describe 
valid biomarkers for COPD. 
 
 Sin et al [209] also proposed criteria for an ideal biomarker specifically for use in COPD which 
include 5 criteria similar to those proposed by Stockley [207]. Rather than a relationship to 
disease severity, however, they suggest an equivalent requirement that there should be ‘a strong, 
consistent and independent association between the biomarker and chronic obstructive pulmonary 
disease’. Again, although this criterion is not fully defined, it would seem to assume a stable 
marker and stable disease activity. This will be discussed further in section 7.3.4. 
 
To date no biomarker has fulfilled the validation criteria proposed by Stockley [207] or by Sin et 
al [209], and therefore the implications of the results of many biomarker studies remain unclear, 
and it is uncertain whether many inflammatory mediators are integral to the pathophysiological 
process or are simply secondary to either the disease process or smoking itself. This is critical 
since a non-specific biomarker, such as CRP, may be elevated in patients with COPD through a 
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variety of mechanisms, not all of which may be directly associated with COPD disease activity 
(i.e. ongoing damage to the airways or lung parenchyma). CRP cannot therefore be considered 
central to the pathophysiology of COPD and hence does not meet the first or second criteria. 
There is therefore an urgent need for new biomarkers of disease activity for use in patients with 
COPD which meet these validation criteria, particularly for phase II and III clinical trials where 
an early appraisal of treatment efficacy is crucial. It is also important to base further development 
of biomarkers on the current state of knowledge of the pathophysiology of COPD.  
 
1.4.3 Biomarker Validation: Summary 
 
Table 4 and Table 5 compare a selection of biomarkers and markers of disease severity against 
the criteria for an ideal biomarker [207], however the 3
rd
 criterion is modified slightly, to separate 
it into stability and exacerbations. Exacerbations are included as one example of an event which 
is known to relate to disease progression in subjects with COPD. 
 
Biomarker 
Criteria 
1 2 3 – stability 3 –  
Exacerbations 
4 5 6 
Physiological 
 
X  X X (stability 
poor relative 
to progression)   
√ √ √ (prolonged 
follow-up) 
X 
Radiological  X X √ (using same 
scanner) 
X √ √ X 
Patient 
reported 
outcomes 
X X X √ (relatively 
insensitive) 
√ √ Relatively 
insensitive 
X 
Measures of 
exercise 
capacity 
X X X √ √ X X 
BODE X X X √ √ X Partly  
Table 4: This table assesses the physiological, radiological and patient reported measures of COPD 
severity against the criteria for an ideal biomarker (in top row) comprising: 1. Central to the 
pathophysiology 2. A direct measure of the disease process 3a. Stability. 3b. Vary with (one) event known 
to relate to disease progression (i.e. exacerbations). 4. Relate to disease severity. 5. Responsive to 
therapies known to modify disease progression. 6. Predict individuals who will progress more quickly.  
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Plasma 
Biomarker 
1 2 3 –  
Stability 
3 –  
Exacerbations 
4 5 6 
TNF-α 
X X √ [210] X [211] 
Relates to 
some severe 
COPD 
phenotypes 
X [212] X [181] 
CRP 
 
X X X [211] √ [211] √ [181] X [184, 213] X [181] 
Surfactant 
protein D 
X X √  [211] √ [211] X [181] 
Possible [183, 
184] 
X [181] 
CC-16 
X X √ [185] X [211] √ [181] 
Insufficient 
data 
Weak 
association 
[181] 
IL-6 
 
X X X  [211] √ [211] X [181] X [184, 213] X [181] 
IL-8 
X X X  [211] X [211] √ [181] 
Insufficient 
data 
X [181] 
Fibrinogen 
 
X X √  [211] √ [211] √ [181] X [182] X [181] 
Table 5: This table assesses a selection of plasma biomarkers against the criteria for an ideal biomarker 
(in top row) comprising: 1. Central to the pathophysiology 2. A direct measure of the disease process 3a. 
Stability (>50% of subjects have a repeat value within 25% of baseline). 3b. Vary with (one) event known 
to relate to disease progression (i.e. exacerbations). 4. Relate to disease severity. 5. Responsive to 
therapies known to modify disease progression. 6. Predict individuals who will progress more quickly. X= 
does not meet criteria, √ = meets criteria.  
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1.5 DEVELOPMENT OF A NOVEL ASSAY FOR NE ACTIVITY 
 
1.5.1 Protease-antiprotease Imbalance is Central to the Pathophysiology of COPD 
 
The pathophysiology of COPD is complex, however it is increasingly accepted that protease-
antiprotease imbalance, in particular relative local excesses of NE and Pr3, is central to the 
pathophysiology of COPD (see 1.2.4). However, the absence of specific assays for the in vivo 
measurement of NE and Pr3 activity prior to their inhibition has restricted the evaluation of their 
role, particularly in pathological states such as COPD, and therefore an alternate approach 
utilising surrogate markers of activity is required. Our research group, together with Merck 
(USA), therefore developed and validated a novel assay to a specific peptide formed when 
fibrinogen is degraded by NE, which provides a specific measure of NE activity prior to its 
inhibition. It is this validation which is described in the current thesis.  
 
1.5.2 Development of Aα-Val360: a specific marker of pre-inhibition NE activity 
 
Data pertaining to this section has previously been published [214]. 
 
Fibrinogen is a glycoprotein consisting of 3 chains, which may be cleaved by NE at multiple 
sites, however, the Aα-Val360 site was chosen for the assay since it is relatively large with a 
disulfide network and therefore more likely to be stable than other smaller cleavage products. 
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Rabbit antisera were generated to the free carboxyl group of Aα-Val360, following conjugation of 
C(Nle)T
355
SESSV
360 
to thyroglobulin using Sulfo-MBS, which ensures conjugation occurs at the 
amine group of the peptide therefore exposing its carboxyl group. A Europium based classical 
sandwich Elisa was then generated using the antisera. The specificity of the antisera, in particular 
to the terminal valine of the peptide sequence, is shown in Figure 7 [214], and further discussed 
in section 3.3.  
 
 
Figure 7: The specificity of the Aα-Val360 antibody. Removal of the terminal valine from the peptide 
sequence completely abrogates antibody binding. 
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1.5.3 Previous Studies Exploring Fibrinogen Cleavage Products as Potential Markers of 
NE Activity 
 
NE cleaves the Aα chain of fibrinogen at multiple sites, including Aα -21 with the subsequent 
generation of a 21 amino acid fragment. This fragment includes fibrinopeptide A (FPA) which is 
the first 16 amino acids of the Aα chain of fibrinogen (excluding the signal peptide) and a normal 
thrombin cleavage product of fibrinogen. Weitz et al [215] considered measurement of the Aα-21 
fragment concentrations may be an effective surrogate marker of NE activity in vivo, however 
they initially developed an assay (thrombin-increasable FPA immunoreactivity (TIFPA)) that 
measured baseline FPA concentrations indirectly. This assay required a 2 step analysis to 
determine the concentration of Aα-21, necessitating precipitation of the remaining whole 
fibrinogen followed by incubation with thrombin to generate FPA, and derivation of the Aα-21 
concentration from the measured concentration of FPA by interpolation. TIFPA could therefore 
not be considered a specific measure of an NE cleavage product but rather a measure of the non-
specific fragment FPA (the concentration of which would also reflect in vivo thrombin activity).  
 
Weitz et al subsequently developed 2 further assays, one based on a specific antibody for Aα-21 
and a second assay (termed ‘elastase-specific fibrinopeptide’ (ESF)) which utilised an antibody 
with cross-reactivity to Aα-21 in addition to smaller FPA containing fragments [216]. Of the 3 
assays developed by Weitz et al, only Aα-21 could therefore be considered NE specific since this 
is the only assay to include an antibody which binds to an NE specific cleavage point. 
Interestingly, in vivo experiments demonstrated that although TIFPA and ESF were highly 
correlated neither related well to the NE specific assay Aα-21. The poor performance of the Aα-
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21 assay was explained by the rapid in vivo degradation of Aα-21 to smaller peptides, a lack of 
stability which makes this a poor target for development as a biomarker. Also, the strong 
relationship between a measure of FPA (TIFPA) and ESF indicated that ESF was not entirely 
specific to NE cleavage. Furthermore, while they demonstrated a relationship between FEV1 and 
ESF (in a study including only 12 PiZ subjects), no relationship was described between either 
TIFPA or Aα-21 and FEV1. The work was never pursued on the basis of these uncertainties and 
there is therefore insufficient clinical evidence to support the use of the Aα-21 peptide (or its 
derivatives) as a biomarker and there are also more fundamental concerns about the specificity of 
the assay.  
 
Both animal and human studies have demonstrated the stability of the larger Aα-Val360 fragment 
of fibrinogen [214], which is an important characteristic of a biomarker. Also, the Aα-Val360 
antibody is specific to the NE cleavage site on the Aα chain of fibrinogen, and does not cross-
react with other fragments of fibrinogen [214], and therefore is predominantly NE specific.  
 
Although these data support the specificity of the Aα-Val360 ELISA to NE degradation products, 
more work was required to demonstrate the validity of Aα-Val360 as a biomarker in COPD and 
emphysema and this formed the basis for my thesis. 
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1.6 IDENTIFICATION OF PR3 SPECIFIC FIBRINOGEN CLEAVAGE 
PRODUCTS 
 
Pr3 is also likely to be central to the pathophysiology of COPD and emphysema and since it is 
less readily inhibited, particularly in the airways, a marker of Pr3 activity may relate better to the 
airways disease activity of COPD and emphysema than a marker of NE activity. The current 
thesis therefore also describes the identification of specific Pr3 fibrinogen cleavage products 
which may be used in future studies to develop a specific marker of Pr3 activity.  
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1.7 PURPOSES OF THE CURRENT THESIS  
 
1.7.1 Aims and Objectives: Studies Evaluating Aα-Val360 
1.7.1.1 Hypothesis 
 
Aα-Val360 is an ideal in vivo biomarker of pre-inhibition NE activity and hence COPD and 
emphysema disease activity in subjects with and without A1AT deficiency. 
 
1.7.1.2 Aims 
 
To evaluate: 
 Aα-Val360 assay variability  
o In vitro 
o In blood (plasma and serum) 
 Factors that influence the concentration of Aα-Val360  
o Within an individual  
 Stability over time 
 Exacerbations 
 The influence of a therapeutic intervention 
o Between individuals (cross-sectional and longitudinal) 
 A1AT level and phenotype 
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 Demographic factors 
 Smoking 
 Physiological and radiological disease severity 
 
1.7.2 Aims and Objectives: Identification of a Pr3 Specific Fibrinogen Cleavage Product 
1.7.2.1 Hypothesis 
 
In a similar manner to NE and Aα-Val360 (subsequent chapters and also [214, 217]), proteinase 3 
(Pr3) will also produce specific fibrinogen cleavage products that can be identified using mass 
spectrometry (MS), and developed into a specific assay to determine pre-inhibition Pr3 activity in 
vivo.  
 
1.7.2.2 Aims 
 
1. To generate specific Pr3 cleavage products of fibrinogen in vitro 
2. To identify the in vitro Pr3 cleavage products using MS 
3. To identify the terminal amino acid sequence of a large Pr3 fibrinogen cleavage product 
(which is more likely to be stable in vivo) by fragmentation and MS analysis 
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1.8 DEFINING THE STUDY POPULATIONS 
 
As discussed in section 1.1, most guidelines suggest that COPD is only diagnosed in the presence 
of airflow obstruction, where the FEV1/FVC is less than 0.7 or the lower limit of normal. 
However, this definition will exclude subjects who nevertheless have significant pathology 
particularly those with emphysema without airflow obstruction [10] and it is therefore important 
to include patients in studies who do not necessarily meet these arbitrary airflow criteria. This 
may also allow the identification of patients with early (rather than mild) disease which may be 
more responsive to treatment [25]. 
 
The inclusion criteria for the individual studies reported in the current thesis are described in the 
methods section, however to ensure the studies were generalisable, the following only included 
subjects with a post-bronchodilator FEV1/FVC<0.7 or healthy controls: 
1. PiM subjects with COPD (section 3.1.3) 
2. Variability Study (section 4.1) 
3. Exacerbation Study (section 4.3) 
4. Aα-Val360 as a marker of A1AT augmentation therapy (Chapter 6) [inclusion criterion was 
a post bronchodilator FEV1:slow vital capacity below 0.7] 
 
The study investigating the use of Aα-Val360 in subjects with symptoms of COPD unrelated to 
A1AT deficiency (Chapter 5) included patients who were current or ex-smokers (>10 pack year 
smoking history) with chronic bronchitis and associated dyspnoea. Spirometric criteria were not 
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used for this study to allow the inclusion of a broad range of phenotypes, however alternate and 
concomitant diseases were excluded by HRCT thorax scans and subgroup analyses were also 
performed for patients with a post-bronchodilator FEV1/FVC below the LLN. 
 
The cross-sectional and longitudinal analyses in the study investigating subjects with A1AT 
deficiency (Chapter 7) included only PiZ A1AT deficient subjects (with and without airflow 
obstruction or emphysema) to investigate the differences in Aα-Val360  formation across a broad 
range of phenotypes.  
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CHAPTER 2. METHODS 
2.1 GENERAL METHODS 
2.1.1 The Alpha-1-antitrypsin Deficiency Assessment and Programme for Treatment 
(ADAPT) Project 
 
The ADAPT project is a UK based registry established in 1996 which now includes over 900 
A1AT deficient subjects (predominantly PiZ), who were either diagnosed following presentation 
with suggestive symptoms (index patients) or through family screening (non-index). Following 
the provision of informed consent, subjects attending the programme undergo annual full lung 
function testing, health status assessment and physical examination and also provide serum, 
plasma and sputum (where possible) at each visit. All subjects also have HRCT scans of the 
thorax, with most performed for quantitative assessment at baseline and/or subsequent visits. 
Subjects continue to attend for annual follow-up at the ADAPT centre until they die or withdraw 
from the study. 
 
Data for the ADAPT subjects is included in 2 separate databases. The first clinical database was 
commenced in 1996 but was superseded by a more comprehensive database in 2000 (which 
includes all subsequent clinical data). For the current studies, a further (anonymised) database 
was established in Microsoft Access 2007 to unify both data sources and also include all 
laboratory analyses.  
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2.1.2 Ethical Approval and Informed Consent 
 
Ethical approval for studies relating to patients included in the ADAPT Registry was provided by 
the University Hospitals Birmingham NHS Trust Research Ethics Committee (local research 
ethics committee reference 3359). Ethical approval for all other studies was obtained from the 
South Birmingham Research Ethics Committee. Informed consent was provided by all 
participants. 
 
2.1.3 Pulmonary Function Tests 
 
Lung function testing was performed by the physiologists in the Lung Function and Sleep 
Department, Queen Elizabeth Hospital Birmingham, United Kingdom in accordance with 
Association of Respiratory Technicians’ and Physiologists’ Guidelines and, to permit accurate 
longitudinal analysis, on the same equipment at each time point (where possible). Spirometry was 
performed post-bronchodilator (salbutamol 2.5 mg and ipratropium 500 mcg via a nebuliser 
unless otherwise stated) on a wedge bellows spirometer (Vitalograph, Buckinghamshire, UK). 
For many studies spirometry was also preformed pre-bronchodilator. Lung volumes were 
performed by helium dilution and/or whole body plethysmography (Morgan Medical, Kent, UK). 
Gas transfer was measured by the single breath carbon monoxide method. The European 
Community for Steel and Coal reference equations [16, 218] were used to derive predicted values 
for spirometry, lung volumes and TLCO, while Cotes’ reference equation [219] was used to 
calculate predicted values for KCO.  
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2.1.4 HRCT Thorax Scans 
 
Scans at the ADAPT centre were performed in one millimetre slices at 10 mm intervals whilst the 
subject was breath-holding at full inspiration. Prior to December 2001, scans were performed on 
a 3
rd
 generation scanner (General Electric Prospeed Scanner, General Electric Medical Systems, 
Milwaukee, USA) with a single row of Xenon detectors. Subsequent scans were performed on a 
General Electric Lightspeed scanner which is a 3
rd
 generation helical scanner with 4 rows of 
detectors. CT scans were reported by an experienced thoracic radiologist for the presence or 
absence of visible emphysema using established criteria [220].  
 
Although emphysema distribution within the lung may be heterogeneous, it characteristically 
involves the apical (usual COPD) or lower zones (A1AT deficient) [221] and therefore scanning 
of selected areas within these regions has been demonstrated to be highly sensitive while 
avoiding the need to assess the whole lung including less ‘active’ areas of emphysema 
progression and the accompanying increase in radiation exposure [222]. In the current thesis, the 
radiological lung density was therefore measured quantitatively in both the upper zone (level of 
aortic arch) and the lower zone (level of the inferior pulmonary vein) by assessing the proportion 
of the low density areas below a threshold of -910 Hounsfield Units and/or -950 Hounsfield Units 
using Density Mask Analysis. The 15
th
 percentile point was also measured on many of the later 
scans using semi-automated computer software (Pulmo-CMS, MEDIS Medical Imaging Systems 
BV, Leiden, the Netherlands).  
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Volume correction is generally only required in longitudinal studies and was not performed for 
the majority of HRCT thorax scans described in the current thesis as most were performed on one 
occasion and correction requires 2 CT scans with differing volumes[223]. In the current thesis, 
this may reduce the sensitivity of the CT densitometry for detecting progression and increase 
variability [223] however uncorrected scans remain a valid form of assessment for patients with 
COPD and have been widely used in other studies. 
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2.1.5 Objective Quality of Life Assessment 
 
2.1.5.1 The St George’s Respiratory Questionnaire (SGRQ) 
 
The SGRQ has been validated for use in subjects with asthma, COPD and bronchiectasis [224]. 
Subjects were provided with the questionnaire which they were asked to self-complete, following 
the guidelines provided with the SGRQ [225].  
 
2.1.5.2 COPD Assessment Test (CAT) 
 
The CAT is a validated assessment tool also designed for self-completion which was introduced 
more recently to assess patients with COPD [123]. Since it includes only 8 items (Figure 8), it 
can be conducted in a timelier manner and is therefore suitable for either research or clinical 
management. Each item is accompanied by 2 statements which describe the best and worst 
scenario and patients decide where they lie on the scale (0 to 5) between these 2 scenarios. The 
overall score therefore ranges from 0 (best health status) to 40 (worst health status). 
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Figure 8 The CAT is a validated tool designed to assess the quality of life experienced by patients with 
COPD. The questionnaire is intended for rapid self-completion, and is therefore appropriate for both 
research and clinical settings [123].  
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2.1.6 Sample Collection and Processing 
 
Spontaneous sputum samples were collected over a 4 hour period (from rising in the morning), 
and the sputum colour was assessed by experienced research staff using a standardised sputum 
colour chart (Bronkotest, Heredilab, Utah, USA). One aliquot was then ultracentrifuged at 50,000 
g for 90 minutes in a Beckman-Coulter Avanti JE centrifuge at 4
o
C to prepare a sol phase sample. 
The remaining sputum was used for quantitative culture which was performed by an experienced 
microbiology technician as described previously [226]. Plasma samples were either collected in 
lithium heparin or EDTA coated tubes and cooled on ice prior to ultracentrifugation (within 2 
hours of sample collection). All samples were stored at -70
o
C prior to measurement of mediator 
concentrations. Unless otherwise specified, the Aα-Val360 concentration was measured in plasma 
samples. 
 
2.1.7 Statistical Analysis 
 
Statistical analysis was performed using PASW Statistics 18.0.0 for Microsoft Windows 
(Chicago, Il, USA). Normally distributed data were presented as mean (SE), while non-
parametric data were presented as median (interquartile range). Normality was confirmed using 
the Kolmogorov-Smirnov test and statistical significance was taken as p<0.05. Statistical 
differences between means were assessed using independent t-tests (Mann-Whitney for non-
parametric data), while paired t-tests (Wilcoxon Rank Tests for non-parametric data) were used 
for dependent variables. The significance of correlations was assessed using a Pearson correlation 
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for normally distributed data or Spearman’s Rho for non-parametric data. Multivariate analysis 
was performed using linear regression (backward stepwise) analysis unless otherwise stated. 
 
2.2 AΑ-VAL360 ASSAY METHODS  
 
The assay was performed using a modified version of a protocol (outlined below) originally 
developed by Professor Rob Stockley (Queen Elizabeth Hospital Birmingham, UK) in 
conjunction with Merck (Rahway, NJ, USA).  
 
Human fibrinogen (Merck, UK) in phosphate buffered saline (PBS) was incubated with human 
NE (Elastin Products Company, Missouri, USA) in PBS at a 200:1 molar ratio for 30 minutes at 
37
o
C to produce cleaved fibrinogen. Aliquots of cleaved fibrinogen were frozen at -70
o
C until 
use.  
 
Voller’s buffer was prepared by adding 15 mM Na2CO3, 35 mM NaHCO3, and 3 mM NaN3 to 
deionised water at a pH of 9.6. Fifty microlitres of the solution of cleaved human fibrinogen 
(diluted 1:1000 in Voller’s buffer) were added to each well of an Opti-96 plate (labelled ‘Plate 
A’), with 2 empty wells forming the negative control wells. Plate A was spun at 5000 g for 5 
minutes to ensure uniform distribution of the cleaved fibrinogen solution and incubated overnight 
at 4
o
C with shaking.  
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Block buffer was prepared by adding 10 g of bovine serum albumin (Sigma-Aldrich, UK), 2 ml 
10% NaN3 and 0.5 ml of Tween 20 to one litre of 1x TBS. The CJTSESSV standard peptide 
(AltaBioscience, University of Birmingham, UK) was diluted in block buffer to form a 1:3 
dilution series, with the highest concentration of peptide at 333.33 nM and the lowest 0.15 nM. 
Seventy five microlitres of each dilution of the standard peptide or 50 µl of plasma sample 
(diluted with 25 µl of block buffer) or 75 µl of block buffer alone (the positive control) were 
added to a low binding polypropylene plate (‘Plate B’) in triplicate. Seventy five microlitres of 
Aα-Val360 antibody, diluted 1:2500 in block buffer, was added to each well of Plate B and this 
plate was incubated overnight at 4
o
C. 
 
Following overnight incubation, Plate A (coated with cleaved fibrinogen) was washed 3 times 
with 300 µl/well of wash buffer (0.5 ml Tween 20 in 1000 ml 1x TBS), and after the final wash 
the plate was inverted and blotted against clean paper towels. All the wells of plate A were 
blocked with 200 µl/well of block buffer for one hour at 37
o
C and then washed (x3). One 
hundred microlitres of standard peptide/sample/control and antibody were then transferred from 
plate B to the corresponding wells on plate A. Plate A was then incubated at room temperature 
for 2 hours with shaking, before further washing (x3). One hundred microlitres of anti-Rabbit 
IgG Europium Antibody (Perkin-Elmer, UK) diluted 1:1500 in block buffer was then added to 
each well of plate A, prior to incubation at room temperature for one hour with shaking. Plate A 
was again washed (x3), 100 µl of enhancement solution (Perkin-Elmer, UK) added to each well 
and the plate was incubated at room temperature in the dark for 20 minutes with shaking. Plate A 
was read on a Biotek Synergy 2 Multimode Microplate Reader (Biotek, Winooski, VT, USA) at 
25
o
C with the excitation wavelength set to 340 nm and the emission filter set to 620/40. The Aα-
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Val
360 
concentration was calculated by interpolation from the standard curve of the CJTSESSV 
peptide (which was generated for each plate). 
 
2.2.1.1 Aα-Val360 Assay Variability 
See chapter 3. 
 
2.3 OTHER BIOCHEMICAL ASSAYS 
 
2.3.1 Samples under or over standard range 
 
Repeat tests were performed for any samples falling outside of the standard working range of the 
assay, using a higher or lower dilution as applicable.  
 
2.3.2 A1AT 
 
To ensure accuracy and repeatability, the A1AT levels and phenotype were performed by a single 
reference laboratory (Heredilab, Salt Lake City, USA). Where specified, an in house assay was 
also performed to quantify the A1AT concentration according to the following methods: 
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Coating antibody solution was prepared by adding 2 μL/ml of sheep antihuman A1AT to coating 
buffer (0.05 M Na2CO3; 0.05 M NaHCO3), and 200 μL was added to the inner wells of a 
Maxisorp microtitre plate (Nunc, UK) which was then incubated overnight at 4
o
C.  
 
Wash buffer was prepared by adding 0.5 ml of Tween 20 (Sigma, UK), and one gram of bovine 
serum albumin (Sigma, UK) to one litre of PBS. Samples were diluted with wash buffer at a ratio 
of 1:20000. Each well was washed 3 times with 300 μL of wash buffer, and then 200 μL of 
sample or standard was added to the inner wells only. The plate was incubated for 2 hours at 
room temperature with shaking, and then washed (x3). Two hundred microlitres of horseradish-
peroxidase conjugate (Sigma, UK) was added to each well, and the plate incubated for 2 hours at 
room temperature with shaking. After washing, 100 μL of tetramethylbenzidine solution (Sigma, 
UK) was added to each well and the plate incubated until a colour change occurred 
(approximately 2 minutes). The reaction was stopped with 50 μL/well of 0.1 M H2SO4, the 
absorbance measured on a plate reader at 450 nm (with 570 nm wavelength correction) and the 
A1AT concentrations interpolated from the standard curve. 
 
Working range     2 ng/ml to 14 ng/ml (post-dilution) 
Inter-assay Coefficient of Variation (CV)  10.20% (at upper end of working range) 
Inter-assay CV     4.35% (at lower end of working range)  
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2.3.3 Alpha-1-antitrypsin-neutrophil Elastase Complex (A1AT/NE complex) 
 
A1AT/NE complex was measured by ELISA using a commercially available kit 
(Merck4biosciences, UK). One hundred microlitres of standard or sample (diluted by sample 
diluent JA6404) were added to duplicate wells of a plate pre-coated with an antibody specific to 
human NE. The plate was incubated at room temperature for one hour with shaking.  
 
Wash buffer was prepared by diluting wash buffer concentrate with deionised water, and each 
well was washed 4 times. One hundred and fifty microlitres of horseradish-peroxidase conjugated 
with rabbit anti-A1AT antibody was added to each well and the plate was incubated at room 
temperature for one hour with shaking. The plate was then washed (x4) and 200 μL of 
tetramethylbenzidine (TMB) added to each well. The plate was incubated at room temperature 
until a colour change was observed within the lowest standard (approximately 20 minutes), and 
the reaction was then stopped by the addition of 50 μL of 2 Molar (M) hydrochloric acid. The 
absorbance of each well was measured using a microplate reader set at 450 nanometres (with 570 
nanometre (nm) wavelength correction). The concentration of A1AT/NE complex was then 
determined for each duplicate sample by interpolation from the standard curve. 
 
Working range  0.00187 to 0.120 nM (post-dilution) 
Inter-assay CV   14.68% (at lower end of working range) 
Inter-assay CV   9.34% (at upper end of working range) 
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2.3.4 MPO 
 
MPO was measured by ELISA using a commercially available kit (R&D Systems, UK). Samples 
were diluted in calibrator diluent RD6-57 and 50 µL of Assay Diluent RD1-62 was added to each 
well. Fifty microlitres of standard, control or diluted sample were added, and the plate incubated 
for 2 hours at room temperature with shaking. The wells were washed 4 times with 400 µL of 
wash buffer and then 200 µL of MPO conjugate added to each well. The plate was then incubated 
at room temperature for 2 hours with shaking and then washed (x4). Two hundred microlitres of 
substrate solution was added to each well, and the plate was then incubated for 20 minutes at 
room temperature in the dark, after which  50 μL of stop solution was added to each well. The 
absorbance was measured on a microplate reader set to 450 nm with wavelength correction set to 
540 nm, and the MPO concentration determined from the standard curve. 
 
Working range  10.42 nM – 666.67 nM (post-dilution) 
Inter-assay CV   5.68% (at lower end of working range) 
Inter-assay CV   4.59% (at upper end of working range) 
 
2.3.5 High Sensitivity C-Reactive Protein (hsCRP) 
 
This assay was performed using a commercially available kit (R&D Systems Europe, Abingdon, 
UK). 
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All samples were diluted with calibrator diluent (100 fold dilution). One hundred microlitres of 
assay diluent was added to each well, followed by 50 μL of standard, control or diluted sample. 
The plate was covered and incubated for 2 hours at room temperature. The plate was then washed 
4 times using an autoplate washer, and following the final wash the plate was inverted and blotted 
against clean paper towels. Two hundred microlitres of CRP conjugate was then added to each 
well, and the plate was incubated for 2 hours at room temperature. The wash step was repeated 
(x4) and then 200 μL of substrate solution was added to each well, prior to incubation for 30 
minutes at room temperature in the dark. Fifty microlitres of stop solution was then added to each 
well in a rapid action to ensure thorough mixing. A microplate reader set to 450 nm (with 
wavelength correction at 570 nm) was used to determine the optical density of each well. The 
CRP concentrations were determined by interpolation from the standard curve.  
 
Working range  1.56 to 50 ng/ml (post-dilution) 
Inter-assay CV   6.00% (at lower end of working range) 
Inter-assay CV   6.60% (at upper end of working range) 
 
2.3.6 LTB4 
 
LTB4 was measured using a commercially available kit (R&D Systems Europe, Abingdon, UK). 
 
One hundred microlitres of calibrator diluent was added to the non-specific binding (NSB) wells, 
while 50 μL of calibrator diluent was added to the zero standard blank control (‘B0’) wells and 
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50 μL of standard (‘B’), control or sample was added to the remaining wells. Fifty microlitres of 
the primary antibody solution was added to all wells (except the NSB wells) and the plates were 
covered and incubated for one hour at room temperature on a plate shaker. Fifty microlitres of 
LTB4 conjugate was added to each well, the plate was re-covered and then incubated at room 
temperature for 3 hours on a shaker. The plate was washed (x4) on an autoplate washer, and after 
the final wash the plate was inverted and blotted on a clean paper towel. Two hundred microlitres 
of substrate solution was then added to each well and the plate was incubated for 30 minutes at 
room temperature in the dark. One hundred microlitres of stop solution was then added to each 
well and the optical density (OD) determined using a microplate reader set to 450 nm (with 
wavelength correction at 570 nm).  
 
The duplicate readings for each standard (‘B’), control and sample were averaged and then the 
NSB optical density was subtracted to produce the ‘corrected OD’. The %B/B0 was calculated by 
dividing the corrected ‘B’ OD by the corrected ‘B0’ OD multiplied by 100. A standard curve was 
generated of %B/B0 against the log transformed known concentration of standards, from which 
the LTB4 concentration of the samples was obtained by interpolation.  
 
Working range  10.3 to 2500 pg/ml (post-dilution) 
Inter-assay CV   8.60% (at lower end of working range) 
Inter-assay CV   8.40% (at upper end of working range) 
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2.3.7 Calprotectin 
 
Calprotectin was measured using a commercially available ELISA (the PhiCalTest ELISA, 
Calpro AS, Norway). 
 
Fifty microlitres of each standard, control or diluted sample were added in duplicate to the plate, 
prior to incubation at room temperature on a plate shaker for 45 minutes. The plate was washed 5 
times on an autoplate washer and after the final wash, the plate was inverted and blotted on a dry 
paper towel. Fifty microlitres of the enzyme conjugate was then added to each well and the plate 
was then covered and incubated for 45 minutes on a plate shaker at room temperature. The plate 
was washed 5 times and then 100 μL of enzyme substrate solution was added to each well. The 
plate was incubated for 30 minutes at room temperature in the dark and then 100 μL of  one 
molar NaOH stop solution was added to each well and the OD values were read at 400 nm (with 
wavelength correction at 470 nm). The calprotectin concentration in the samples was then 
determined by interpolation from the standard curve. 
 
Working range  216 – 13,889 nM (post-dilution) 
Inter-assay variability  14.8% 
 
  
82 
 
2.3.8 NE Activity Assay 
 
The activity of NE was measured spectrophometrically using an in-house method based on the 
original assay described by McGillivray et al [227]. 
 
NE buffer was prepared by combining 0.01 M Tris-HCl, 0.5 M NaCl and 0.1% Triton x100 at 
pH8.6. Doubling dilutions of NE (one μM to 15.62 nM) were made in NE buffer as standards. 
Thirty microlitres of standard or sample were added in triplicate to the plate followed by150 µL 
of either the synthetic substrate N-succinyl-ala3-p-nitroanilide
 
(in PBS at pH 8.6) in 2 wells or 
buffer alone in one well (to provide the optical density control for each sample). The plates were 
incubated for 45 minutes at 37
o
C. The absorbance of each sample or standard was then measured 
at 410 nm, the absorbance of the relevant control well subtracted and the NE activity determined 
by interpolation from the standard curve.  
 
Working range  15 nM to 1000 nM (post-dilution) 
Inter-assay CV   4.56% (at lower end of working range) 
Inter-assay CV   4.76% (at upper end of working range) 
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2.3.9 Interleukin-8 (IL-8) Assay 
 
IL-8 was measured using a commercially available kit (R&D Systems Europe, Abingdon, UK). 
One hundred microlitres of assay diluent was added to each well, followed by 50 μL of standard, 
control or sample. The plate was covered and incubated for 2 hours at room temperature. The 
plate was then washed 4 times using an autoplate washer and after the final wash, the plate was 
inverted and blotted against clean paper towels. One hundred microlitres of IL-8 conjugate was 
then added to all wells, the plate was re-covered and incubated for one hour at room temperature. 
The plate was again washed (x4) and 200 μL of substrate solution added to each well, followed 
by a further 30 minute incubation at room temperature (in the dark). Fifty microlitres of stop 
solution was rapidly added to each well (to ensure thorough mixing) and  the OD of each well 
was determined using a microplate reader at 450 nm (with wavelength correction at 570 nm). The 
optical densities of the (duplicate) samples were averaged and the concentrations determined by 
interpolation from the standard curve.  
 
Working range  31.30 to 2000 pg/ml (post-dilution) 
Inter-assay CV   6.24% (at lower end of working range) 
Inter-assay CV   7.22% (at upper end of working range) 
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2.4 AΑ-VAL360 ASSAY REPEATABILITY 
 
2.4.1 Interplate and Intraplate Repeatability (Peptide Standard) 
 
Four serial dilutions of the CJTSESSV peptide standard (AltaBioscience, University of 
Birmingham, UK) were generated, and the concentrations of Aα-Val360 were measured in each 
sample following the standard protocol. One serial dilution was designated to be the standard 
curve and the concentrations of Aα-Val360 in the remaining 3 serial dilutions were derived by 
extrapolation from this standard curve. These steps were repeated in 2 further assays and the 
intra-plate and inter-plate CV were calculated. Further assays were performed following minor 
adjustments to the assay protocol and plate reader settings to obtain the best CV. These settings 
were then used in all future experiments and are described earlier in this chapter (section 2.2). 
 
2.4.2 Intraplate Repeatability (Plasma) 
 
If repeated testing is carried out on the same sample, all biochemical assays will exhibit a degree 
of unavoidable variation whether tested within the same plate (intra-assay variability) or in 
different assay runs (inter-assay variability). However this variability may be reduced by using 
the average measurements of 2 or more aliquots per plate to determine the concentration of the 
target peptide or protein within a sample. In order to establish the optimal number of sample 
aliquots per plate for the Aα-Val360 assay, plasma was obtained from one healthy volunteer into 4 
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ml Vacuette tubes (Greiner Bio-One, UK) coated with 7.2 mg of EDTA on a single occasion. 
Twelve 50 µl aliquots of this plasma sample were placed in separate wells and analysed on a 
single plate following the standard Aα-Val360 protocol. The Aα-Val360 value was then determined 
by interpolation from the standard curve using the averaged fluorescence output of 2, 3 or 4 wells 
(chosen at random from the 12 aliquots). These steps were repeated on 2 further plates to ensure 
that representative values were obtained, and the intraplate CVs were calculated for each 
potential combination. 
 
In a further analysis, the Aα-Val360 concentration was obtained by interpolation from the standard 
curve using the mean concentration of all 12 aliquots of the single plasma sample on a single 
plate. Variation from this derived concentration was then calculated using progressively fewer 
aliquots (selected from the same plate using random number generation). These data were used to 
establish the number of aliquots required to provide an acceptable balance between minimising 
the intra-assay CV for the use of least plasma.   
 
2.4.3 Interplate Repeatability (Healthy Control Plasma) 
 
A plasma sample obtained from a healthy PiM individual was analysed in 9 separate assays to 
determine the interplate variability. Three aliquots of the plasma sample were analysed per plate 
since earlier experiments determined this minimised intraplate variability whilst using the least 
plasma. The interplate CV of any assay may be reduced by determining the average mediator 
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concentrations across 2 or more plates. The average Aα-Val360 was therefore derived from one, 2 
or 3 plates (selected at random) and the interplate CV was then calculated across these groupings. 
 
2.4.4 Intraplate and Interplate Variability (PiM Subjects with COPD) 
 
It is possible that intraplate and interplate variability for the Aα-Val360 assay may be different in 
plasma obtained from subjects with COPD compared to PiM healthy controls. To determine 
whether this is the case, samples were obtained from 8 consecutive PiM subjects attending a 
COPD outpatient clinic. All provided written informed consent, were current or ex-smokers, and 
had a clinical history consistent with COPD with a post-bronchodilator FEV1/FVC below 0.7.  
 
The Aα-Val360 concentration was measured in plasma samples obtained from all 8 subjects. The 
measurements were performed in 9 plates for each sample (with 3 aliquots of sample per plate), 
with the average measurement from 3 plates used to calculate the Aα-Val360 concentration and the 
interplate CV.  
 
The Aα-Val360 concentration was also compared with the FEV1. 
 
2.4.5 Serum versus Plasma 
 
Analysis of mediator concentrations in blood may be performed using either serum or plasma 
samples and the choice of media may influence the assay performance. To demonstrate the 
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influence of serum or plasma on the Aα-Val360 assay, plasma (4 ml EDTA tube) and serum (10 
ml tube containing serum clot activator) were obtained from 4 PiZ A1AT deficient individuals 
and 2 PiM healthy controls. Samples were obtained by venepuncture at a single time point for 
each individual and processed within 2 hours of collection. The concentration of Aα-Val360 was 
determined using the mean fluorescence output of 9 aliquots on a single plate. The serum and 
plasma were both analysed on the same assay to minimise the influence of assay variability, since 
the intraplate CV is less than the interplate CV. 
 
2.5 PILOT STUDIES: AΑ-VAL360 IN HEALTHY AND A1AT DEFICIENT 
SUBJECTS  
 
In this initial pilot study, plasma was obtained from 12 healthy controls and 15 PiZ A1AT 
deficient subjects. The Aα-Val360 (using the optimal methodology (section 2.2)), MPO and 
Calprotectin were measured in plasma both before and after the addition of a neutrophil activator 
(calcium ionophore A23187). Blood samples were drawn from all subjects into 2 lithium heparin 
tubes and 150 micromoles (μM) of calcium ionophore was added to one (within 90 minutes of 
sample collection). Both tubes were incubated at 37
o
C for 60 minutes after the addition of 
ionophore to one, and then centrifuged (500 g for 10 minutes) to obtain plasma which was then 
stored at -70
o
C until analysis. The FEV1, A1AT concentration, Aα-Val
360
, MPO, A1AT/NE 
complex and Calprotectin were also measured in a larger group of 40 PiZ and 24 healthy 
individuals. 
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2.6 IN VIVO VARIABILITY 
2.6.1 The Variability Study  
 
It is important to assess for changes in marker concentrations over time, particularly in the 
presence or absence of factors known to influence progression. The Variability Study was 
designed to assess the variability of inflammatory indices in both plasma and spontaneous sputum 
samples from subjects with A1AT deficiency over an 84 day time period.  
 
Subjects were assessed and both blood and sputum samples were obtained on 11 occasions (daily 
for 5 days, then on days 7, 14, 21, 28, 56 and 84). Clinical stability was assured by the use of a 
daily diary card [228] in which symptoms (including dyspnoea, sputum colour and volume) were 
recorded by each patient. 
 
Inclusion and Exclusion Criteria 
 
PiZ A1AT deficient patients with an FEV1/FVC<0.7 who had a history of chronic bronchitis (as 
defined by MRC criteria [229]) and were daily sputum producers were recruited. Both clinical 
assessment and HRCT scanning of the thorax were used to exclude concomitant lung disease and 
to characterise the patients. All subjects attended the ADAPT assessment programme and 
provided further consent to participate in this study. 
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2.6.2 Variability over 3 consecutive annual measurements 
 
This study was designed to assess the variability of Aα-Val360 over a 2 year period. Plasma was 
obtained from 40 individuals who were selected at random from the ADAPT database of 
samples.  
 
Inclusion and Exclusion Criteria 
 
All PiZ A1AT deficient patients were eligible if plasma samples were available for a minimum of 
3 consecutive annual visits.  
 
2.7 THE EXACERBATION STUDY (SUBJECTS WITH PIZ A1AT 
DEFICIENCY) 
 
Individuals who suffer more frequent exacerbations of COPD have a greater rate of disease 
progression [118]. Furthermore, these episodes are often associated with an inflammatory 
response [230] and hence it would be predicted that such episodes would be associated with an 
increase in Aα-Val360 as a marker of the NE activity during these episodes. To investigate this 
possibility, Aα-Val360 was measured in plasma obtained from 8 PiZ A1AT deficient subjects with 
chronic bronchitis during an acute exacerbation. Sputum and plasma samples were collected 
within 48 hours of the start of an exacerbation and the patient was then commenced on oral 
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antibiotics (amoxicillin or cefuroxime for 14 days) but not steroids. Sputum and plasma samples 
were also collected on 6 further occasions over a 28 day period. Sputum NE activity was 
measured spectrophotometrically as described earlier (section 0). 
  
Inclusion and Exclusion Criteria 
 
Subjects with PiZ A1AT deficiency (and a post-bronchodilator FEV1/FVC<0.7) were identified 
from the ADAPT registry and included in the study following further informed consent. An acute 
exacerbation of COPD was defined in the current study as a sustained increase in all three of the 
symptoms of sputum purulence, sputum volume and breathlessness compared to the usual clinical 
state [3].  
 
2.8 AΑ-VAL360 IN SUBJECTS WITH SYMPTOMS OF COPD 
UNRELATED TO A1AT DEFICIENCY 
 
Patients aged 40 to 80 years who were smokers or ex-smokers with a diagnosis of COPD (based 
on symptoms with and without supportive spirometry) and who presented in primary care with an 
acute exacerbation were recruited to the study. All had a history of chronic bronchitis [229] and 
exertional breathlessness and had the normal PiM A1AT phenotype (Heredilab, Salt Lake City, 
USA). Exacerbations were defined by the presence of increased dyspnoea, cough and sputum 
production (although the volume of the latter had not always increased) and new or increased 
sputum purulence that persisted for at least 2 days was a feature of a proportion [231]. 
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Spirometric confirmation of COPD was not used as an entry requirement to allow the inclusion of 
participants with a broad range of phenotypes, and therefore subgroup analyses were also 
performed for patients with chronic bronchitis and dyspnoea but with an FEV1 and FEV1/FVC 
within the normal range, and additionally for subjects with COPD defined spirometrically. 
Physiological normality was defined as within ±1.64 standardised residuals as recommended by 
ATS/ERS guidelines to overcome sex and age differences in lung function, a threshold which is 
often termed the ‘lower limit of normal’ (LLN).[17] 
 
Subjects were assessed at presentation with the exacerbation and all patients provided a 
spontaneous sample of sputum over a 4 hour period after waking. Sputum samples were analysed 
macroscopically using a standardised colour chart used to classify sputum colour (Bronkotest, 
Heredilab, Utah, USA) and those with mucopurulent or purulent sputum (grade 3 to 8) were 
treated with an antibiotic (oral cefuroxime), while those with mucoid sputum (grade 0 to 2) were 
not. The patients were assessed in detail 8 weeks after the episode (when in the stable clinical 
state) with full lung function tests and an HRCT scan of the thorax.  
 
Aα-Val360 was measured in plasma samples obtained both at presentation with the exacerbation 
and when clinically stable using the highly specific assay as described earlier in section 2.2. In 
addition, comparisons were made with physiological parameters and visual assessment of the 
HRCT scan. All scans were assessed for the presence or absence of visible emphysema by an 
experienced thoracic radiologist using established criteria [220]. Aα-Val360 was also measured in 
plasma samples obtained from 39 healthy controls.   
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Finally, the patients were reviewed 4 years later (where possible) and repeat lung function testing 
and an HRCT scan of the thorax was performed at full inspiration using the same General 
Electric Prospeed Scanner. Densitometric analysis was undertaken to assess the severity of the 
emphysema and its progression accurately using the voxel index (-950 Hounsfield Units (HU)) 
and the 15
th
 percentile point in both the upper zone (level of aortic arch) and lower zone (level of 
inferior pulmonary vein) (see 2.1.4). Post-bronchodilator (salbutamol 400 mcg and ipratropium 
60 mcg via a large volume spacer) spirometry was performed using a wedge bellows spirometer 
(Vitalograph, Buckinghamshire, UK) and gas transfer by the single breath carbon monoxide 
method.  
 
2.9 AΑ-VAL360 AS A MEASURE OF THE EFFICACY OF 
AUGMENTATION THERAPY 
 
Aα-Val360 was measured in plasma samples obtained from participants in the EXACTLE trial 
[111], which was a randomised, double-blind, placebo controlled parallel group study conducted 
in Copenhagen (Denmark), Birmingham (UK) and Malmo (Sweden). Study participants were 
randomised to receive weekly intravenous infusions of either A1AT (60 mg/kg body weight of 
Prolastin; Talecris Biotherapeutics, NC, USA) or placebo (2% albumin) over a 24 to 36 month 
period. CT scans were performed at baseline, 12 and 24 months, while post-bronchodilator lung 
function was assessed at baseline, and at months 6, 12, 18, 24 and 36 (where participants 
continued to month 36). 
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In the EXACTLE trial, plasma samples were obtained at baseline (one month prior to the 
commencement of the interventional study product), month 6, month 12 and at the study 
termination visit (one week after the last infusion of the interventional study product). A 24 
month sample was therefore not available from all 36 individuals in whom the trial was extended 
to 36 months. It was therefore decided to measure Aα-Val360 and A1AT/NE complexes at 
baseline and at 6 months to maximise the number of patients still participating at this time point 
and available samples. 
 
 Inclusion and Exclusion Criteria 
 
The EXACTLE trial [111] required PiZ A1AT deficient subjects to be at least 18 years old, with 
a history of at least one exacerbation in the 2 years prior to screening for the study. Subjects were 
only included if they demonstrated a KCO below 80% predicted and/or a post-bronchodilator 
FEV1 between 25% and 80% predicted with an FEV1:slow vital capacity below 0.7. Patients were 
excluded if their body mass was below 42 kg or greater than 92 kg; if they had undergone (or 
were on the waiting list for) any thoracic surgery; if they had smoked in the 6 months prior to 
screening; or had detectable cotinine in plasma.   
 
Subjects were only included in the current study (‘Aα-Val360 as a Measure of the Efficacy of 
Augmentation Therapy’) if plasma samples were available at both baseline (pre-study 
intervention) and at month 6.   
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2.10 AΑ-VAL360 IN A1AT DEFICIENT SUBJECTS: CROSS-SECTIONAL 
AND LONGITUDINAL RELATIONSHIPS 
 
Patients with PiZ A1AT deficiency who had been assessed at 3 or more annual visits were 
identified from the UK A1AT registry (ADAPT) which has been recruiting patients since 1997. 
All patients had a baseline HRCT thorax performed and at each visit had undergone full lung 
function testing and clinical assessment. Although the registry primarily includes PiZ subjects, a 
number of patients with alternate A1AT phenotypes had also undergone assessment and were 
included in the cross-sectional component of the current study, along with 24 never smoking PiM 
healthy controls (asymptomatic with lung function tests within the normal range). A1AT 
phenotypes were confirmed or determined in all subjects by a single reference laboratory 
(Heredilab, Salt Lake City, USA).  
 
All subjects were assessed when in the clinically stable state, at least 6 weeks after any 
exacerbation, and patients who had received A1AT augmentation therapy were not included in 
the current study. 
 
Aα-Val360 was measured in plasma samples using the highly specific assay as described earlier 
(section 2.2). Other inflammatory markers relevant to neutrophilic inflammation including MPO, 
IL-8 and LTB4 in sol phase sputum samples and plasma hsCRP and A1AT/NE complexes were 
also measured as described in section 2.3. 
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Detailed cross-sectional and longitudinal analyses were only performed in the PiZ A1AT 
deficient subjects to reduce confounding. All patients completed the SGRQ [224], and a subset 
(those who had attended more recently after 2009) was also assessed using the CAT, which is a 
validated objective measures of the quality of life of patients with COPD [123].  
 
Inclusion and Exclusion Criteria 
 
Patients with A1AT deficiency were identified from the UK A1AT registry (ADAPT). The aim 
of the current study was to evaluate Aα-Val360 in subjects with A1AT deficiency and therefore the 
inclusion criteria did not require participants to have either a diagnosis of COPD or abnormal 
lung function, to enable inclusion of patients with a broad range of clinical phenotypes. The 
detailed cross-sectional and longitudinal analyses only included PiZ subjects who had attended 
for assessment at 3 or more annual visits.  
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2.11 GENERATION AND IDENTIFICATION OF PR3 SPECIFIC 
FIBRINOGEN CLEAVAGE PRODUCTS 
 
2.11.1 Generation of a Pr3 Fibrinogen Cleavage Product 
 
Three test tubes containing solutions of 3.37 μM human fibrinogen in PBS were warmed to 37oC 
in a water bath and NE (16.83 nM), Pr3 (16.83 nM) or PBS were added prior to incubation for 15 
minutes. A 100 μL aliquot was then extracted from each tube and mixed with an excess of 0.1% 
trifluoroacetic acid (TFA) to inhibit enzyme activity, and each sample was then frozen at -70
o
C 
until further analysis. Further 100 μL aliquots were removed from the 3 test tubes at 30, 60, 120 
and 180 minutes, inhibited as above and stored until analysed. This process was repeated on 
several occasions to produce samples for duplicate analysis to enable the assessment of the 
repeatability of fragment formation. 
 
2.11.2 Mass Spectrometry  
 
An initial matrix assisted laser desorption/ionisation (MALDI)-MS analysis was performed to 
detect low molecular weight products in unmodified solutions of the fibrinogen cleavage 
products. Since the sensitivity and resolution of MALDI-MS decreases as the target peptide mass 
increases and also MS-MS does not easily identify peptides much larger than 30 to 40 residues 
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[232], analysis of larger molecular fragments was performed following gel electrophoresis and 
in-gel digestion (which is described in section 2.11.4). 
 
A solution of α-cyano-4-hydroxycinnamic acid (CHCA) was prepared by adding 500 μL of 100% 
acetonitrile to 5 mg of CHCA and 500 μL of deionised water, followed by sonication for 5 
minutes and then centrifugation (one minute at 13000 RPM). A solution of 3,5-dimethoxy-4-
hydroxycinnamic acid (sinapinic acid) was prepared by adding 5 mg of sinapinic acid to 200 μL 
of 50% acetonitrile and 0.5% TFA. This was sonicated for 5 minutes, and then centrifuged for 
one minute at 13000 RPM. One microlitre of each sample was then added to a MALDI plate 
(Figure 9) and overlaid with either one microlitre of sinapinic acid solution or 1.5 μL of CHCA 
solution and 1.5 μL of 10 mM ammonium bicarbonate. The CHCA and sinapinic acid are both 
aromatic ‘matrix’ compounds which absorb laser energy, and help prevent fragmentation of the 
peptides prior to analysis. 
 
The plate (or the ‘target’) was then placed in the vacuum chamber of a MALDI-MS 
(UltrafleXtreme, Bruker). The analyte/matrix mixture was targeted with a laser which converted 
the analyte into gas phase ions (Figure 9). A delayed electrical field then accelerated the ions, 
which were focussed through a lens system before leaving the source, and which then travelled 
though a field-free region to the detector.  The time of flight (TOF) of the singly charged ions 
produced in this process is inversely proportional to the square root of their molecular mass 
[233]. In addition to the samples, calibrants of known molecular weights were added to each plate 
to externally calibrate the spectra.  
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Figure 9A: The plates used for MALDI TOF mass spectrometry. Each sample is added to a single ‘spot’ 
on each plate and then overlaid with an aromatic laser absorbing ‘matrix’ consisting of either sinapinic 
acid or CHCA with ammonium bicarbonate. 2B. The initial burst of ions generated by the laser pulse are 
accelerated into the flight tube towards the linear detector. For more detailed analysis, a constant 
electrostatic field is generated by the reflector which further separates parent ions and their fragments by 
their mass:charge ratio. 
 
MS was performed with the instrument in linear mode for fragments >5 kilodaltons (kDa) giving 
average masses at moderate resolution.  For smaller peptides MS was performed in reflectron 
mode where an ion mirror focuses the ions to give much higher resolution (>15000 full width at 
half-maximum) allowing charge state and monoisotopic masses to be determined.   
 
A 
B 
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2.11.2.1 MALDI TOF-TOF and High Performance Liquid Chromatography (HPLC) MS-MS 
 
Tandem MS (MALDI TOF-TOF or MALDI MS-MS) was also used to identify peptides using 
the instrument in ‘LIFT’ mode. Following laser induced fragmentation of the peptides, the 
fragments corresponding to a particular parent ion are isolated by an initial time of flight ‘gating’, 
focussed and re-accelerated via the ion reflector to the detector, and this generates an MS peak 
list of the fragment ions.  
 
Peptide identification was also assisted by HPLC MS-MS which fractionates the peptides, prior 
to MS analysis. This process enabled MS-MS spectra to be produced from a greater proportion of 
the peptides in complex mixtures, being particularly useful for separating peptides of a similar 
mass. The samples were centrifuged to remove large particles and were then mixed with 100 μL 
of 0.5% TFA, prior to injection into an Acclaim PepMap100 C18 reverse-phase HPLC (75 μM x 
25 cm) column. The HPLC matrix was prepared by adding 10 μL of 100 mM ammonium 
phosphate, 45 μL of CHCA solution, 10 μL of 10% TFA and 47 μL of deionised water to 888 μL 
of 100% acetonitrile. Two solvents were used in the column, namely 0.1% TFA in water and 
0.1% TFA in 100% acetonitrile, at a flow rate of 350 nL/min. The HPLC eluent and matrix were 
added directly to a MALDI plate in up to 384 spots using an automated procedure (Proteineer fc 
II), followed by MS-MS analysis.    
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2.11.2.2 Data Analysis 
 
Analysis was performed using peptide mass fingerprinting: a peak list was generated from the 
mass spectra and searched against the SWISS-PROT human sequence database using MASCOT 
to identify the intact peptides by their unique mass signature. The computer software has the 
capability to virtually ‘digest’ the intact protein or peptide using designated enzymes (e.g. 
trypsin), to produce lists of expected peptide fragments with specific and accurate molecular 
weights. This allows the identification of peptide fragments in an unknown solution using their 
precise molecular weight. Peptides were also identified by searching MS-MS data against the 
SWISS-PROT human database using MASCOT, using a 5% significance level for a peptide 
match. 
 
2.11.3 Gel Electrophoresis of Fibrinogen Cleavage Products 
 
Non-reducing and reducing polyacrylamide gel electrophoresis (PAGE) were used to fractionate 
NE and Pr3 cleavage products. A running buffer was prepared by adding 760 ml of deionised 
water to 40 ml of NuPage SDS running buffer. A 10% Bis-Tris Gel (1.0 mm x 10 wells; Nupage 
Novex, Invitrogen) was bathed in deionised water containing running buffer (with the addition of 
an antioxidant to the inner well of the electrophoresis apparatus for the reducing gel). Five 
microlitres of loading buffer was added to 25 μL of each sample, prior to loading into the gel. For 
the reducing gels, 3 μL of a reducing agent (500 mM DTT) was also added to the samples prior 
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to heating at 70
o
C for 10 minutes, which were subsequently loaded into the gel together with 10 
μL of a molecular weight marker. 
 
The gels were run at 200 volts until an acceptable separation of the bands of the molecular weight 
marker had occurred (around 2 hours).  
 
2.11.4 Mass Spectrometry of High Molecular Weight Products 
 
Although the resolution of MS decreases with increasing molecular weight, the larger molecular 
weight fibrinogen cleavage products are likely to be of greater importance as potential 
biomarkers since they would be expected to represent the first Pr3 related cleavage products of an 
intact fibrinogen molecule (and hence have the greatest specificity for Pr3) and are more likely to 
be stable with a greater circulating half-life [214]. Since direct MS analysis of large molecular 
weight proteins is difficult, an alternate approach was to use in-gel digestion followed by MS. 
 
2.11.4.1 In-Gel Digestion of Proteins Separated on PAGE 
 
The gel was placed on a clean, glass plate and the bands of interest were excised from the gel, 
prior to washing twice with 50% acetonitrile/50 mM ammonium bicarbonate for 45 minutes at 
37
o
C. The bands were dried and then 50 mM dithiothreitol (DTT) was added followed by an 
incubation for one hour at 56
o
C. Iodoacetamide (100 mM) was then added followed by a further 
incubation for 30 minutes at room temperature. The bands were washed three times with 10% 
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acetonitrile/40 mM ammonium bicarbonate. Acetonitrile (100%) was added until the bands 
became opaque and shrunken, and they were then dried at 60
o
C. A known concentration of an 
enzyme (Asp-N, trypsin or Arg-C) was then added to the bands followed by incubation for one 
hour at room temperature. A solution of 10% acetonitrile and 40 mM ammonium bicarbonate was 
then added to the solution and the bands were incubated for 18 hours at 37
o
C. The supernatant 
was then extracted and retained, and the band mixed with 3% formic acid for one hour at 37
o
C. 
The supernatant was again extracted and retained before the final 30 minute incubation with 3% 
formic acid. The collected supernatant was then frozen at -70
o
C prior to further analysis. 
 
2.11.5 MS Analysis of Proteins Isolated by PAGE 
 
The samples were added to an MS plate and overlaid with either sinapinic acid or 10 mM 
ammonium phosphate and 5 mg/ml CHCA in 50% acetonitrile, prior to analysis using MALDI 
MS, MS-MS and HPLC MS-MS (as described earlier). 
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CHAPTER 3. ASSAY VALIDATION AND THE PILOT 
STUDY: RESULTS AND DISCUSSION 
 
3.1 ASSAY REPEATABILITY RESULTS 
3.1.1 Intra- and Interplate Repeatability (Peptide Standard) 
 
Following optimisation of the standard operating procedure, the Aα-Val360 assay demonstrated 
good intra-plate repeatability for the peptide standard, with CVs of 19.16% and 12.12% when 
measuring the fluorescence of 2 and 3 aliquots respectively, and repeated analysis demonstrated 
these CVs were consistent. However, even using 3 aliquots, the within plate CV increased as the 
peptide concentration decreased: 13.61%, 26.09% and 89.84% at 4.12, 1.37 and 0.46 nM 
respectively (Figure 10).  
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Figure 10: Variability of the Aα-Val360 peptide standard (range 0.46 nM to 333.33 nM). The chart shows 
the result of 3 series of experiments using different concentrations of the peptide. Each point represents 
the OD (expressed as %B/B0) against the log of the known concentration of the peptide. The variability 
increases as the known concentration decreases. 
 
The inter-plate CV across the 3 assay plates (using the average fluorescence of 3 aliquots on each 
plate) also increased as the peptide concentration decreased and ranged from 9.87% for 333.33 
nM to 44.07% for 1.37 nM and 95.57% for the 0.46 nM Aα-Val360 standard. 
 
It was therefore determined that working range of the assay should include peptide concentrations 
between 1.37 nM and 333.33 nM (Figure 11). Within this range, the repeatability of the assay 
was deemed acceptable and consistent with the repeatability demonstrated by other assays or 
physiological tests [141, 211]. 
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Figure 11: An example standard curve for the Aα-Val360 assay, including the equation of the curve and its 
correlation coefficient (R
2
). Each point represents the OD (expressed as %B/B0) and known peptide 
concentration (expressed on a logarithmic scale). For comparison, the fluorescence measures for the 3 
further serial dilutions of the peptide standard are included (range 1.37 nM to 333.33 nM).  
 
3.1.2 Assay Repeatability (Plasma from a Single Healthy Control) 
3.1.2.1 Intraplate CV (Plasma) 
 
The concentration of Aα-Val360 was determined using the fluorescent readings from 2, 3 or 4 
aliquots of the same sample on the same plate. The intraplate CV for the plasma sample varied 
depending on the number of aliquots analysed, with CVs of 13.39%, 9.44% and 6.43% using the 
average fluorescence of 2, 3 or 4 aliquots of the plasma standard respectively. However, there 
was little difference in the Aα-Val360 concentration determined using 3 aliquots of a sample on a 
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single plate when compared to the Aα-Val360 concentration determined using the full 12 aliquots 
of the same sample (Table 6). Future Aα-Val360 assays were therefore performed by measuring 
the average fluorescence output of 3 aliquots of the sample on the same plate, since this offered 
both acceptable repeatability and economic sample use. 
   
Number of aliquots 
Averaged 
Concentration of Aα-Val360 (nM) Variation from Aα-Val360 calculated 
using 12 aliquots (%) 
2 5.92 13.15 
3 7.26 6.63 
4 7.14 4.90 
5 6.38 6.37 
6 7.27 6.75 
8 7.27 6.78 
9 7.23 6.17 
10 6.91 1.43 
11 6.66 2.26 
12 6.81 0 
Table 6 The Aα-Val360 concentration was interpolated from the standard curve using the mean 
fluorescence output of a progressively greater number of aliquots of the plasma sample (selected at 
random) and the percentage variation from the measurement derived using the mean of 12 aliquots was 
calculated. 
 
3.1.2.2 Interplate Repeatability (Plasma from a Single Healthy Control) 
 
The Aα-Val360 concentration in the plasma from the single healthy control was measured using a 
total of 9 plates. Based on the data of the intraplate CV of the Aα-Val360 assay (section 3.1.2.1), 3 
aliquots of sample were used per plate. The mean concentration of Aα-Val360 in the standard 
plasma sample measured in the 9 individual plates was 10.11 nM, with an interplate CV of 
35.07%. The interplate CV was reduced to 23.59% by averaging the measurements of Aα-Val360 
from 3 plates, however using the average of 2 plates did not influence the CV (35.02%).  
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3.1.3  Interplate CVs (Plasma from PiM Subjects with COPD) 
 
The 8 patients with COPD (7 males and one female) included in this section of the study were 
recruited consecutively at a single specialist COPD clinic. Spirometry was available from 7 
subjects (all male) as one subject was unable to produce consistent results (Table 7). The Aα-
Val
360
 concentration was measured following the standard operating procedure in a single sample 
obtained from each individual and the concentration was derived from the average result of 3 
plates. This was repeated on 2 further occasions (i.e. 9 plates in total) and the mean, standard 
deviation and interplate CV was calculated between these 3 results for each individual. When the 
average result from 3 plates was used to calculate the Aα-Val360 concentration, the mean 
interplate CV was 22.37% which is consistent with results from the healthy controls.  
 
There was a negative correlation between the Aα-Val360 and the absolute FEV1 values although 
this did not reach statistical significance in this relatively small group (r=-0.414; p=0.178; Figure 
12) and there was no relationship with FEV1 expressed as % predicted. 
 
Subject 
number 
Mean Aα-Val360 
concentration nM (SD) 
FEV1 (L) FEV1 (% 
predicted) 
Age (yrs) 
1 5.12 (1.44) 1.42 82 84 
2 2.85 (0.83) 0.61 23 68 
3 5.00 (0.73) NA NA 71 
4 3.00 (0.23) 1.72 50 50 
5 4.60 (0.87) 1.04 56 86 
6 2.46 (0.61) 1.12 26 47 
7 4.25 (1.41) 1.11 45 79 
8 8.87 (2.00) 0.59 23 69 
Table 7: The mean Aα-Val360 concentration, FEV1 and age of the 8 PiM subjects with COPD. 
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Figure 12: The relationship between the plasma Aα-Val360 concentration and the FEV1 in the 7 subjects 
with COPD for whom data were available (r=-0.414, p=0.178).  
 
 
 
3.1.4 Serum versus Plasma 
 
The repeatability and accuracy of the assay in serum compared to plasma was assessed using 
samples obtained from 6 subjects (4 PiZ A1AT deficient and 2 healthy PiM control subjects). 
The plasma and serum from a subject was analysed on the same plate to minimise variability. The 
intraplate CV for the plasma samples was similar to that obtained in earlier experiments (8.59%). 
However, the intraplate CV for Aα-Val360 within serum was consistently higher than plasma 
while the detected concentration was lower. Similar differences were observed between plasma 
and serum samples from both PiZ and PiM patients (Table 8). 
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Subject 
number 
Mean Plasma 
concentration (nM) 
Mean Serum 
concentration  
(nM) 
Serum standard 
deviation 
Serum 
Intraplate CV 
A1AT 
phenotype 
1 12.11 3.46 0.57 16.33 PiZ 
2 10.21 2.77 0.72 26.13 PiZ 
3 12.41 4.25 0.77 18.22 PiZ 
4 7.88 5.09 1.20 23.59 PiZ 
5 1.96 0.36 0.13 36.29 PiM  
6 2.17 0.11 0.04 31.61 PiM  
Table 8  The Aα-Val360 concentration was measured in both plasma and serum obtained from 6 subjects (4 
PiZ and 2 PiM healthy control subjects). Serum and plasma samples from each individual were analysed 
in 9 aliquots in the same assay run and the mean Aα-Val360 concentration, standard deviation and CV 
were calculated. There was a significant reduction in the Aα-Val360 concentration detected in serum 
compared to plasma (p=0.013). The results obtained for each individual in a single assay run are shown 
in the table, however, similar results were obtained when the samples were reanalysed in 2 further runs. 
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3.2 PILOT STUDIES: AΑ-VAL360 IN HEALTHY AND A1AT DEFICIENT 
SUBJECTS RESULTS. 
 
These data have been published in a high impact factor peer reviewed journal (Carter RI, 
et al. The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase 
activity in vivo. Thorax 2011; 66: 686 – 91).  
 
Following neutrophil stimulation with calcium ionophore, the production of both Aα-Val360 and 
A1AT/NE complex was both time and ionophore concentration dependent, with the maximal 
formation of Aα-Val360 occurring within 15 minutes [214]. The LDH concentration within the 
sample did not increase, which suggests NE was released by degranulation of the azurophil 
granule rather than neutrophil death. The data also demonstrate that Aα-Val360 is generated in the 
presence of high concentrations of the plasma NE inhibitors A1AT and α2-macroglobulin, which 
supports the premise that Aα-Val360 could also be generated within the target tissue. 
 
Aα-Val360 was detected at a range of 3.5 to 18.9 nM in (non-stimulated) plasma samples from 
both healthy controls and PiZ subjects, however there was no relationship to the numbers of 
circulating neutrophils in either population. This suggests that Aα-Val360 is not generated within 
the blood sample following collection and also that the generation of Aα-Val360 reflects the 
amount of neutrophil degranulation rather than neutrophil numbers (at least in subjects who are in 
the stable state). The hypothesised relationship to neutrophil degranulation was further supported 
by the increase in Aα-Val360 following the addition of calcium ionophore. This rise was 
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accompanied by increases in both MPO and calprotectin, which are both markers of neutrophil 
degranulation (Table 9).  
 
 
 
 
 
Aα-Val360 (nM) MPO (nM) Calprotectin (nM) 
 Basal Stimulated 
p (basal vs. 
stimulated) 
Basal Stimulated 
p (basal vs. 
stimulated) 
Basal Stimulated 
p (basal vs. 
stimulated) 
Normal 
(n=12) 
3.64 
(0.38) 
76.51 
(6.03) 
1.02x10-7 
15.57 
(2.41) 
321.05 
(34.95) 
2.67x10-6 
69.92 
(13.94) 
261.63 
(29.42) 
3.32x10-4 
PiZ 
(n=15) 
9.46 
(1.06) 
157.43 
(20.60) 
1.98x10-5 
20.16 
(2.77) 
291.40 
(17.32) 
1.19x10-7 
70.04 
(18.28) 
287.05 
(80.33) 
0.016 
          
 
Table 9: The table shows the mean (SE) concentrations of Aα-Val360, myeloperoxidase (MPO) and 
calprotectin measured in samples (stimulated and unstimulated) obtained from normal healthy individuals 
and PiZ A1AT deficient subjects. 
 
 
 
In the 2
nd
 part of the pilot study, which included 40 PiZ individuals and 24 healthy controls, the 
Aα-Val360 related to the concentrations of calprotectin, MPO and A1AT/NE complex. The Aα-
Val
360 
concentration was also significantly greater (p<0.001) in plasma from subjects with A1AT 
deficiency with a mean of 9.28 nM (SE 0.61) compared to healthy controls with a mean of 3.16 
(SE 0.25). Importantly, the A1AT/NE complex concentration did not vary between PiZ subjects 
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with a mean of 11.57 μM (SE 1.40) compared to healthy controls with a mean of 13.05 (SE 1.96), 
although there was a slightly greater (p=0.042) concentration of MPO with a mean of 21.12 (SE 
1.94) and 15.62 (SE 2.05) respectively. The absence of a significant difference in A1AT/NE 
complex between PiZ patients and healthy controls, despite the significant difference in Aα-
Val
360
, suggests that there is greater pre-inhibition NE activity in PiZ subjects without an increase 
in total NE release. The differing relationships between Aα-Val360 and A1AT/NE complex 
concentrations are demonstrated in Figure 13 and would be consistent with the process of 
quantum proteolysis described by Campbell et al [52-54]. 
 
 
 
 
 
Aα-Val360 vs. 
A1AT/NE Complex 
Aα-Val360 vs. 
MPO 
Aα-Val360 vs. 
Calprotectin 
Normal 
(n=24) 
 
r=0.414 
p=0.045 
 
r=0.694 
p= 1.66x10-4 
r=0.535 
p=0.007 
PiZ 
(n=40) 
 
r=0.644 
p= 7.25x10-6 
 
r=0.762 
p= 1.11x10-8 
r=0.492 
p=0.001 
    
 
Table 10: The table shows the Spearman correlation coefficients (r) and significance (p) for A-Val360 
with A1AT/NE complex, myeloperoxidase (MPO), and Calprotectin (CP) for subjects with and without 
A1AT deficiency. 
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Figure 13: The Aα-Val360 concentration is greater in PiZ subjects (open circles) than PiM healthy controls 
(crosses) despite similar levels of total NE release (as measured by A1AT/NE complex) [214] 
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3.3 DISCUSSION: ASSAY VALIDATION AND THE PILOT STUDY 
 
Prior to the evaluation of any assay in patient populations it is essential that adequate validation is 
performed which should include assessment of the lower limit of quantification, reproducibility 
and performance in relevant biological fluids [6].There are a number of commercially available 
assays which are widely used to measure inflammatory indices, owing to their simple 
methodologies and reported reproducibility. Although many assays may be described by 
manufacturers to have been ‘validated’, this is usually performed in vitro and few quote the assay 
reproducibility in biological fluids [234]. Analysis of assay variability in biological fluids is 
important since mediator recovery may be influenced by protein binding or the presence of 
proteolytic enzymes. As a new assay, it was therefore important to subject Aα-Val360 to the 
vigorous validation outlined in this thesis. 
 
Aα-Val360 is a unique assay which is based on a specific fibrinogen cleavage product, and 
demonstrates good intraplate and interplate variability. Although the CV of the peptide standard 
increased as the peptide concentration decreased, the CV was deemed acceptable within the 
working range of the assay (1.37 nM to 333.33 nM) and consistent with other assays [211]. The 
intraplate CV was improved by measuring 3 aliquots of the same sample on each plate, however 
measuring greater numbers did not influence the repeatability. Similarly the measurement of Aα-
Val
360 
across 3 plates reduced the interplate variability still further (to around 22%) and this was 
consistent in samples obtained from healthy controls and PiM subjects with COPD. Further 
increases in the number of replicates of sample which were analysed did not influence the 
115 
 
variability and therefore subsequent assays were conducted using 3 aliquots of sample on each 
plate, with an average value taken from 3 plates. The total sample required for this analysis was 
450 μL.  
 
3.3.1 Plasma versus Serum  
 
Lower concentrations of Aα-Val360 were detected in serum samples compared with plasma 
samples obtained from the same individual at the same time point. This difference is likely to be 
explained by clotting since serum is obtained from clotted blood using a clot activator prior to 
centrifugation. During clotting, the Aα chain of fibrinogen is cleaved at Aα-16R-17G by 
thrombin which produces fibrinopeptide A and initiates fibrin assembly [235] and furthermore, a 
number of other proteins (for example factor Xa) interact with fibrinogen, fibrin and/or their 
degradation products [199]. In these circumstances, binding of the Aα-Val360 peptide to the clot is 
likely to occur, and this may ‘hide’ or remove the Aα-Val360 neoepitope and hence reduce 
interaction with the Aα-Val360 antibody in the remaining serum. 
 
3.3.2 Other Published Data 
 
Published data on the Aα-Val360 neoepitope also provide further evidence of the validity of this 
assay [214]. The Aα-Val360 antibody is highly specific and does not recognise peptides lacking 
the C-terminal valine. Furthermore, other proteinases (including plasmin and cathepsins B, H and 
L) do not generate Aα-Val360, although Pr3 produces this neoepitope at 15% of the rate of NE. 
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Also the addition of L233, a specific intracellular NE inhibitor, completely blocked the formation 
of A1AT/NE complex and the generation of Aα-Val360 (even in the presence of the neutrophil 
stimulant calcium ionophore) which further confirms the NE specificity of this assay [214].  
 
3.3.3 Relationship with FEV1 
 
Interestingly, even within the small group of subjects (n=8) with COPD in the initial part of the 
study, there was a negative correlation between the Aα-Val360 and the absolute FEV1 (a widely 
used measure of disease severity in patients with COPD). Although this relationship did not reach 
statistical significance and there was no relationship with FEV1 (% predicted), the sample size 
was small and therefore follow-up in a larger population was warranted and is described in this 
thesis. 
 
3.3.4 Relationship with Other Markers of Neutrophil Degranulation 
 
Data from the pilot study demonstrate a good correlation between Aα-Val360 and MPO and 
calprotectin which are independent markers of neutrophil activation. MPO is stored within the 
azurophil granule and is released at degranulation along with NE, while Calprotectin accounts for 
60% of the protein within the cytosol of neutrophils (although it is also found in monocytes and 
macrophages) and has both bacteriostatic and fungistatic properties [236]. The relationship 
between Aα-Val360, MPO and calprotectin therefore indicates that Aα-Val360 is (at least partly) a 
marker of neutrophil degranulation. 
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3.3.5 Quantum Proteolysis 
 
A marker of neutrophil degranulation provides indirect quantification of the total amount of NE 
likely to have been released, however this is an inadequate indicator of NE activity and hence 
tissue damage prior to NE inactivation. This was shown in elegant mathematical and in vitro 
studies by Campbell et al [52-54] which demonstrated an area of quantum proteolytic damage in 
the immediate vicinity of the neutrophil at degranulation, because NE is released at an 
exceptionally high concentration which exceeds the surrounding inhibitor concentration by 100 
fold. Although the area of proteolytic damage is exponentially greater in subjects who are A1AT 
deficient, this phenomenon also occurs in individuals with a normal A1AT concentration. 
However, in either population when in the stable clinical state, all NE is eventually inhibited 
within the neutrophil microenvironment, (Figure 14) [52-54].  
 
The mathematical and in vitro data of Campbell et al [52-54] are supported by the in vivo data 
from the current study which demonstrated that the Aα-Val360 concentration (and therefore pre-
inhibition NE activity) was higher in subjects who were A1AT deficient than healthy controls, 
despite similar levels of NE release (A1AT/NE complex). The absence of a difference in 
A1AT/NE complex concentrations suggests that subjects with A1AT deficiency who are in the 
stable state do not have an overall increase in either neutrophil activity or degranulation. The 
development of the pathological changes of COPD in subjects with A1AT deficiency therefore 
relates to the greater volume of proteolytic damage around each point of NE release.  
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Figure 14: The figures illustrate time lapse photographs from the in vitro studies by Campbell et al [54]. 
Neutrophils were placed in sera from PiM individuals (a) and PiZ individuals (d) and incubated at 37
o
C 
for 30 minutes on opsonised fluoresceinated fibronectin. Neutrophils remaining on the surface are white 
because of ingested fibronectin fragments (broad arrows). The areas of quantum proteolysis (thin arrows) 
are exponentially larger in the PiZ serum than the PiM serum. Published with permission of JCI 1999; 
104 (3):337-44.  
 
3.4 SUMMARY: ASSAY VALIDATION AND THE PILOT STUDY 
 
These initial data support the robustness of the Aα-Val360 assay which demonstrates an acceptable 
variability both in vitro and in vivo (in plasma from subjects with and without COPD). Although 
there is potentially some minor cross-reactivity with Pr3 mediated cleavage of fibrinogen, the 
assay is otherwise highly NE specific which was supported by the absence of Aα-Val360 
generation by other enzymes or by neutrophils in the presence of a specific NE inhibitor. The 
initial data also suggest a relationship between the Aα-Val360 concentration and markers of 
disease severity (FEV1) which may reflect the disease process but required confirmation in the 
larger studies reported in subsequent chapters of the current thesis.  
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CHAPTER 4.  IN VIVO VARIABILITY 
4.1 THE VARIABILITY STUDY 
 
This study included 8 male and 2 female PiZ A1AT deficient subjects with chronic bronchitis and 
a post-bronchodilator FEV1:FVC<0.7. There were 2 current smokers, 5 ex-smokers and one 
never smoker, while 8 of the subjects were on inhaled steroids (one of whom was also being 
treated with a long-acting antimuscarinic). Other baseline demographic data are listed in Table 
11. No subject experienced an exacerbation or medication change during the study or in the 8 
weeks prior to commencement of the study, and there were no significant changes in symptoms 
on the patients’ diary cards. All subjects were also seen on 11 occasions over an 84 day period 
when stability was confirmed by clinical examination and medication review. 
 
Parameter Mean (SE) 
Age 52.03 (3.86) 
BMI 23.29 (1.69) 
Pack year smoking history 26.91 (5.27) 
FEV1 (litres) 1.24 (0.21) 
FEV1 (% predicted) 36.30 (4.22) 
FEV1/FVC 0.30 (0.04) 
KCO (mmol/min/kPa/L) 0.94 (0.14) 
KCO (% predicted) 56.82 (8.76) 
Table 11: Baseline demographic data for the 10 PiZ subjects included in  
the ‘Variability Study’ 
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4.1.1 Cross-sectional Relationships 
 
The mean biomarker concentrations (and within patient CVs) for each subject over the 11 visits 
are listed in Table 12. The mean Aα-Val360 concentration correlated well with both the baseline 
FEV1 expressed as % predicted (r= -0.662; p=0.019) and the baseline KCO expressed as % 
predicted (r=-0.514, p=0.064). However, there were no cross-sectional relationships between the 
sputum markers and lung function, nor sputum markers and Aα-Val360. There were however 
significant relationships between sputum MPO and both sputum IL-8 (r=0.818, p=0.002) and 
sputum LTB4 (r=0.794, p=0.003). Sputum IL-8 also correlated with sputum LTB4 (r=0.731, 
p=0.008).    
 
Subject Plasma Aα-Val360 (nM) 
Mean (SE/CV) 
Sol MPO (nM) 
Mean (SE/CV) 
Sol IL-8 (nM) 
Mean (SE/CV) 
Sol LTB4 (pg/ml) 
Mean (SE/CV) 
1 11.50 (0.20/5.77) 1.51 (0.14/31.39) 13.58 (1.39/33.93) 29.82 (6.70/74.49) 
2 10.24 (0.53/17.18) 4.18 (0.23/18.06) 28.71 (3.78/43.72) 42.37 (7.40/57.91) 
3 10.10 (0.85/27.77) 1.65 (0.10/20.83) 15.70 (2.10/44.40) 48.27 (13.81/94.87) 
4 14.93 (0.70/15.51) 3.96 (0.89/74.76) 13.60 (1.86/45.23) 76.23 (24.69/107.41) 
5 9.09 (0.21/7.53) 0.28 (0.03/36.84) 0.50 (0.15/97.27) 3.66 (1.21/110.41) 
6 12.76 (0.91/23.56) 0.27 (0.03/39.52) 1.69 (0.31/61.24) 1.94 (0.31/53.48) 
7 19.12 (1.26/21.88) 0.71 (0.03/12.31) 10.21 (1.55/50.32) 34.13 (6.11/59.40) 
8 9.48 (0.16/5.72) 0.53 (0.02/15.74) 10.39 (1.85/59.14) 33.47 (23.09/228.90) 
9 23.15 (0.91/13.01) 0.76 (0.03/11.77) 35.79 (3.47/32.14) 67.92 (16.01/78.15) 
10 17.46 (1.06/20.18) 0.61 (0.05/27/25) 2.59 (0.81/104.23) 22.65 (7.35/107.60) 
Mean 13.78 (1.51/15.81) 1.44 (0.46/28.85) 13.28 (3.62/57.16) 36.05 (7.65/97.26) 
Table 12: The table displays the mean (SE/CV) concentration of the markers by patient over the 11 visits 
of the Variability study. The final row lists the mean marker concentration and SE for all 10 subjects as a 
group. 
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4.1.2 Longitudinal Analysis 
 
The mean CV of 15.81% for the Aα-Val360 assay is consistent with the previously established 
inter- and intraplate variability, and was less than any other marker (Table 13). There were no 
longitudinal relationships between any of the biomarkers studied.  
 
 
Day Plasma Aα-Val360 (nM) 
Mean (SE) 
Sol MPO (nM) 
Mean (SE) 
Sol IL-8 (nM) 
Mean (SE) 
Sol LTB4 (pg/ml) 
Mean (SE) 
1 16.00 (2.27) 1.44 (0.44) 9.31 (3.56) 31.21 (12.37) 
2 14.13 (1.99) 1.32 (0.43) 9.65 (3.03) 20.48 (6.77) 
3 11.43 (1.94) 1.36 (0.45) 14.50 (4.76) 38.34 (13.70) 
4 17.76 (3.81) 1.43 (0.49) 16.03 (5.99) 33.38 (8.24) 
5 13.79 (1.52) 1.59 (0.63) 13.39 (3.49) 47.50 (25.17) 
7 12.44 (1.34) 2.43 (1.19) 15.36 (5.00) 53.04 (29.96) 
14 10.91 (1.54) 1.06 (0.32) 14.89 (4.72) 45.47 (19.02) 
21 12.74 (1.28) 1.40 (0.43) 11.28 (3.19) 34.70 (11.19) 
28 17.08 (1.71) 1.43 (0.45) 12.20 (2.62) 36.08 (10.77) 
56 16.82 (3.09) 1.30 (0.34) 17.35 (4.79) 31.89 (8.68) 
84 16.50 (3.45) 1.20 (0.31) 12.06 (3.04) 24.44 (7.30) 
CV 15.81% (2.44) 28.85% (5.97) 57.16% (7.85) 97.26% (16.15) 
Table 13: The mean biomarker concentrations are listed by day of the study and include average data for 
all 10 subjects. The final row lists the mean (SE) CV for each marker (the CV was calculated for each 
patient over the 11 visits and then these results were averaged).  
 
 
The study also explored the use of a ‘rolling mean’ which has previously been used as a method 
of reducing the influence of inter-visit variability [141]. The 3 day rolling mean was calculated 
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for each subject by averaging the biomarker
 
concentration for 3 visits, starting with visits one, 2 
and 3 (termed visit 3.1) then visits 2, 3 and 4 (termed visit 3.2) and this process was continued 
until all visits were included. A similar process was conducted using a 5 day rolling mean 
(termed visit 5.1 onwards). Analysis was also performed of a 3 day mean in which there was no 
overlap of data (i.e. the mean biomarker concentration was calculated for visits one, 2 and 3, then 
4, 5 and 6 etc until all visits were included). Analysis of the rolling mean data demonstrated a 
reduction in the mean CV for Aα-Val360 (Table 14 and Figure 15), however greater reductions 
were seen in the CVs for the sputum markers using this technique where greater variability of a 
single sample may be expected [141]. 
 
 
 
Method Aα-Val360 mean CV 
(SE) 
MPO mean CV (SE) IL-8 mean CV (SE) LTB4 mean CV (SE) 
Raw 15.81 (2.45) 28.85 (5.97) 57.16 (7.85) 97.26 (16.16) 
3 day rolling 14.44 (2.18) 15.80 (3.30) 28.12 (3.06) 48.16 (7.58) 
5 day rolling 8.62 (1.48) 9.20 (1.92) 17.01 (1.65) 32.32 (4.12) 
3 day non-
overlapping 
12.04 (1.91) 18.99 (4.49) 29.56 (4.21) 55.61 (8.46) 
Table 14. The table includes the mean (SE) CV data for each marker as raw data, as a 3 day rolling mean, 
5 day rolling mean and 3 day non-overlapping mean. The CV for each marker was reduced by the average 
biomarker concentration from samples obtained over 3 or 5 days, rather than on one occasion. 
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Figure 15A, each point represents the mean Aα-Val360 for the 10 PiZ A1AT deficient patients at each visit. 
In B, each point represents the rolling mean of 3 visits (3.1 represents the mean of visits 1,2 and 3; 3.2 
represents the mean of visits 2,3 and 4 etc). The mean CV was reduced to 14.44 (SE 2.18). In C, each 
point represents the rolling mean of 5 visits which reduced the mean CV to 8.62 (SE 1.48) 
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4.2 VARIABILITY OF AA-VAL360 OVER 3 CONSECUTIVE ANNUAL 
MEASUREMENTS 
 
The study included 40 PiZ A1AT deficient subjects who were selected at random from the 
ADAPT UK registry. Their demographic data is described in Table 15. There was no significant 
difference in the Aα-Val360 concentrations over the 2 year period (p=0.554, Friedman’s test) 
demonstrating the stability of this marker (Figure 16). The data for each individual is also shown 
(Figure 17). 
 Mean (SE) 
Age 52.48 (1.55) 
FEV1 (litres) 2.23 (0.25) 
FEV1 (% predicted) 70.13 (7.09) 
FEV1/FVC 0.50 (0.04) 
KCO (mmol/min/kPa/L) 1.13 (0.05) 
KCO (% predicted) 71.00 (2.77) 
Mean Aα-Val360 (nM) at 1st visit 15.01 (1.53) 
Table 15 Demographic data for subjects included in the 2 year variability study 
 
 
Figure 16: The mean (SE) Aα-Val360 concentrations for plasma obtained from 40 PiZ individuals at 3 
consecutive annual visits demonstrating the stability of this marker of disease activity (p=0.554, 
Friedman’s test).  
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Figure 17A and B show the 1
st
 20 subjects and 2
nd
 20 subjects respectively who were included in the 2 
year variability study, with each line representing a single subject. The CV of 17.13% (mean of all 
subjects) is within the range expected for the intra-plate variability of the assay which is approximately 12 
to 15%.    
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4.3 THE EXACERBATION STUDY  
 
The study include 6 male and 2 female PiZ A1AT deficient subjects, all of whom had chronic 
bronchitis and an FEV1/FVC<0.7. Their demographic details are listed in Table 16. 
 Mean (SE) 
Age 49.77 (3.18) 
FEV1 (litres) 1.41 (0.35) 
FEV1 (% predicted) 41.01 (8.35) 
FEV1/FVC 0.41 (0.07) 
KCO (mmol/min/kPa/L) 1.07 (0.20) 
KCO (% predicted) 66.02 (11.68) 
Table 16: Demographic data for the 8 PiZ A1AT deficient subjects  
included in the ‘exacerbation study’ 
 
Following their initial presentation with an exacerbation, there was an improvement in the self-
reported symptoms of the subjects over the course of the study (as assessed by diary card) which 
was associated with a decrease in the Aα-Val360 concentration (Figure 18A; Table 17). Although 
there was no statistically significant difference in the Aα-Val360 concentrations on the 1st day of 
presentation with the exacerbation (‘day 1’) when compared with day 28 (p=0.164), there was 
variation between individuals, with some demonstrating a large increase in Aα-Val360 compared 
to the stable state (n=5), while others did not demonstrate any rise (n=3).  
 
In this group of individuals with chronic bronchitis who were experiencing an exacerbation, it 
was also possible to measure sputum sol NE and this related to their plasma Aα-Val360 
concentrations (Figure 18B). Again, there was no significant difference in the sputum NE 
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concentration on day one versus day 28 (p=0.173) (Figure 18). However, the sputum sol NE 
concentrations were low in the stable state (day 28), and only above the lower limit of 
quantification in 3 of the 8 subjects and therefore the stable state NE data should be interpreted 
with caution. 
 
Day 1 2 3 5 7 14 28 
Mean Aα-Val360 nM 
(SE) 
20.61 
(6.16) 
17.56 
(3.95) 
18.40 
(5.67) 
14.58 
(2.36) 
14.38 
(2.12) 
13.83 
(1.75) 
14.78 
(2.09) 
Mean CRP (mg/L) 
(SE) 
22.47 
(14.46) 
33.63 
(25.97) 
13.20 
(7.69) 
5.26 
(2.58) 
6.20 
(2.87) 
5.45 
(3.11) 
3.79 
(1.82) 
Mean NE (nM) 
(SE) 
51.67 
(28.00) 
16.33 
(5.53) 
15.97 
(3.66) 
8.70 
(2.81) 
10.22 
(3.48) 
9.94 
(3.25) 
10.59 
(3.43) 
Table 17: The mean (SE) biomarker concentrations for the 8 subjects who took part in the exacerbation 
study. All subjects completed a 14 day course of antibiotics. 
 
The mean Aα-Val360 concentrations correlated highly with the plasma CRP concentrations 
(Figure 19), and a significant correlation also existed between the plasma CRP concentration and 
the sputum sol phase NE concentration (r=0.714, p=0.036). The plasma CRP concentration was 
significantly greater on day one of the exacerbation compared to day 28 (p=0.043), however 3 
individuals did not demonstrate any change (of whom 2 also did not have an increase in Aα-
Val
360
). Two individuals demonstrated persistently low CRP values throughout the study period 
and also had little variance in their Aα-Val360 concentrations.  
 
For each individual, the CVs were calculated over the 7 days of the study period. There was a 
significant correlation (r=0.683, p=0.031) between the CVs for CRP and Aα-Val360, 
demonstrating the longitudinal variation of these biomarker is similar within each subject. 
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Figure 18: A: The figure depicts the mean Aα-Val360 and sputum sol phase NE concentrations for each day 
of the exacerbation study. Although the Aα-Val360 was higher on day one of an exacerbation, this did not 
reach statistical significance compared to day 28 when patients had returned to the clinically stable state. 
B Each point represents the mean plasma Aα-Val360and sputum NE concentrations at for a single day of 
the study. There was a significant correlation between the plasma Aα-Val360 and sputum sol phase NE 
concentrations. 
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Figure 19. Each point on this figure represents the mean plasma Aa-Val
360
 and CRP concentrations for a 
single day of the exacerbation study (n=8). The correlation coefficient (r) and the p-value are shown. 
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4.4 IN VIVO VARIABILITY: DISCUSSION 
4.4.1 Aα-Val360 in the Stable State 
4.4.1.1 Selection of Sputum Markers 
 
A number of inflammatory mediators are raised in the sputum of patients with COPD, 
particularly during exacerbations, although few have been fully validated or monitored in 
longitudinal studies. Sputum IL-8 was measured in the current study, as it is increased in subjects 
with COPD and relates to FEV1/FVC in cross-sectional studies [143] and progression of 
emphysema measured by lung densitometry (but not lung function) in longitudinal studies [21]. 
Also other markers of neutrophilic inflammation including sputum MPO and LTB4 have been 
shown to correlate with FEV1 and TLCO decline respectively [21].   
 
4.4.1.2 Variability of Aα-Val360 and Sputum Biomarkers 
 
In this study which only included clinically stable patients, there were strong cross-sectional 
relationships between the mean Aα-Val360 concentration and baseline markers of physiological 
disease severity of COPD, which is an important feature of any potential biomarker of disease 
activity. Additionally, stability is an important characteristic of an ideal biomarker of disease 
activity since this allows clinically useful measurements to be taken at any time, and the 
Variability Study showed that within patient variation was low, at least when in the clinically 
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stable state. Further evidence of the stability and repeatability of the Aα-Val360 marker was 
provided by data over a 2 year period in 40 PiZ A1AT deficient individuals.  
 
The assay variability is likely to be the main explanation for the observed variation in values of 
the Aα-Val360 assay. However, the variability of Aα-Val360 remained within acceptable limits, 
was much lower than any of the sputum markers and is consistent with the previously reported 
variability of a number of other plasma biomarkers [211]. These data therefore add further 
support for the use of a plasma marker (such as Aα-Val360) rather than a sputum marker, since 
plasma is less influenced by changes in water content, which can result in major changes in 
marker concentrations within the airways, or the sample collection process.  
 
Although changes in the water content of airway secretions may partly account for the variability 
of the spontaneous sputum markers, this cannot be the only explanation since it would be 
expected that dilutional changes would affect all markers equally at the same time point. This 
would be demonstrated by correlations in the longitudinal variability between the sputum 
biomarkers, however this was not observed in the current study. It is thus possible that the 
variability in the sputum markers related to changes in the underlying disease activity or 
processes within individuals, although again, the absence of correlations in the longitudinal 
variability would not support the hypothesis that this reflects the central pathophysiological 
process. Importantly, all subjects were carefully reviewed at each visit to ensure that they had not 
developed new symptoms or started taking new medications and this was reinforced by the use of 
daily diary cards, suggesting that clinical features of changes in disease activity did not account 
for the variability of the sputum markers. Finally, oropharyngeal contamination may contribute to 
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the intra-patient variability of the sputum markers, despite the use of mouth rinsing in the current 
study to minimise this influence, although again this would be expected to affect all mediators 
equally and hence result in significant longitudinal correlations of these biomarkers. 
 
4.4.1.3 Cross-sectional Relationships 
 
Interestingly, in the current study there were cross-sectional relationships between the sputum 
biomarkers but not to either the Aα-Val360 concentration or the physiological markers such as 
FEV1. Although this may be partly explained by the variability of the sputum biomarkers, the 
mean biomarker concentrations for all 11 visits were used in these calculations (rather than the 
values for individual visits) which would have minimised the influence of collection variability. 
However, since the study involved relatively small numbers of individuals, and demonstrated 
marked variability of sputum measures, the study is likely to be underpowered to completely 
exclude any associations between sputum markers and other parameters such as physiology and 
Aα-Val360. 
 
4.4.1.4 Rolling Mean Data 
 
This study demonstrated that the use of 3 or 5 day average data reduced the intra-patient 
variability of all the biomarkers studied, including Aα-Val360, although it had the greatest 
influence on the sputum markers. This difference is almost certainly related to the greater 
underlying variability of the absolute values of the sputum biomarkers demonstrated in the 
133 
 
current study. Although the improvement may be partly accounted by the use of overlapping data 
(which will always be associated with a reduction in variability), there was a similar reduction in 
variability observed with the non-overlapping data suggesting that this is a true effect rather than 
an artefact of the methodology.   
 
The relatively small improvement in Aα-Val360 repeatability when the average is calculated from 
3 samples over 3 days, as opposed to using the absolute values, further demonstrates the stability 
of this marker within the variability of the assay measurement. The greater repeatability offered 
by the 5 day rolling mean data may be of particular use in interventional clinical trials where a 
high sensitivity for the detection of change is critical. However, this would usually be 
unnecessary under most circumstances as the advantages associated with less variability would 
usually be offset by the logistical difficulties of obtaining samples over a prolonged period and 
the expected change with time during an interventional study.  
 
4.4.2 Aα-Val360 in Subjects Experiencing an Acute Exacerbation 
 
The Aα-Val360 concentration was generally higher on the 1st day of an acute exacerbation and 
decreased overall as symptomatic improvement occurred (as recorded in the patient diary cards). 
It is recognised that at least some exacerbations are associated with an excess of neutrophilic 
activity [230] and patients with a greater number of exacerbations decline at a greater rate [118]. 
Thus the Aα-Val360 data reported here demonstrate that exacerbations are also associated with an 
increase in NE associated disease activity.  
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The Aα-Val360 did not increase in all study subjects which may be partly explained by the diverse 
nature of acute exacerbations of COPD and the absence of a universally accepted definition. The 
inclusion criteria for the current study required subjects to have experienced an increase in all 
three of the symptoms of sputum purulence, sputum volume and breathlessness, which is 
consistent with the definition of the widely referenced ‘type I exacerbation’ devised by 
Anthonisen et al [231]. Anthonisen also suggested the terms type II exacerbation (to include 2 of 
the type I symptoms) and type III exacerbation (to include one of the type I symptoms plus one or 
more of: an upper respiratory tract infection in the last 5 days, fever without other cause, 
increased wheezing or cough, or an increase in heart rate or respiratory rate by 20% compared to 
baseline). The use of ‘type I’ criteria in the current study aimed to ensure the inclusion of patients 
with a similar clinical phenotype. However, and despite the use of diary cards, these terms 
(particularly increase in breathlessness) are still open to subjective interpretation, and furthermore 
will encompass a wide range of severities. An exacerbation may therefore be associated with an 
impact which is slightly greater than the nature of symptoms experienced during normal day-to-
day variation, and it would be interesting to determine whether ‘mild’ clinical exacerbations are 
similarly associated with ‘mild’ inflammatory and neutrophilic response. 
 
4.4.2.1 Relationships with other Biomarkers 
 
The current study still demonstrated a highly significant relationship between the CRP and Aα-
Val
360 
concentrations. Furthermore, the longitudinal variation in both inflammatory mediators 
was similar over the course of the Variability Study. The CRP (although non-specific) is the most 
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sensitive marker of acute exacerbations of COPD (when ranked against 35 other biomarkers) 
[177], and in the current study a significant difference was demonstrated between CRP on day 
one of the onset of the exacerbation and day 28.  
 
The data demonstrated that 3 individuals did not have an increased CRP on the 1
st
 day of the 
study, of whom 2 also did not generate an increase in Aα-Val360. It is difficult to comment on the 
relative sensitivity of the CRP compared to the Aα-Val360 for detecting acute exacerbations, since 
relatively few subjects were included in the current study. It is however interesting that some 
subjects experience an exacerbation without a significant rise in any marker despite clinically 
equivalent symptoms and this indicates key issues in the use of biomarkers to define 
exacerbations in subjects with COPD or potentially as markers of severity. Importantly, it raises 
the question of whether diseases (and their exacerbations) should be defined by their clinical 
features or whether this will be surmounted by the use of blood tests alone. 
 
There was a relationship between sputum NE concentrations and both the plasma Aα-Val360 and 
CRP. While this is important, since it shows the plasma biomarkers relate to active inflammation 
within the airways, sputum NE would be an impractical marker of disease activity in clinical 
practice since it is present at the limit of quantification in the sputum of subjects in the stable 
state (even in subjects who produce sputum) [71].   
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4.5 SUMMARY 
 
The data from these studies demonstrate that Aα-Val360 is a stable footprint of pre-inhibition NE 
activity in subjects who are not experiencing an acute exacerbation. The low level variability 
which has been demonstrated in the current studies is almost certainly accounted for by the 
variability of the assay itself, rather than reflecting true changes in the concentration of this 
biomarker or in the underlying disease activity. In these same subjects, Aα-Val360 also generally 
related to physiological markers of disease severity but not sputum inflammatory markers, which 
may be accounted for by the high variability of the sputum markers or the anatomical relationship 
to the samples collected and the site of disease activity (e.g. airway or lung parenchyma). 
 
Aα-Val360 was higher at the onset of an acute exacerbation, and related to both sputum NE and 
plasma CRP concentrations. This demonstrates that exacerbations characterised by all 3 of the 
Anthonisen criteria are associated with an increase in disease activity which is consistent with the 
observation that subjects with these exacerbations decline more rapidly [118]. The data also 
suggest a potential role for biomarkers to both diagnose exacerbations and classify their severity 
and hence guide treatment.  
 
The relationship of Aα-Val360 with acute exacerbations will be discussed further in Chapter 7. 
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CHAPTER 5.  AA-VAL360 IN SUBJECTS WITH 
SYMPTOMS OF COPD UNRELATED TO A1AT 
DEFICIENCY: RESULTS AND DISCUSSION 
 
These data have been accepted for publication by a high impact factor peer reviewed 
journal (Carter RI, et al. Aα-Val360: A Marker Of Neutrophil Elastase And COPD Disease 
Activity. Manuscript published online ahead of print by the ERJ, April 2012).  
 
5.1 RESULTS 
5.1.1 Initial Stable State Assessment 
 
Eighty one subjects (36 female and 45 male) with chronic bronchitis and exertional dyspnoea but 
a broad range of spirometric disease severity (Table 18) were included in the study. Of these 
patients, 58 had spirometric criteria consistent with COPD as defined by current guidelines (with 
an FEV1/FVC<LLN), while 61 subjects had an FEV1/FVC<0.7 and therefore met the alternate 
spirometric threshold for COPD. 
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Parameter 
 
Mean (SE)  
   
Age (years)   65.75  (0.92)  
Height (metres)   1.64  (0.01)  
    
FEV1 (L)   1.79  (0.08) 
 
 
 
FEV1 (% predicted)   73.28 (2.86)  
FEV1 (SR)   -1.44  (0.16)  
    
FEV1/FVC  0.55  (0.02)  
FEV1/FVC (% predicted)  72.27 (2.35)  
FEV1/FVC (SR)  -3.01  (0.25)  
    
Residual Volume (L)  2.20  (0.04) 
 
 
RV (% predicted)  126.20 (3.78)  
RV (SR)  1.52  (0.22)  
    
TLC (L)  6.03  (0.15)  
TLC (% predicted)  107.24 (1.66)  
TLC (SR)  0.60  (0.14)  
    
KCO (mmol/min/kPa/L)   1.41  (0.48)  
KCO (% predicted)   96.69 (3.21)  
KCO (SR)   -0.28  (0.20) 
 
 
 
    
Plasma Aα-Val360 (nM)  24.39 (2.20) 
 
 
Plasma A1AT/NE Complex (nM)  2.63 (0.18)  
Plasma hsCRP (mg/L)  730.60 (146.67)  
    
Sputum MPO (nM)  0.82 (0.17)  
Sputum LTB4 (pg/ml)  9.41 (2.22)  
Sputum IL-8 (nM)  6.79 (1.04)  
    
Table 18: Aα-Val360 was measured in 81 stable state subjects with symptoms of COPD and their baseline 
demographic and lung function data (performed on the same day as the plasma sample was obtained) are 
displayed. Plasma samples refer to stable state results at baseline. Sputum results refer to the 55 subjects 
able to produce spontaneous sputum in the stable state at baseline. Data represent the group mean (SE). 
 
The stable state plasma Aα-Val360 concentration related to baseline FEV1 (% predicted) (r=-
0.340; p=0.001) and KCO (% predicted) (-0.246; p=0.013). Multivariate analysis accounting for 
age, sex, smoking history, height and sputum colour demonstrated that the stable state Aα-Val360 
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was an independent predictor of KCO (standardised B co-efficient=-0.243, R
2
 change=0.048, 
p=0.037) however the independent relationship with FEV1 fell short of conventional levels of 
significance (standardised B co-efficient=-0.231, R
2
 change=0.037, p=0.070). Importantly, in 
subjects with an FEV1/FVC below the normal range, similar relationships were also observed 
between Aα-Val360 and KCO (% predicted) (r=-0.214; p=0.054) and FEV1 (% predicted) (r=-
0.297; p=0.013). 
 
In the full cohort, plasma Aα-Val360 showed a reasonable correlation with plasma A1AT/NE 
complex in the stable state (r=0.459, p<0.001; Figure 20). Also, the A1AT/NE complex did not 
relate to either FEV1 % predicted (r=-0.087, p=0.451) or KCO % predicted (r=-0.172, p=0.126). 
Furthermore, the Aα-Val360 was significantly higher (p<0.001) in subjects with chronic bronchitis 
and dyspnoea (n=80) with a median Aα-Val360 value of 20.76 nM (IQR 13.99 – 25.44) than 
healthy controls (n=39) with a median value of 3.50 nM (IQR 2.35 – 5.14).  
 
There was no relationship of Aα-Val360 with high sensitivity CRP (r=0.004, p=0.361), a non-
specific measure of inflammation. The hsCRP did not relate to FEV1 % predicted (r=0.111, 
p=0.165) but there was a positive correlation with KCO % predicted (r=0.235, p=0.036). 
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Figure 20: The Aα-Val360concentration (a marker of NE activity) related to the A1AT/NE complex 
concentration (a marker of total NE release). The correlation co-efficient (r) and p value are shown. All 
samples were obtained from subjects when in the clinically stable state. 
 
5.1.2 Aα-Val360 in Subjects With and Without Visible Emphysema on HRCT 
 
In the overall group, the plasma Aα-Val360 concentration was greater (p=0.013) in those with 
visible emphysema on HRCT (n=43) compared to those without (n=38). Also, subjects with 
visible emphysema had a significantly lower FEV1 (% predicted; p=0.014), FEV1/FVC  
(p<0.001) and KCO (% predicted; p<0.001) than those without (Table 19). However, there was 
no difference in the plasma CRP or A1AT/NE complex or sputum MPO, LTB4 and IL-8 (in the 
141 
 
55 subjects able to produce a spontaneous sputum sample for the stable state assessment) 
between those with and without emphysema.  
 
Subset of Patients Parameter No visible emphysema on 
HRCT 
Visible emphysema on 
HRCT 
P 
All Aα-Val360 (nM) 16.98 (IQR 13.15 to 22.29) 21.77 (IQR 15.58 – 27.13) 0.013 
FEV1 (% predicted) 79.75 (±4.12) 67.27 (±3.80) 0.014 
FEV1/FVC  0.62 (±0.03) 0.48 (±0.14) <0.001 
KCO (% predicted) 114.76 (± 3.55) 80.71 (±3.76) <0.001 
 
Subjects with an 
FEV1 and 
FEV1/FVC within 
normal range 
(>LLN) 
 
Aα-Val360 (nM) 
 
13.98 (IQR 12.31 to 21.00) 
 
22.88 (IQR 14.09 to 42.17) 
 
0.071 
FEV1 (% predicted) 100.77 (2.98) 100.61 (2.38) 0.488 
FEV1/FVC  0.77 (0.01) 0.70 (0.02) 0.003 
KCO (% predicted) 114.88 (5.09) 93.83 (10.43) 0.030 
 
Subjects with an 
FEV1/FVC below 
the normal range 
 
Aα-Val360 (nM) 
 
17.96 (15.26 – 24.13) 
 
21.77 (16.12 – 27.13) 
 
0.141 
FEV1 (% predicted) 62.73 (4.31) 61.56 (3.63) 0.420 
FEV1/FVC  0.50 (0.02) 0.45 (0.02) 0.06 
KCO (% predicted) 114.67 (5.04) 78.59 (3.98) <0.001 
Table 19: Data are shown for all subjects, for subjects with an FEV1 and FEV1/FVC within the normal 
range (>LLN) and for subjects with an FEV1/FVC below the normal range (<LLN). Mean and standard 
error or median and interquartile range are shown for normally distributed and non-parametric data 
respectively. In the whole cohort, subjects with visible emphysema on HRCT had significantly worse lung 
function tests and a greater Aα-Val360. Similar differences were seen in subjects with an FEV1 and 
FEV1/FVC within the normal range and those with an FEV1/FVC below the normal range. 
 
Subgroup analysis was performed for subjects with chronic bronchitis and dyspnoea but an FEV1 
and FEV1/FVC in the normal range as confirmed by SRs (Table 19). This demonstrated that the 
Aα-Val360 was also greater in those with visible emphysema (median 22.88 nM; IQR 14.09 to 
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42.17; n=6) on HRCT compared to those without (13.98; IQR 12.31 to 21.00; n=17), which is 
similar to that seen in the larger cohort but the difference just failed to achieve statistical 
significance in this subgroup (p=0.09). There was no significant difference in the FEV1 (% 
predicted) in those with visible emphysema compared to those without. However, the FEV1/FVC 
was lower in those with emphysema (mean 0.70±0.01) than those without (0.77 ± 0.02 ; 
p=0.003). In addition, the KCO (% predicted) was also lower (Figure 21) in those with visible 
emphysema (93.83±10.43) than those without (114.88±5.09; p=0.030).   
 
 
Figure 21: In subjects with both an FEV1 and FEV1/FVC within the normal range, the KCO (% predicted) 
is significantly lower (p=0.030) in subjects with visible emphysema on CT thorax (open circles) compared 
to those without (closed diamonds), although the KCO  (% predicted) largely remains above 80% (dotted 
line). 
 
Analysis of patients with an FEV1/FVC below the normal range demonstrated that the average 
Aα-Val360 was also greater in those with visible emphysema (n=37) compared to those without 
(n=21), but this difference was not significant (p=0.141). There was no difference in the FEV1 (% 
predicted), or the sputum markers between the 2 groups of patients although the FEV1/FVC 
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(p=0.06) and KCO (% predicted) (p<0.001) were lower in subjects with visible emphysema on 
HRCT (Table 19).  
 
5.1.3 Aα-Val360 During an Acute Exacerbation  
 
Both the Aα-Val360 and hsCRP were higher at presentation with the exacerbation than in the 
stable state even when stratified by sputum colour into visibly purulent or non-purulent episodes 
(Table 20). Furthermore, both the Aα-Val360 and CRP at presentation with the exacerbation were 
significantly greater (p=0.030 and p=0.019 respectively) in subjects who presented with purulent 
sputum compared to those with mucoid sputum. Interestingly, although Aα-Val360 fell in both 
groups following resolution of the exacerbation, the difference between these 2 groups persisted 
(p=0.024; Table 20). In addition, the sputum IL-8 (p<0.001) and plasma A1AT/NE complex 
(p=0.036) were also higher at resolution in those who had experienced an exacerbation associated 
with purulent sputum. However, importantly there was no longer a difference in the plasma 
hsCRP (p=0.573), sputum colour or sputum MPO and LTB4 concentrations in the stable state. In 
the stable state, no correlation was seen between Aα-Val360 and sputum MPO (r=0.059; p=0.337), 
however there remained positive correlations with the key neutrophil chemoattractants: LTB4 
(r=0.227; p=0.048) and especially IL-8 (r=0.486; p<0.001).  
 
There was a weak correlation between the hsCRP and plasma Aα-Val360 at presentation with the 
exacerbation (r=0.225, p=0.054). Interestingly, there was also a correlation between the hsCRP at 
the presentation with the exacerbation and both the stable state Aα-Val360(r=0.234, p=0.047) and 
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hsCRP (r=0.211, p=0.038).  However, the hsCRP at exacerbation onset did not correlate with 
either the stable state FEV1 or KCO. 
 
 
 Aα-Val360 (nM) 
Exacerbation 
presentation 
Aα-Val360 (nM) 
Stable State 
P 
(Aα-Val360 
Exacerbation 
vs stable state) 
hsCRP (mg/L) 
exacerbation 
presentation 
hsCRP (mg/L) 
stable state 
P 
(hsCRP 
presentation 
vs stable 
state) 
All 23.72  
(18.1 – 35.41) 
21.28 
 (13.99 – 24.65) 
 
0.005 2459.8  
(809.72-7029.20) 
212.24  
(90.34 - 809.05) 
<0.001 
Non-purulent 
sputum group 
21.22  
(17.42 – 27.44) 
20.00 
 (12.83 – 21.69) 
0.022 1246.79 (530.70 - 
5292.33) 
 
234.94 (120.12 - 
902.03) 
 
p=0.003 
 
Purulent 
sputum group 
26.29  
(19.43 – 39.07) 
21.83 
 (14.91 – 28.45) 
0.043 3539.97 (1313.65 
- 8324.34) 
 
198.49 (78.77 - 
752.32) 
 
P<0.001 
 
Table 20: The table demonstrates the significantly higher median hsCRP and Aα-Val360 (IQR) in subjects 
with COPD at presentation with the exacerbation compared to the stable state (in all subjects and in those 
with non-purulent sputum or purulent sputum at the onset of the exacerbation).  
 
5.1.4 Longitudinal Analysis 
 
Forty individuals were alive and consented to assessment with full lung function tests and 
densitometric analysis of HRCT scans at both baseline (stable state) and at follow-up 4 years 
later. Aα-Val360 obtained from subjects at baseline related cross sectionally to both baseline and 
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follow-up physiological and radiological measures (Table 21). However, there was no 
relationship between hsCRP or A1AT/NE complex concentration and any physiological or 
radiological parameter at either baseline or follow-up. Both physiological and radiological 
markers demonstrated disease progression in the 40 subjects (Table 22), however statistical 
significance was not observed for all parameters. The absence of a significant change may at least 
partly be explained by the lack of sensitivity of these physiological and radiological tests for 
detecting disease progression in subjects with COPD and emphysema, and again supports the 
need for new markers of disease severity and activity. 
 
 
 Correlation with Baseline (Stable State) Plasma Aα-Val360 
 Baseline Follow-up 
 R p r p 
FEV1 (% predicted) -0.319 0.022 -0.357 0.012 
KCO (% predicted) -0.401 0.005 -0.403 0.008 
UZVI (-950 HU) 0.416 0.004 0.434 0.003 
LZVI (-950 HU) 0.279 0.041 0.382 0.008 
UZ 15th percentile point (HU) -0.338 0.017 -0.350 0.013 
LZ 15th percentile point (HU) -0.224 0.083 -0.299 0.031 
Table 21: UZ = upper zone; LZ=lower zone; VI=voxel index; HU=Hounsfield Units. In 40 individuals, 
plasma Aα-Val360 was measured at baseline (stable state) and related to physiology and CT densitometry 
performed both at baseline (stable state) and at follow-up 4 years later. The correlations (r) and p values 
are shown for these relationships. Physiological parameters were expressed as % predicted (corrected for 
age, height and sex). 
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Parameter 
Baseline  
Mean (SE) 
4 Year Follow Up  
Mean (SE) 
 
P 
 
Age 
 
64.07 (1.20) 
 
68.36 (1.20) 
 
 
FEV1 (L) 1.93 (0.11) 1.79 (0.11) <0.001 
FEV1 (% predicted) 78.23 (4.16) 75.79 (4.49) 0.071 
FEV1 (SR) -1.24 (0.22) -1.25 (0.23) 0.453 
FEV1/FVC 0.57 (0.03) 0.55 (0.03) 0.005 
FEV1/FVC (SR) -2.84 (3.78) -3.11 (0.36) 0.024 
KCO (mmol/min/kPa/L) 1.42 (0.07) 1.36 (0.08) 0.006 
KCO (% predicted) 95.35 (4.73) 93.14 (5.48) 0.273 
KCO (SR) -0.35 (0.30) -0.55 (0.40) 0.273 
    
UZ 15 PCP -920.34 (5.70) 929.07 (5.03) 0.002 
UZ VI (-950) 9.49 (1.92) 11.59 (2.08) <0.001 
UZ VI (-910) 24.70 (2.85) 27.44 (2.69) 0.004 
LZ 15 PCP -907.51 (5.44) -913.05 (4.75) 0.021 
LZ VI (-950) 7.96 (1.21) 9.53 (1.36) <0.001 
LZ VI (-910) 22.96 (2.63) 25.73 (2.58) 0.007 
    
Aα-Val360 (nM) 25.73 (4.32) N/A N/A 
A1AT/NE Complex (nM) 2.37 (0.24) N/A N/A 
Table 22: The baseline and follow up data for 40 subjects (19 female and 21 male). 
 
There was a significant decrease in the FEV1 (p<0.001) and KCO (p<0.001) over the 4 year 
period. There was also significant emphysema progression as measured by absolute change in the 
voxel index (-950 HU) and 15
th
 percentile point in both the upper (p<0.001 and p=0.002 
respectively) and lower (p<0.001 and p=0.021) zones. The baseline Aα-Val360 related to both the 
subsequent decline in KCO (% predicted) (r=-0.406, p=0.008) and progression in lower zone 
emphysema expressed as change in the voxel index at -950 HU (r=0.306, p=0.027), however the 
relationship of the baseline Aα-Val360 with change in the lower zone 15th percentile point did not 
achieve statistical significance (r=-0.212, p=0.095). There was no significant association between 
Aα-Val360 and decline in FEV1 (% predicted) (r=-0.196, p=0.113), upper zone voxel index 
(r=0.103, p=0.264) or 15
th
 percentile point (r=-0.049, p=0.381). There was no relationship 
between the A1AT/NE complex and any measure of decline. Receiver operating characteristic 
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analysis of Aα-Val360 in subjects who demonstrated a decline in KCO (% predicted) over the 4 
year period compared to non-decliners gave an area under the curve of 0.711 (p=0.037). An Aα-
Val
360 
threshold of 11 would have a sensitivity and specificity of 91% and 43% respectively for 
the identification of subjects who will demonstrate a decline in KCO (% predicted) over a 4 year 
period, while a threshold of 22 would have a sensitivity of 33% and specificity of 93%.  
 
In the subgroup analyses of patients with chronic bronchitis and dyspnoea but a baseline 
FEV1/FVC SR and FEV1 SR within the normal range (n=14), the baseline Aα-Val
360 
also 
correlated with subsequent decline in KCO (% predicted) (r=-0.534, p=0.025) but not to 
spirometric or radiological progression. In those with a baseline FEV1/FVC SR below the LLN 
(n=26), the Aα-Val360 related to radiological progression (change in lower zone voxel index 
r=0.348, p=0.041) but there was no significant relationships with other measurements. 
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5.2 DISCUSSION 
 
This is a unique assay based on an NE specific fibrinogen degradation product (Aα-Val360) which 
measures the damaging potential of NE at the point of release from the neutrophil prior to its 
inhibition by the surrounding protease inhibitors [214]. Previous authors have investigated the 
use of an alternate fibrinogen degradation product (formed by the cleavage of the fibrinogen 
alpha chain at Aα-21), however this was not pursued further because of low NE specificity and 
the very short half-life of this smaller fibrinogen fragment [216]. In contrast, the Aα-Val360 
neoepitope is highly specific and shows stability over time, which are both important features of 
a biomarker [214]. 
 
It is possible that a synergistic relationship may exist between the fibrinogen cleavage product 
A-Val360 and the fibrinogen concentration, since fibrinogen may also relate to COPD disease 
severity [237]. However, although NE is released from the azurophil granule at an initial 
concentration which exceeds most substrates, the total amount of NE released is very low and 
therefore the abundant fibrinogen protein is present in excess. Thus fibrinogen is only likely to 
influence A-Val360 formation if the clotting factor concentration varies between individuals by 
several orders of magnitude. However, published data show this not to be the case since the 
median plasma concentration of fibrinogen in stable state subjects with COPD who had suffered 
a severe exacerbation in the last 12 months was reported as 3.75 compared to 3.45 g/L in those 
who had not [237]. Also, while it is recognised that fibrinogen is an acute phase protein, the 
fibrinogen concentration only increases from 4.55 to 5.45 g/L in subjects experiencing an acute 
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exacerbation of COPD [238], which again suggests the fibrinogen concentration has little 
influence on A-Val360 formation. Furthermore, stimulation of neutrophils in plasma with 
ionophore increases the A-Val360 concentration (Table 9) to levels greater than stable state 
physiological concentrations, in the presence of constant levels of fibrinogen, which indicates the 
substrate concentration is not rate limiting. Also, the A-Val360 is detected in plasma at 
nanomolar concentrations, which again suggests that the formation of this product will not be 
dependent on the micromolar concentrations of fibrinogen.  
 
In common with many other inflammatory mediators, fibrinogen is a non-specific marker of 
inflammation which may be elevated in the absence of ongoing tissue damage. In contrast A-
Val
360 
is a specific marker of NE activity with a more certain association with tissue damage. 
 
5.2.1 Relationship to Markers of Disease Severity 
 
In the absence of more suitable gold standard markers, the Aα-Val360 was related to physiological 
and radiological measures of COPD disease severity since (despite their flaws) they are widely 
used and reasonably well validated. The Aα-Val360 was not compared with other potential 
biomarkers since (to date) none have been effectively validated and therefore interpretation of 
relationships (if any) would be difficult. For example, while urinary desmosine may differ 
between healthy individuals, smokers with normal lung function and subjects with COPD, it is 
not influenced by augmentation therapy [197] (perhaps because it is neither organ nor disease 
specific).  
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In the current study, it has been demonstrated that Aα-Val360 relates to several specific features of 
COPD in subjects without A1AT deficiency. Firstly it relates cross-sectionally to physiological 
and radiological markers of current COPD severity. This relationship is likely to be complex (and 
therefore consistent with the strength of the observed associations) since a marker of activity may 
also relate to the process leading to the current disease state (or severity) or to future disease 
progression. The relationship between a marker of disease activity and disease severity will also 
depend on both the stability of the marker and the underlying pathophysiological disease activity 
with respect to time. If (in the stable clinical state) both marker and true disease activity are stable 
over time then there will be a relationship between a marker of disease activity, current disease 
severity and future disease severity. This is not necessarily the case and will therefore be 
discussed further in section 7.3.4. Nevertheless, the strongest relationship was observed between 
Aα-Val360 and markers of the severity of the emphysematous process (gas transfer and the voxel 
index), and in particular Aα-Val360 was the best independent predictor of gas transfer. These data 
suggest Aα-Val360 is likely to an important surrogate marker of the pathogenesis of COPD 
however it is of greatest relevance to the development of emphysema. 
 
5.2.2 Aα-Val360 as a Marker of Emphysema 
 
Further confirmation of the relationship between NE activity
 
and the emphysematous process was 
provided by the observation that Aα-Val360 is greater in subjects with visible emphysema on 
HRCT compared to those without. Although the difference was less marked in subjects who also 
had obstructive spirometry, this may be explained by the smaller number and discordance 
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between the severity of the airway obstruction and alveolar destruction within individuals since 
the average observed differences were similar to that seen for the whole cohort.  
 
It is increasingly recognised that COPD is a heterogeneous disease, and the current study 
demonstrated that visible emphysema was present even in 6 of the 23 subjects with spirometry 
within the normal range, and those with visible emphysema also had a greater Aα-Val360 and 
significantly lower gas transfer and lower FEV1/FVC than those without visible emphysema, 
even though these physiological tests remained either largely or entirely within the normal range. 
This observation supports the use of a symptomatic diagnosis of COPD (chronic bronchitis and 
exertional dyspnoea) for inclusion of patients in the current study since spirometric criteria would 
have excluded a number of subjects with either ‘early’ disease or an emphysema predominant 
phenotype. The difference in Aα-Val360 between these 2 subgroups with normal spirometry fell 
just short of conventional levels of statistical significance, however the absolute difference in Aα-
Val
360 
concentrations mirrored that observed in the entire cohort suggesting that this is not due to 
chance alone but rather reflects the smaller number of subjects identified. There is therefore 
likely to be a subset of patients with an active NE related disease process, yet relatively mild 
physiological changes who do not meet current spirometric criteria for the diagnosis of COPD, 
but may be identified by Aα-Val360 and benefit from targeted therapeutic intervention to prevent 
deterioration to the more classical stages of COPD. Clearly further studies are required to 
investigate this possibility in depth. 
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5.2.3 Aα-Val360 and the A1AT/NE Complex 
 
Aα-Val360 is a specific marker of pre-inhibition NE activity, while the A1AT/NE complex is a 
marker of total NE release as a result of neutrophil degranulation.  In general, the Aα-Val360 was 
related to the plasma A1AT/NE complex and subjects with symptoms suggestive of COPD had 
higher levels of both Aα-Val360 and A1AT/NE complex than healthy controls indicating both 
greater NE activity and neutrophil enzyme release, as may be expected. However, the differences 
between Aα-Val360 and other markers of neutrophil activation were emphasised by the absence of 
any correlation between either MPO (a marker of neutrophil degranulation) or A1AT/NE 
complex and the physiological and radiological markers of COPD disease severity (either cross-
sectionally or longitudinally), demonstrating that a measure of NE release alone is a poor 
surrogate of the enzyme’s proteolytic potential.  
 
5.2.4 Aα-Val360 and Acute Exacerbations  
 
The Aα-Val360 also related to exacerbations which are episodes known to relate to FEV1 
progression [118]. Aα-Val360 was higher at the presentation with an exacerbation than in the 
stable state 8 weeks later, reflecting greater NE activity which may at least partly impact on 
subsequent evidence of disease progression. The hsCRP was also greater at the onset of an 
exacerbation, and correlated (albeit weakly) with the Aα-Val360 (both at presentation with the 
exacerbation and in the stable state) which is of interest, since one study has suggested that CRP 
may relate to exacerbation severity [177] although the relatively non-specific nature of CRP may 
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limit its use as a surrogate of disease activity in clinical practice. Importantly, the Aα-Val360 was 
higher not only at the presentation with an exacerbation in subjects who experienced an 
exacerbation associated with purulent (neutrophilic) sputum compared to those with mucoid 
sputum but remained higher even in the stable state supporting the concept that these episodes 
may mark subjects with a greater likelihood of progression [118]. Furthermore, the higher Aα-
Val
360
 in this group of patients was associated with a higher stable state sputum IL-8 and plasma 
A1AT/NE complex concentration (but not hsCRP), demonstrating a greater ongoing process 
leading to neutrophil recruitment, enzyme release and hence potential tissue damage.  
 
Although these data could represent a slower recovery, it is unlikely since all subjects were seen 
2 months after the exacerbation onset when they were confirmed to be clinically stable, supported 
by the observation that there was no difference in the hsCRP (which has previously been 
demonstrated to be higher in acute exacerbations of COPD [177]) between these 2 groups. The 
Aα-Val360 related both to the stable state and 4 year follow-up physiological and radiological 
measures, and these relationships would be less likely if patients had not been in the stable state 
at the time of assessment (with further resolution after the study). In particular, there was no 
evidence of an ongoing bacterial trigger since there was no difference in the subjective 
assessment of the stable state sputum colour or objective measurement of MPO between the 2 
groups of patients. Although further studies are required, it is probable that patients who 
experience an exacerbation associated with purulent sputum have greater NE activity in general 
(leading to tissue damage which enhances the subsequent risk of a bacterial infection) and 
therefore experience exacerbations associated with purulent rather than mucoid sputum. It is also 
possible that subjects who experience a more severe exacerbation have a greater Aα-Val360 signal 
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even following recovery and hence decline at a greater rate. However, although CRP may partly 
relate to the severity of exacerbations [177], this has yet to be proven definitively and therefore 
there is currently no accepted inflammatory marker of exacerbation onset or severity in subjects 
with COPD to confirm this concept, although it is possible that Aα-Val360 itself may fill this role 
in specific targeted studies. 
 
5.2.5 Aα-Val360 as a Marker of Disease Progression 
 
There appears to be a relationship between NE activity (measured by Aα-Val360) and disease 
progression. Current pathophysiological activity is likely to reflect not only preceding but also 
future disease progression and in the current study it was demonstrated that baseline Aα-Val360 
related to deterioration and subsequent severity measured by gas transfer. The data also suggest a 
relationship with Aα-Val360 and disease progression measured by CT densitometry, although this 
is slightly inconsistent and would warrant further exploration in a larger prospective study. Aα-
Val
360 
did not relate to spirometric decline, suggesting tissue damage reflected by Aα-Val360 is 
more indicative of the emphysematous process, not only in the presence of established COPD but 
importantly even in those with emphysema but without airflow obstruction. Clearly larger 
studies, especially in this latter group, are now indicated including data on longitudinal 
progression.  
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5.2.6 Summary  
 
In summary, the current study reports the first in vivo data in human subjects which  support the 
role of NE in the pathophysiology of chronic bronchitis, COPD and emphysema in human 
subjects without A1AT deficiency. Furthermore, when considered in combination with previous 
circumstantial data (see 1.5.1), the current study suggests NE may represent a final common 
pathway leading to tissue destruction in this disease process.  Aα-Val360 is the first specific 
biomarker of pre-inhibition NE activity which relates to cross-sectional measures of disease 
severity and exacerbations and appears to relate to disease progression in the current study. 
Although further work in a larger cohort of patients is required, particularly to explore the 
relationship with longitudinal markers of disease progression in subjects at risk, Aα-Val360 
therefore represents a new concept of specific biomarkers that may be central to the 
pathophysiology of emphysema and potentially COPD. 
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CHAPTER 6. AΑ-VAL360 AS A MEASURE OF THE 
EFFICACY OF A1AT AUGMENTATION 
 
Data pertaining to the Aα-Val360 in the EXACTLE study have been published (Carter RI, et 
al. The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase 
activity in vivo. Thorax 2011; 66: 686 – 91.) 
 
The EXACTLE study included 77 PiZ A1AT deficient subjects from the UK, Sweden and 
Denmark who were randomised to receive weekly infusions of either placebo or 60 mg/kg human 
A1AT augmentation therapy (Prolastin) for 2 to 2.5 years [111]. The current study included 67 of 
these subjects, excluding 10 of the original patients for whom suitable plasma samples were not 
available for analysis at either baseline (prior to commencing the interventional study product) or 
6 months later. For 6 of the 10 subjects who were excluded, samples were deemed unsuitable for 
analysis due to visible, heavy bloodstaining (which leads to a rise in Aα-Val360), while paired 
baseline and month 6 plasma samples were not available for 4 subjects. 
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6.1 RESULTS 
 
The following data only relate to the 67 subjects included in the current Aα-Val360 study in 
whom paired viable samples were available.  
 
As reported in the original EXACTLE study [111], there was a significant difference in the 
distribution of males and females between the 2 arms of the current Aα-Val360 study, however 
there were no differences in other baseline characteristics (Table 23). 
 
 
 Placebo Prolastin P (placebo vs. 
Prolastin) 
N 34 33  
Males n (%) 
Females n (%) 
14 (41.18) 
20 (58.82) 
22 (66.67%) 
11 (33.33%) 
0.036 
Mean age (SE) in yrs 54.44 (1.67) 55.03 (1.32) 0.783 
Smoking history 
  Current   
  Ex 
  Never 
 
0 
31 
3 
 
0 
30 
3 
 
 
0.969 
Median baseline FEV1 % predicted 
(IQR) 
38.32  
(30.88 - 55.45) 
38.89  
(30.33 - 61.28) 
0.964 
Median FEV1/FVC 
(IQR) 
0.35  
(0.27 – 0.54) 
0.37 
(0.26 – 0.50) 
0.821 
Median baseline KCO % predicted 
(IQR) 
56.67  
(43.99 - 66.94) 
53.67  
(43.55 - 62.92) 
0.854 
Table 23: the baseline characteristics of the 67 PiZ A1AT subjects who took part in the Aα-Val360 study 
‘(where paired, viable samples were available). There was a significant difference in the sex distribution 
between the 2 groups, but all the other baseline parameters were similar.  
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6.1.1 Change in Lung Function and CT Densitometry 
The data were expressed and analysed in 3 different ways. Firstly, the data were compared cross-
sectionally between the placebo and treatment groups at each time point. Secondly the data were 
compared longitudinally between baseline and 6 months within each arm of the trial. However, 
since HRCT scans were performed at baseline and month 12 (but not month 6), data comparisons 
were performed with the CT densitometry at these time points in those subjects with both paired 
plasma and HRCT scans (n=31 placebo, n=31 Prolastin). Finally the baseline Aα-Val360 was 
related to the rate of change of each parameter from baseline over the full 2 year period of the 
original trial.  
 
There was no significant difference in the physiological measures between the 2 treatment groups 
at either baseline or month 6 (Table 24). Also, there was no significant change in FEV1 (% 
predicted) or KCO (% predicted) in either treatment group between baseline and month 6. At 
month 6 and 12, the rates of change in FEV1 and KCO were the same in both treatment groups 
(data not shown). 
 FEV1 (% predicted) KCO (% predicted) 
Visit Placebo Prolastin 
P (placebo vs. 
Prolastin) 
Placebo Prolastin 
P (placebo vs. 
Prolastin) 
Baseline 46.73 (3.83) 45.22 (3.42) 0.769 56.13 (2.75) 55.20 (3.83) 0.844 
Month 6 47.16 (3.73) 44.11 (3.31) 0.544 57.52 (2.73) 56.45 (3.67) 0.816 
P (Baseline vs. 
month 6) 
0.621 0.117  0.288 0.434  
Table 24: The table shows the mean (SE) FEV1 and KCO (% predicted) for the subjects who were 
included in the EXACTLE study [111] in whom paired, viable plasma samples were available at baseline 
and at month 6. There was no significant difference in the FEV1 or KCO between the 2 treatment groups 
or from baseline to month 6.  
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Visit Upper Zone 15
th Percentile Point Lower Zone 15th Percentile Point 
Placebo Prolastin 
P (placebo vs. 
Prolastin) 
Placebo Prolastin 
P (placebo vs. 
Prolastin) 
Baseline 65.39 (3.60) 61.14 (4.93) 0.489 35.72 (2.74) 36.24 (3.09) 0.900 
Month 12 65.13 (4.01) 59.98 (5.18) 0.435 35.12 (2.82) 36.00 (3.19) 0.837 
P (Baseline vs. 
month 12) 
0.873 0.380  0.521 0.783  
Table 25: The table shows the mean (SE) 15
th
 percentile point in the upper and lower zones for subjects 
who took part in the EXACTLE trial [111] in whom paired baseline and month 6 plasma samples were 
available AND paired baseline and month 12 HRCT scans were performed (n=31 placebo, n=31 
Prolastin). There was no difference in the 15
th
 percentile point in either the upper or lower zone between 
the 2 groups at any time during study. There was a decrease in the 15
th
 percentile point in both the upper 
and lower zone by month 24 but not month 12. 
 
In the subjects included in the current study (with paired plasma samples), there was no 
significant difference in the 15
th
 percentile point (a measure of lung density) between the placebo 
and treatment group at either baseline or month 12 (Table 25). Also there was no significant 
change in the 15
th
 percentile point between baseline and month 12 in either treatment group. The 
rate of change of the lower zone and the whole lung 15
th
 percentile point was greater in the 
placebo group than the Prolastin group over the 2 year study period, (p=0.034 and p=0.09 
respectively), however there was no difference in the rate of change in the upper zone (p=0.599). 
 
6.1.2 Aα-Val360 as a Measure of the Efficacy of Augmentation Therapy 
 
At baseline, there was no difference in the median Aα-Val360 between the 2 study groups. 
Between baseline and month 6, the Aα-Val360 decreased significantly in the treatment group 
(p=0.022) but not the placebo group (p=0.313; Figure 22). Also, the Aα-Val360 was lower in the 
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Prolastin group than the placebo group at month 6, although this just fell short of conventional 
statistical significance (p=0.084).  
 
 
 
Figure 22 The mean (SE) Aα-Val360 concentrations are shown for the 2 treatment arms at baseline and at 
month 6. There was a significant reduction in the Aα-Val360 between baseline and month 6 in the treatment 
but not the placebo arm in the 67 subjects from the EXACTLE trial. 
  
There was no significant difference in the median Aα-Val360 between men and women at either 
baseline or month 6. Within these relatively small groups, there were no relationships between 
the baseline physiological or radiological measures and Aα-Val360.  
 
Within the placebo arm, the data suggested a potential relationship between Aα-Val360 and the 
rate of decline of FEV1 (% predicted) and possibly the upper zone 15
th
 percentile point, although 
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these relationships were far from clear (Table 26). The Aα-Val360 did not relate to the rate of 
decline of any other parameter. 
 
Relationship of baseline 
Aα-Val360 with rate of 
decline between: 
 
FEV1 (% Predicted) 
 
Upper zone 15th percentile point 
r p r p 
Baseline and  month 6 -0.314 0.035 - - 
Baseline and month 12 -0.164 0.190 0.240 0.097 
Baseline and month 18 -0.331 0.037 - - 
Baseline and month 24 -0.151 0.218 0.199 0.151 
Table 26: the table depicts the relationship (r) between the baseline Aα-Val360 and the rate of decline of 
either the FEV1 (% predicted) or upper zone 15
th
 percentile point at various time points. Although the 
relationships at each time point were not all statistically significant, the trends were nevertheless similar.  
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6.2 AΑ-VAL360 AS A MEASURE OF THE EFFICACY OF A1AT 
AUGMENTATION: DISCUSSION 
6.2.1 Current Evidence Supporting the Use of Augmentation Therapy 
 
The association between a deficiency of A1AT (the main inhibitor of NE) and early onset 
emphysema was first noted in the 1960s [68], and this was closely followed by the demonstration 
in animal studies that NE may directly induce the development of emphysema [69]. Also, both 
mathematical and in vitro modelling demonstrate that the area of quantum proteolytic damage 
(around the point of NE release) is exponentially greater in subjects with A1AT deficiency 
compared to healthy controls [52-54]. On the basis of this evidence alone, it would therefore 
seem logical to suggest that A1AT augmentation therapy would either effectively prevent the 
onset of COPD or slow disease progression in subjects with PiZ A1AT deficiency. However, to 
date there is little evidence from randomised controlled trials to support this hypothesis.  
 
Weekly augmentation therapy with pooled A1AT in PiZ subjects has been shown to raise trough 
plasma levels to around 0.7 grams/litre (13.46 μmols) [239], which therefore exceeds the putative 
protective threshold of 11 μmols. Also, further evidence supporting the use of augmentation 
therapy has been provided by national registry data which showed that German PiZ A1AT 
deficient subjects (who received augmentation therapy) demonstrated a lesser FEV1 decline than 
matched Danish control subjects [240]. However, these data were comparative , the study was not 
randomised, and furthermore, the German subjects included more women, had a significantly 
greater FEV1 at baseline and were followed up for a shorter period than the Danish subjects, 
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which may all influence determination of the rates of decline. In 1999, the Dutch-Danish 
randomised controlled trial of monthly infusions of placebo versus A1AT augmentation therapy 
(250 mg/kg) demonstrated a reduction in the rate of emphysema progression on CT scan. 
However, this did not quite achieve conventional statistical significance (p=0.07) and there was 
no difference in the rate of disease progression measured by physiological parameters [241]. 
More recently, a randomised controlled trial of placebo versus A1AT augmentation therapy (the 
EXACTLE study [111]) was conducted using CT densitometry as the primary outcome measure 
since this is a more sensitive marker of emphysema progression than physiological tests [106]. 
However, there remains controversy regarding the most appropriate method to measure 
longitudinal densitometric change and therefore this study explored 4 different methodologies. 
All 4 methods demonstrated a trend towards decreased progression in the treated population, 
however only one methodology (which used only the baseline and final 15
th
 percentile point 
measurements) showed statistically significant differences between the 2 groups. This method 
was also the most sensitive measure of progression within the placebo group [111]. Finally, a 
study using pooled raw data from the Dutch-Danish and the EXACTLE study demonstrated a 
statistically significant decrease in emphysema progression measured by the 15
th
 percentile point 
(whole lung) [242]. 
 
6.2.2 Physiological and Radiological Disease Progression 
 
The current study investigated the Aα-Val360 concentrations in plasma obtained from 67 subjects 
during the EXACTLE study. As there were fewer patients included in the Aα-Val360 study 
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(compared to the clinical study), the influence of treatment on the physiological and radiological 
measures of disease severity was also re-examined.  
 
There was no difference in the FEV1 or KCO (% predicted) in the placebo group compared to the 
treatment group at baseline or month 6, nor was there a significant change in these physiological 
measures between baseline and month 6 in either treatment group. Additionally, there was no 
significant change in FEV1 or KCO over the 2 year period of the clinical study [111], FEV1 and 
these data therefore demonstrate the insensitivity of physiological parameters for monitoring 
disease progression in patients with COPD especially if they deteriorate at a slow rate.  
 
In the current (Aα-Val360) study, the rate of change of the 15th percentile point was greater in the 
placebo group than the treatment group (although this only achieved statistical significance in the 
lower zone). The data are therefore consistent with the original EXACTLE study which showed a 
slowing of disease progression measured by CT, and this is important since it suggests the 
population studied here is comparable to that of the original EXACTLE study despite the 
exclusion of some subjects. 
 
6.2.3 Aα-Val360 as a Measure of Treatment efficacy 
 
In these small subgroups, the Aα-Val360 did not relate to the physiological and radiological 
markers of disease severity. It is plausible that the study was insufficiently powered to examine 
cross-sectional relationships, particularly in this multi-centre trial where variation in the 
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physiological and radiological measures is likely to be much greater and potentially compounded 
by a centre effect. Therefore further study in larger groups was required (discussed in this thesis). 
 
The Aα-Val360 did not change significantly over the 6 month period in the placebo arm of the trial 
which confirms the stability of this marker of disease activity. In contrast to markers of disease 
severity (such as KCO) which would be anticipated to decline as the disease progresses, an 
effective marker of disease activity would be stable over time, yet higher in subjects who 
deteriorate at a greater rate. There was a significant decrease in the Aα-Val360 in the treatment 
arm of the trial by month 6. This is in contrast to the physiological measures of disease severity at 
month 6 which neither demonstrated a significant decline in the placebo arm nor a treatment 
response in the Prolastin arm. Also, in the clinical study there was no demonstrable difference in 
the CT lung densitometry between the 2 arms of the trial until 2 years after commencement and 
no difference in the physiological measures at any time [111]. These data support the greater 
sensitivity of Aα-Val360 as a potential measure of treatment efficacy compared to either 
physiological or radiological measures of disease severity, although further longitudinal studies 
are required.  
 
The Aα-Val360 concentration at baseline (at least partly) related to the subsequent rate of decline 
of both the FEV1 and the upper zone 15
th
 percentile point in patients within the placebo arm. 
Since it would be anticipated that a marker of disease activity would predict subjects who would 
decline at a greater rate, and there was trend towards a relationship at all time points this is 
unlikely to be explained by chance alone. The absence of more significant relationships may be 
explained by sample size and the relatively short duration of the study, particularly when there 
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was no significant difference in the FEV1 between baseline and month 24. Furthermore, decline 
in FEV1 and CT densitometry may not be linear [181] and may also account for the variation in 
these relationships. 
 
Of interest, even in the treated population, the Aα-Val360 did not fall to the concentrations 
observed in healthy controls (even after 6 months of treatment). A number of factors may account 
for this: firstly variability of the assay (or its insensitivity), secondly that a greater duration of 
treatment is required to allow disease activity (and its markers) to decrease to ‘normal’ levels, 
thirdly there was inadequate dosing with A1AT or finally that once the COPD disease process is 
initiated, additional factors (other than the A1AT concentration) are also important stimuli of 
neutrophilic COPD disease activity.  
 
6.2.4 There is Ongoing Disease Activity Despite Augmentation Therapy 
 
Inadequate dosing or an ongoing pathophysiological process are plausible reasons for the failure 
of Aα-Val360 to return to the concentration of healthy controls, since the CT densitometry 
continues to decline despite augmentation therapy [111]. Current A1AT augmentation doses are 
based on the quantity required to achieve a plasma level over the likely protective threshold 
[243]. This threshold is partly based on the observation that PiZ subjects with a mean plasma 
concentration of 5 μmols are at risk of developing emphysema while PiSZ subjects (who largely 
have an A1AT concentration greater than 11 μmols) are not particularly susceptible, however this 
remains controversial [56]. Furthermore, it has been suggested that although current dosing 
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regimens may provide adequate basal levels of A1AT, weekly or monthly augmentation therapy 
would not mirror the physiological acute phase rise in A1AT concentrations that occur in healthy 
individuals during periods of increased (and potentially damaging) inflammatory activity [243]. 
Exacerbations in deficient individuals would therefore be associated with an increase in the 
release of NE which is not mirrored by a rise in its predominant inhibitor (A1AT), and may 
explain why exacerbations are associated with a more rapid decline [118].  
 
More recent studies have suggested that A1AT polymers are chemoattractants [244] and have 
indicated that polymers and neutrophils tend to aggregate in the interstitium of the lung in A1AT 
deficient subjects [245], which may be a further potential cause for ongoing pathological activity 
despite augmentation therapy. However, it is also possible that these findings simply reflect the 
increased neutrophil traffic within the lung in subjects with A1AT deficiency that continues or 
only slowly declines to normal.   
 
An inflammatory process is likely to be central to the pathophysiology of usual COPD in subjects 
who smoke (but have normal A1AT concentrations), however many inflammatory markers 
remain elevated  in ex-smokers [246], which is thought to explain the ongoing progressive 
disease in some subjects even after smoking cessation. It is therefore possible that subjects with 
A1AT deficiency who develop COPD have a sustained general inflammatory response even after 
initiation of augmentation therapy. Although analysis of sputum samples in A1AT deficient 
subjects receiving augmentation therapy has demonstrated a decrease in LTB4 (a key neutrophil 
chemoattractant in A1AT deficiency), there is no decrease in MPO (which is a marker of 
neutrophil activity) [247] and this suggests (at least in the short term) that there is a continued 
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inflammatory response. Additionally, studies have not shown a decrease in the number of 
exacerbations in subjects receiving augmentation therapy [111], which may be important because 
exacerbations are periods of intense inflammatory activity [230]. A marker of disease activity 
(such as Aα-Val360) would be a potential method of further investigating this ongoing 
inflammatory process. 
 
6.2.5 The Efficacy of ‘Early’ Augmentation Therapy 
 
It is possible that the initiation of augmentation therapy in subjects with A1AT deficiency prior to 
the development of COPD will be more effective than treating people with established lung 
disease. This would seem a logical step, since the initial pathophysiological process leading to 
emphysema within these individuals almost certainly relates directly to the deficiency of A1AT 
with associated exponentially larger areas of tissue destruction at points of NE release. If this is 
also the initial trigger for an ongoing inflammatory process (if present), then early augmentation 
therapy may prevent the onset of this process and further lung destruction. Early treatment may 
also prevent aggregation of A1AT polymers within the lung interstitium since A1AT polymer 
formation is concentration dependent (at least in vitro) [49], however this remains controversial 
[243, 245] and is difficult to fully assess in the absence of an effective in vivo marker of 
polymerised A1AT. Additionally, the in vitro marker of A1AT polymers cross-reacts with 
A1AT/NE complex and possibly with other antigens [245] which further complicates assessment 
of this potential mechanism. Assessment of early treatment would also be complicated by 
smoking history since, at standard  doses, A1AT augmentation will not prevent smoking induced 
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lung damage, which is a significant risk factor for more rapid disease progression in A1AT 
deficient subjects [248]. 
 
Subgroup analysis of observational studies which have been conducted in subjects with PiZ 
A1AT deficiency have in part considered the implications of treating people with early disease. 
For example, the National Heart Lung and Blood Institute A1AT deficiency registry study group 
reported that subjects with an FEV1 >80% deteriorate at a greater rate following the initiation of 
augmentation therapy. However, there were only 11 subjects with an FEV1>80% included in the 
study registry who received augmentation therapy, and although decline was greater it did not 
achieve conventional statistical significance (p=0.09), suggesting this was a chance finding. In 
support of the concept of early treatment, however, Wencker et al [25] demonstrated that some 
subjects with ‘early’ disease (defined by the study team as FEV1>65%) decline at a greater rate 
(irrespective of smoking status), and these rapid decliners respond more effectively than others to 
augmentation therapy. Nevertheless, the study design (which explored the rates of decline within 
individuals pre- and post augmentation therapy) does not allow definitive conclusions on 
treatment effect to be reached since FEV1 decline is not linear and therefore may have slowed 
with or without augmentation.  
 
Recent registry data have also suggested that subjects with an FEV1>65% who receive 
augmentation therapy decline at a greater rate than those who do not [249]. However, subjects in 
the registry are initiated on augmentation therapy on a clinical (and not random) basis and 
therefore treatment may be more likely to be commenced in subjects who are already declining at 
a more a rapid rate. Also, it would be difficult to consider a biologically plausible hypothesis to 
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support the proposition that augmentation therapy truly causes more rapid decline in subjects 
with a higher FEV1 at baseline, although this requires a more pragmatic approach to studying 
patients before and after augmentation therapy.  
 
6.2.6 Defining ‘Early Disease’ 
 
Data from observational studies conducted in subjects with PiZ A1AT deficiency therefore 
neither support nor refute the hypothesis that early treatment with augmentation therapy is 
beneficial. Furthermore, these studies have classified disease severity using FEV1 alone, which is 
a poor measure of the degree of emphysema [10] and may therefore have misclassified some 
subjects as having early disease when pathologically it is advanced. This also raises the question 
of the definition of early disease since there may be a difference between subjects with mild 
disease (who currently have few symptoms and do not progress) and those with early disease 
(who initially have minimal physiological and symptomatic disease but progress rapidly) in 
whom early treatment may be beneficial [25].  
 
There is also the issue of identifying subjects at an early stage, prior to the development of 
significant pathological lung disease, since under-diagnosis of A1AT deficiency and COPD in 
general has long been recognised. Although this could be overcome by screening, the distinction 
between early and mild disease would then become even more important since people with 
A1AT deficiency who have never smoked and are identified through screening have a markedly 
different prognosis and achieve a normal average lifespan [250]. Irrespective of screening, it is 
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interesting to speculate that a marker of disease activity (such as Aα-Val360) would effectively 
identify patients with early disease who are progressing rapidly and would potentially benefit 
from early treatment [25]. The definitive answers to these questions would be provided by a 
randomised controlled trial of augmentation therapy incorporating a marker of disease activity, 
although this is clearly beyond the scope of the current thesis. However, given the financial 
burden and implications of lifelong augmentation therapy, these are questions that need to be 
addressed. 
 
6.2.7 Future Clinical Trials 
 
To date no study has demonstrated statistically significant improvements in clinically relevant 
outcomes in PiZ A1AT deficient subjects receiving augmentation therapy. It has been shown that 
such a study would require 147 subjects per treatment arm over a 4 year period to demonstrate a 
23 ml/year difference in FEV1 or 684 subjects in a 5 year study to demonstrate a 40% reduction 
in mortality [251]. Such a study is probably feasible, although it would require significant 
international co-operation (in countries where augmentation is currently unavailable) and 
funding. However, this is unlikely to be forthcoming since A1AT augmentation therapy is 
available in many countries throughout the world, which is a disincentive to both study 
participants and potential funders from the pharmaceutical industry. Again surrogate endpoints 
(including biomarkers) may help to address these questions, but are currently not validated 
sufficiently to be acceptable to regulatory authorities and clinicians alike.  
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6.2.8 Summary: Aα-Val360 as a Measure of the Efficacy of A1AT Augmentation 
 
Evidence from biochemical, observational and randomised controlled studies suggest that 
augmentation therapy is probably effective, and the current study provides further evidence of 
treatment efficacy since there was a statistically significant decrease in Aα-Val360 (a marker of the 
potential destructive process in these patients) after just 6 months of treatment. The study also 
confirmed the insensitivity of FEV1 (which is widely used in clinical trials) since it did not 
significantly change over the 2 year study period in either the placebo or treatment groups [111] 
or alternatively demonstrated the relative stability of the disease in these patients. 
 
Further work is required to ensure that where augmentation therapy is initiated, subjects are 
treated with optimal A1AT doses (potentially supplemented during periods of acute infection or 
exacerbations) and to establish definitively if augmentation can return disease activity to normal 
levels, with an associated improvement in clinical outcomes. Finally, there are likely to be some 
patients with early or no lung disease who may decline more rapidly and potentially benefit from 
earlier treatment and a marker of disease activity (such as Aα-Val360) may effectively identify this 
subgroup. However, a significantly larger and longer trial would be required to investigate the 
concept of early augmentation therapy, particularly using conventional markers of disease 
progression. 
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CHAPTER 7. AΑ-VAL360 IN SUBJECTS WITH A1AT 
DEFICIENCY: RESULTS AND DISCUSSION 
 
7.1 PIZ AND NON-PIZ A1AT DEFICIENT SUBJECTS RESULTS 
 
The Aα-Val360 concentration was measured in a plasma sample obtained at the baseline visit from 
the first 463 subjects recruited to ADAPT with a variety of A1AT phenotypes and concentrations 
(Table 27). . There was an inverse exponential  relationship between A1AT and Aα-Val360  
(Figure 23) in the form Aα-Val360=ek/A1AT (where k is a constant) as demonstrated by the linear 
relationship between A1AT and the function 1/ln(Aα-Val360) (Figure 24) which was predicted by 
previous mathematical and in vitro modelling [52-54]. There were highly significant (p<0.001) 
differences between the Aα-Val360 concentrations in subjects with PiZ A1AT deficiency 
compared to the other phenotypes (Table 27 and Figure 25). However, differences were also 
present between subjects with PiSZ and PiS deficiency and other A1AT phenotypes. 
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Figure 23: The exponential relationship between the A1AT concentration and Aα-Val360 concentration in 
subjects with differing A1AT phenotypes. 
 
 
Figure 24. An exponential relationship exists between A1AT and the Aα-Val360 concentration since there is 
a linear relationship between A1AT and the function 1/ln(Aα-Val360) where ln is the natural logarithm. 
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 PiZ PiSZ PiS PiMZ PiM healthy 
controls 
n 350 51 8 30 24 
n with  
FEV1/FVC <0.7 (%) 
284 
(81.14) 
26 
(50.98) 
7 
(87.50) 
14 
(46.67) 
0 
(0) 
Mean FEV1 [L] (SE) 
2.01 SZ, M 
(0.06) 
2.76 Z 
(0.17) 
2.04 M 
(0.33) 
2.57 
(0.26) 
3.38 Z, S 
(0.24) 
Mean FEV1 % 
predicted (SE) 
63.13 SZ, MZ, M 
(1.71) 
86.82 Z, S, M 
(4.22) 
64.54 SZ, M 
(9.37) 
86.90 Z, M 
(7.05) 
112.27 Z, SZ, S, MZ 
(3.34) 
Median A1AT [μM] 
(IQR) 
3.85 SZ, S, MZ, M 
(2.90– 5.00) 
14.20 Z, S, MZ, M 
(11.58 – 15.80) 
17.80 Z, SZ, M 
(14.40 – 18.20) 
18.20 Z, SZ, M 
(15.80 – 20.77) 
24.98 Z, SZ, S, MZ 
(21.80 – 29.04) 
Median Aa-Val360 [nM] 
(IQR) 
16.60 SZ, S, MZ, M 
(12.72 – 23.09) 
11.95 Z, MZ, M 
(10.62 – 14.49) 
11.92 Z, M 
(10.22 – 12.70) 
9.58 Z, SZ 
(5.90 – 19.79) 
2.96 Z, SZ, S, MZ 
(2.10 – 4.04) 
Smoking Status: 
Current (%) 
Ex (%) 
Never (%) 
 
88 (25.1) 
240 (68.6) 
22 (6.3) 
 
13 (25.5) 
28 (54.9) 
10 (19.6) 
 
2 (25) 
6 (75) 
0 (0) 
 
11 (36.7) 
14 (46.7) 
5 (16.7) 
 
0 (0) 
0 (0) 
24 (100) 
Table 27: The Aα-Val360 concentration was measured in a variety of subjects with varying A1AT 
phenotypes. Letters in superscript indicate significant differences (significance was taken as p<0.05). The 
median age was similar between the groups although was slightly (not significantly) higher in PiS subjects 
 
Figure 25: The median (IQR) Aα-Val360 by A1AT phenotype  
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The Aα-Val360 was significantly higher (p<0.001) in subjects with an A1AT concentration below 
11 μmol/litre (median 15.91; IQR 11.97 – 21.62) compared to those with a level greater than this 
putative protective threshold who had a median of 10.39 nM (IQR 5.12 – 13.57). Also, PiZ 
A1AT deficient subjects (n=53) who had never smoked and had an FEV1 (% predicted) above 
80% had a median Aα-Val360 concentration of 15.25 nM (IQR 10.69 – 19.36), which was 
significantly higher (p<0.001) than the normal healthy controls. 
 
The numbers of index cases (who were identified following presentation with respiratory 
symptoms) and non-index cases (who were identified through family screening) varied by A1AT 
phenotype (p<0.001; Table 28).   
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A1AT phenotype Non-index cases n (%) Index cases  
n (%) 
Total 
n 
MZ 11 (36.67) 19 (63.33) 30 
S 4 (50) 4 (50) 8 
SZ 41 (80.39) 10 (19.61) 51 
Z 100 (28.57) 250 (71.43) 350 
Table 28: There were differences (p<0.001) in the numbers of non-index and index cases between the 
A1AT phenotypes which reflects the referral patterns to the ADAPT project.  
 
There were also differences in the numbers of index and non-index cases within each A1AT 
phenotype when stratified into those with and without an FEV1/FVC<0.7 (commonly used 
physiological criteria for COPD). However, the majority of subjects with an FEV1/FVC<0.7 were 
both index cases and current or ex-smokers regardless of A1AT phenotype (Table 29). 
 
FEV1/FVC<0.7 A1AT phenotype Non-index cases 
n (%) 
Index cases  
n (%) 
Current or ex 
Smokers n 
(%) 
Total 
n 
No 
MZ 11 (68.75) 5 (31.25) 7 (43.75)  16 
S 1 (100) 0 (0) 0 (0) 1 
SZ 20 (80) 5 (20) 15 (60.00) 25 
Z 49 (74.24) 17 (25.75) 26 (39.39) 66 
Yes 
MZ 0 (0) 14 (100) 12 (85.71) 14 
S 3 (42.86) 4 (57.14) 6 (85.71) 7 
SZ 21 (80.77) 5 (19.23) 23 (88.46) 26 
Z 51 (17.96) 233 (82.04) 236 (83.10) 284 
Table 29: The proportion of subjects with COPD (defined using FEV1/FVC<0.7) varied by index and non-
index status as well as by A1AT phenotype. The majority of subjects with an FEV1/FVC<0.7 were current 
or ex-smokers irrespective of A1AT phenotype.  
178 
 
7.2 SUBJECTS WITH PIZ ALPHA-1-ANTITRYPSIN DEFICIENCY 
 
Detailed cross-sectional and longitudinal analyses were performed on the 350 PiZ A1AT 
deficient subjects who were assessed with full lung function tests at 3 or more annual visits 
(median follow-up 6 years). There was no significant difference (p=0.246) in the plasma Aα-
Val
360 
concentration between the 141 females with a median of 16.51 nM (IQR 12.09 – 21.33) 
and the 209 males with a median of
 
16.87(IQR 13.15 – 24.13). The Aα-Val360 was significantly 
higher (p=0.007) in current smokers with a median of 21.6 nM (IQR 16.32 to 32.8) compared to 
ex-smokers with a median of 16.65 (12.85 – 23.76) and never smokers (median=15.3; IQR 10.80 
– 19.88). There was also a weak, though statistically significant, relationship between Aα-Val360 
and pack year history (r=0.131, p=0.007), however this relationship was not observed if never 
smokers were excluded from the analysis (p=0.123).   
 
At baseline, there were 137 patients (39.14%) on inhaled steroids, 91 (26%) on a long-acting beta 
agonist (LABA), 96 (27.43%) on a combined steroid and LABA, and 76 (21.71%) on a long 
acting antimuscarinic. The proportion of subjects on inhaled combination therapy (steroid and 
LABA) rose to 52.6% by the end of the study period. For the purposes of the current study, 
subjects were therefore considered to be on a particular therapy if on treatment for at least 50% of 
the study period. There was no difference in Aα-Val360 at baseline in subjects receiving inhaled 
corticosteroids (compared to those who were not). However, the baseline Aα-Val360 was greater 
(p=0.018) in those receiving combination therapy with a median of 18.02 nM (IQR 13.98 -26.98) 
compared to those not on combination therapy with a median of 16.22 (12.23 - 22.23). The Aα-
179 
 
Val
360 
was also greater (p=0.013) in those receiving a long-acting antimuscarinic with a median 
of 18.81 (14.28 to 27.92) compared to those who were not (median 16.2; 12.44 to 21.59).  
  
The median Aα-Val360 was higher (p<0.001) in index cases (n=250) who presented with 
symptoms of chronic lung disease (17.72 nM; IQR 19.93 – 26.00) compared to non-index cases 
(n=100) who were identified through family screening (13.87; IQR 9.99 – 17.84). This difference 
(p<0.001) persisted in never smokers with a median Aα-Val360 of 17.32 nM (IQR 14.30 – 22.25) 
in the 46 PiZ index cases compared to 13.32 (9.93 – 17.82) in the 42 non-index cases. 
 
7.2.1 Cross-Sectional Relationships in PiZ Subjects 
 
The Aα-Val360 related to both physiological and radiological measures of COPD disease severity 
as well the SGRQ, which is a quality of life score (Table 30) [224]. The Aα-Val360 concentration 
also related to symptom severity measured by the COPD assessment tool (CAT) [123], in the 
subset (n=156) who underwent this evaluation (r=0.289, p<0.001). Although the Aα-Val360 
concentration did not relate to age (p=0.213), height (p=0.389) or weight (p=0.085), a weak 
relationship was observed between Aα-Val360 and BMI (r=-0.091, p=0.047). 
 
Multivariate analysis accounting for age, sex, height, smoking history, and A1AT concentration 
demonstrated significant relationships between Aα-Val360 and both the KCO (adjusted R2 -0.166; 
p<0.001) and FEV1 (adjusted R
2 
-0.129; p=0.005). However, the patient’s age was the strongest 
predictor of both physiological measures. 
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The Aα-Val360 related to the A1AT/NE complex concentration (r=0.339, p=0.004), a measure of 
total NE release, however there was no relationship with the plasma CRP (r=-0.023, p=0.378) 
which is a non-specific measure of inflammation. Furthermore, and of interest, the Aα-Val360 also 
related to the plasma A1AT concentration (r=-0.133, p=0.007) even within this group of subjects 
with severe (PiZ) A1AT deficiency. However, the absolute A1AT concentration did not relate to 
physiological or radiological measures of disease severity. The Aα-Val360 related better to sputum 
LTB4 (r=0.328, p=0.008) than to sputum IL-8 (r=0.222, p=0.053) or sputum MPO (r=0.243, 
p=0.061) in the 50 subjects in whom spontaneous sputum was available and analysed. 
 
 
Parameter r p 
FEV1 (litres) -0.210 <0.001 
FEV1 (% predicted) -0.229 <0.001 
KCO (mmol/min/kPa/litre) -0.243 <0.001 
KCO (% predicted) -0.229 <0.001 
Upper zone voxel index (-910 Hounsfield units) 0.197 0.002 
Lower zone voxel index (-910 Hounsfield units) 0.197 0.002 
St George’s respiratory questionnaire (symptoms) 0.257 <0.001 
St George’s respiratory questionnaire (activity) 0.235 <0.001 
St George’s respiratory questionnaire (impact) 0.251 <0.001 
St George’s respiratory questionnaire (total) 0.267 <0.001 
Table 30: The relationship (r) between Aα-Val360 and physiological, radiological and symptomatic 
markers of disease severity in PiZ subjects with A1AT deficiency.  
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7.2.2 Longitudinal Relationships 
 
There was significant progression of all physiological parameters in the 350 PiZ subjects who 
were reviewed annually over a median period of 6.00 years (IQR 3.97 – 8.61) (Table 31). The 
median annual decline in FEV1 (% predicted) was 0.52% (IQR 0.11 – 1.63), while the annual 
decline in absolute FEV1 was 33.5 ml/yr (IQR 10.0 – 68) and the annual decline in KCO (% 
predicted) was 1.30% (IQR 0.22 – 2.29).  
 
Parameter Baseline 
Median (IQR) 
Follow-up 
Median (IQR) 
p 
(Baseline vs Follow-up) 
Age (years) 51.26 (43.92 – 57.33) 58.05 (49.14 to 63.85)  
FEV1 (litres) 1.69 (1.17 to 2.61) 1.40 (1.05 to 2.22) <0.001 
FEV1 (% predicted) 55.62 (36.84 to 85.51) 47.82 (33.23 to 81.45) <0.001 
KCO (mmol/min/kPa/litre) 1.08 (0.86 to 1.36) 0.91 (0.72 to 1.18) <0.001 
KCO (% predicted) 67.06 (54.47 to 82.41) 59.50 (47.80 to 73.73) <0.001 
FEV1:FVC 41.25 (30.59 to 61.29) 35.42 (26.72 to 55.17) <0.001 
Table 31: Aα-Val360 was measured in 350 subjects with PiZ alpha-1-antitrypsin deficiency with a wide 
range of disease severity. The age and full lung function tests at baseline and at follow-up (median of 6 
years later) are quoted. The statistical significance refers to the difference between follow-up and baseline 
values. 
 
 
The Aα-Val360 concentration related to physiological parameters at both baseline and follow-up, 
however it did not relate to progression of either FEV1 or KCO.  
 
Linear regression analysis was performed using the following parameters: Aα-Val360, BMI, index 
status, smoking status (current, ex, never), age, sex, inhaled therapy (combination therapy, long 
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acting antimuscarinic or steroid) and baseline lung function (either FEV1 or KCO). This 
identified inhaled steroid use, increasing age, index case status and higher baseline KCO as 
independent predictors of a more rapid decline in KCO (standardised b values of -0.114, -0.142, -
0.132 and -0.225; p values 0.04, 0.022, 0.029, 0.001 respectively). Linear regression identified 
being male, a current smoker, and having a higher baseline FEV1 as independent predictors of a 
more rapid decline in FEV1 (standardised b values -0.158, -0.139, -0.144; p values 0.004, 0.020, 
0.017 respectively).  
 
7.2.3 Cross-Sectional and Longitudinal Relationships in Subjects with a ‘normal’ FEV1 
 
There was a subgroup of 96 PiZ subjects with an FEV1 (% predicted) within the normal range 
(>80%), of whom 53 (55.2%) were never smokers, 39 (40.6%) were ex-smokers and 4 (4.2%) 
were current smokers. There were 62 non-index and 34 index patients. Within this subgroup, 
there was no relationship between Aα-Val360 and age, weight, BMI or pack year smoking history, 
however, there were significant relationships between Aα-Val360 and measures of disease severity 
(Table 32). 
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Parameter r p 
FEV1 (% predicted) -0.181 0.039 
KCO (% predicted) -0.187 0.034 
Upper zone voxel index (-910 Hounsfield units) 0.262 0.028 
Lower zone voxel index (-910 Hounsfield units) 0.197 0.032 
St George’s respiratory questionnaire (symptoms) 0.268 0.004 
St George’s respiratory questionnaire (activity) 0.216 0.017 
St George’s respiratory questionnaire (impact) 0.241 0.010 
St George’s respiratory questionnaire (total) 0.265 0.005 
Table 32: Relationships between Aα-Val360 and markers of disease severity in subjects with an FEV1 (% 
predicted) within the normal range 
 
These 96 subjects were followed up on an annual basis for a median of 6.64 years (IQR 4.49 – 
9.50). The median annual change within this subgroup was -0.25 (IQR -1.68 – 0.60) for FEV1 (% 
predicted) and -0.96 (-1.86 – -0.04) for KCO (% predicted). The annual change in FEV1 
(%predicted) was greater (p=0.011) in index patients with a median of -1.04 (IQR -2.71 to 0.11) 
compared to non-index patients with a median of 0.03 (-1.20 to 0.84). There were no significant 
relationships between Aα-Val360 or other parameters, however, and of importance, the baseline 
Aα-Val360 concentration related to the annual change in KCO (% predicted) (r=-0.172, p=0.047) 
in this subgroup, although no factor was independently associated in linear regression analysis. 
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7.3 AΑ-VAL360 IN SUBJECTS WITH A1AT DEFICIENCY: DISCUSSION 
 
The role of NE in the pathogenesis of COPD, particularly related to A1AT deficiency, has long 
been recognised and elegant mathematical and in vitro modelling predicted an exponential 
relationship between the A1AT concentration and extent of neutrophil mediated proteolytic 
damage [52-54]. Although NE is released from the neutrophil at a high concentration, its 
concentration rapidly decreases with diffusion and complete inhibition occurs within the 
neutrophil micro-environment when an equimolar concentration is reached with its main inhibitor 
(A1AT), even in A1AT deficient subjects. Therefore free NE activity cannot be detected 
regularly even in sputum obtained from subjects in the stable clinical state, and is never 
detectable in plasma samples [71]. The current study describes the use of a unique surrogate 
marker of NE activity (Aα-Val360) which demonstrates exponentially greater NE activity in 
subjects with severe PiZ A1AT deficiency compared to those with less severe A1AT deficiencies 
or healthy controls, and is therefore consistent with the earlier mathematical model [52-54].  
 
7.3.1 Aα-Val360 in PiZ and non-PiZ A1AT Deficiencies  
 
There were a number of subjects with non-PiZ phenotypes who met the spirometric criteria for 
the diagnosis of COPD, however this relates to the number of smokers within this study 
population. Interestingly, the proportion of current or ex-smokers with an FEV1/FVC<0.7 was 
similar irrespective of A1AT phenotype (although, as expected, was slightly less in the PiZ 
subjects) which indicates the importance of tobacco smoke in disease pathogenesis, even in the 
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A1AT deficient population (as reported previously [248, 252]). The non-random referral pattern 
to the ADAPT project may also influence the distribution of emphysema seen amongst the 
different phenotypes, since subjects in the UK are not identified through population screening. 
Instead, patients are included in the registry if they are referred with an abnormal A1AT 
phenotype after presenting to their clinician with symptoms (index cases) or through family 
screening (non-index cases). Although this may not reflect the true distribution of the disease by 
phenotype within the general population, the data are nevertheless highly relevant since this large 
group of patients will be representative of those who present in clinical practice (i.e. with 
symptoms or as family members of those identified as having A1AT deficiency).  
 
There remains controversy regarding the risk conferred by the PiSZ phenotype for the 
development of COPD [56], and it is therefore of interest that the current study shows that 
subjects with PiSZ A1AT deficiency have a greater Aα-Val360 concentration than either PiMZ or 
PiM subjects. The difference between PiSZ and healthy (never smoking) PiM subjects may partly 
be accounted for by differences in their smoking history or the presence of COPD (since these 
subjects were not matched). However, there were significant differences in Aα-Val360 
concentrations between PiSZ and PiMZ subjects despite similar smoking patterns, spirometry, 
and distribution of subjects with an FEV1/FVC below 0.7 between the 2 groups. Although, a 
greater proportion of the PiMZ subjects were index cases (63.33% vs. 19.61%; p<0.001), it 
would be anticipated that this would be associated with a higher (and not lower Aα-Val360 
concentration) since in the current study, index status in PiZ subjects was associated with a 
greater Aα-Val360 concentration. The greater Aα-Val360 in PiSZ subjects may indicate an 
increased risk of developing progressive lung disease compared to similar patients with less 
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severe deficiencies or normal A1AT concentrations. However, the Aα-Val360 is greatest in PiZ 
subjects, and furthermore the data demonstrated a relationship between the A1AT concentration 
and this marker of NE activity even within PiZ subjects suggesting the greatest risk remains for 
those with the most severe A1AT deficiencies. This is also consistent with the differences in 
clinical phenotype observed between PiZ, PiSZ patients and other A1AT phenotypes [56]. It 
should also be noted that physiological impairment is reported to be even greater in patients with 
the null versions of A1AT deficiency [253] and it would be of interest to study Aα-Val360 in these 
individuals where it would be predicted to be higher still. 
 
Subjects with PiSZ A1AT deficiency have a significantly lower A1AT concentration than those 
with PiS A1AT deficiency yet have a similar Aα-Val360 concentration. However, in this relatively 
small group of patients, confounding factors have the potential to have a greater influence. For 
example, the higher than expected Aα-Val360 concentration in the PiS subjects may be explained 
by the chance inclusion in the registry of PiS patients with more severe disease since they have a 
significantly lower FEV1 (% predicted) and number of subjects with an FEV1/FVC<0.7 than the 
PiSZ population and in this respect they behave more like patients with usual COPD (Chapter 5).  
Additionally, there were greater numbers of index cases with a PiS rather than PiSZ phenotype 
which may reflect pathophysiological processes and would also explain differences in 
neutrophilic disease activity between these populations (Figure 26 and Figure 27).  
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Figure 26: The complex relationship between disease severity, activity and risk factors. In subjects with 
A1AT deficiency, there are a number of risk factors (blue circles) that are associated with greater disease 
progression and disease activity (red circle). In turn greater disease activity will be reflected by increases 
in Aα-Val360 and eventually by changes in markers of disease severity (such as FEV1 or CT densitometry). 
In the current study, PiS subjects had a higher Aα-Val360 concentration and worse disease severity than 
PiSZ subject. It is likely that other factors (perhaps genetic or as yet unrecognised) have led to greater 
disease/neutrophil activity (and hence more severe disease and greater Aα-Val360) in the PiS population or 
acquisition to the registry. In the latter instance, there is likely to be a relationship between current 
disease activity and disease severity irrespective of phenotype (Figure 27) although this is discussed 
further in section 7.3.4.  
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Figure 27: A marker of current disease activity would relate to future disease severity (since an active 
disease process would eventually lead to progressive tissue damage detectable by a marker of disease 
severity in the future). If the marker of disease activity is stable then it would also relate to past disease 
activity and hence there would be at least a partial relationship with current disease severity. This is 
discussed further in section 7.3.4. 
 
7.3.2 Aα-Val360 in PiZ A1AT Deficient Subjects 
 
There was a relationship between Aα-Val360 and pack year smoking history, however this was not 
observed if never smokers were excluded and suggests a binary population effect rather than a 
continuum. This is also consistent with previous studies which demonstrate a threshold 
(irrespective of pack year history) beyond which the risk of COPD increases exponentially [254]. 
It is therefore likely that significant previous cigarette exposure is sufficient to create ongoing 
evidence of NE activity, although the evidence of NE activity is greater in those who continue to 
smoke (i.e. greater Aα-Val360 concentrations in current versus ex-smokers).  
189 
 
 
A1AT deficiency is the only recognised genetic risk factor for the development of COPD, 
however the current study demonstrates that non-index subjects with PiZ deficiency have a lower 
Aα-Val360 concentration than other PiZ subjects. Of significant importance, it was also shown that 
never-smoking index cases have significantly greater Aα-Val360 concentrations than never-
smoking non-index cases. This suggests the presence of additional neutrophilic risk factors 
(genetic or environmental) in index patients that have yet to be identified, and is consistent with 
previous work suggesting non-index, never smokers with PiZ deficiency have a normal life 
expectancy [250]. 
 
7.3.3 Stability of Aα-Val360 
 
The stability of Aα-Val360 over time has previously been demonstrated (Chapter 4 and [214]) and 
in the current study the concentration of Aα-Val360 does not relate to age. Since in a cross-
sectional study, age is partly a reflection of disease duration, this again indicates the stability of 
Aα-Val360 which is important for a biomarker.  
 
7.3.4 The Cross-sectional Relationship of Aα-Val360 with Markers of COPD Disease 
Severity 
 
It is likely that an important characteristic of an ideal biomarker of disease activity is to relate to 
cross-sectional markers of disease severity (such as FEV1) [207, 209]. A marker of severity at a 
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single time point will broadly reflect disease activity but will be influenced by age (length of 
disease progression) and predisposing factors such as tobacco exposure, but will not predict 
progression (Figure 27).  
 
However, this is also complicated by the absence of a gold standard marker of COPD disease 
severity or activity. For example, FEV1 may exhibit greater day-to-day variability than its decline 
over several years [255], and pharmacological interventions may significantly increase FEV1 yet 
fail to influence mortality or subsequent progression [101]. However, FEV1 is widely used and 
relates to overall and lung specific mortality [206], and therefore importantly there was a 
relationship between FEV1 and Aα-Val
360
. Additionally, Aα-Val360 also related to other widely 
accepted markers of disease severity in this large cohort of patients including gas transfer and CT 
densitometry demonstrating that this marker is (at least partly) a measure of current emphysema 
severity. Furthermore, there were highly significant relationships with 2 independent measures of 
quality of life in subjects with COPD: the SGRQ [224] and the CAT score [123]. This is 
important since it is well recognised that patients may have relatively severe symptoms despite 
relatively mild physiological changes [91], and therefore an ideal biomarker of disease severity or 
activity should relate to measures of symptoms, as well as markers of disease severity 
(radiological, physiological or otherwise).  
 
Some caveats should be applied to the hypothesised relationship between disease activity and 
disease severity since it assumes disease activity is stable throughout or alternatively that the 
biomarker measures the predominant level of disease activity over the course of the disease 
process. If activity is not stable, when biomarkers are measured in large cross-sectional studies it 
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is more likely that they will be obtained at a point which reflects the predominant (and 
presumably longstanding) level of disease activity with a resulting relationship between disease 
severity and activity across the population, even if this relationship is not observed for each 
individual. Currently, there is no gold standard marker of disease activity and therefore it is 
difficult to conclusively address these important issues, however the current thesis provides some 
data to suggest that the marker Aα-Val360 (and hence disease activity) is stable at least over a 
period of 2 years (section 4.2) and is stable in repeated measures over a period of 84 days (section 
4.1). Importantly, there is no relationship to age in the large population of PiZ A1AT deficient 
subjects which suggests that there is no systematic variation in disease activity over time in this 
cross-sectional study. Also, while patients experience exacerbations and an associated increase in 
Aα-Val360, it returns relatively rapidly to baseline which is consistent with both the stability of 
underlying disease activity and the small contribution of exacerbations to decline in FEV1 [181].  
 
Data from studies investigating other potential biomarkers of disease activity also suggest a 
relationship between disease activity and disease severity, since urinary desmosine concentration 
relates to disease severity (albeit relatively weakly) [201] which again indicates that activity may 
be relatively stable throughout the course of the disease (or alternatively that urinary desmosine is 
increased in more severe disease). There is also the potential that underlying pathophysiological 
disease activity may be stable, but changes in markers of severity such as FEV1 may not be linear 
with respect to time, owing to the complex relationship between airflow obstruction and 
pathological changes within the airway and parenchyma. With this in mind, more recent data 
suggest that the natural history of the decline in physiological parameters is more heterogeneous 
than previously thought [88]. However, further data are required to establish the true longitudinal 
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variability of progression in patients with COPD using a range of measures including change in 
FEV1, gas transfer and CT densitometry in combination with serial measurement of biomarkers 
ideally over a period of 15 to 20 years. This clearly is beyond the scope of the current thesis.  
 
7.3.5 Aα-Val360 and BMI 
 
The current study also demonstrates that Aα-Val360 relates to BMI, which is of interest since a 
low BMI is associated with a higher mortality in subjects with COPD [129] and is therefore 
indicative of the systemic nature of this disease process. This concept is increasingly recognised 
since weight loss is a relatively common phenomenon in subjects with COPD, and relates to both 
excessive energy expenditure and insufficient calorie intake [256]. Also, a link between 
antinuclear autoantibodies and low BMI in subjects with COPD has been reported, which is not 
present in subjects without COPD [257], although this was not replicated in a second study [258]. 
If true, this may partly explain the systemic aspect of the disease process since subjects with 
COPD and a lower BMI are more likely to be positive for an autoantibody, have an emphysema 
predominant phenotype (indicating lung parenchymal destruction which may be associated with 
an autoimmune process) [259], and have a higher Aα-Val360 (as a measure of the final common 
pathway leading to connective tissue destruction). However, the underlying pathological 
mechanism explaining the relationship between BMI, emphysema and autoantibodies has yet to 
be identified, and therefore this can only be considered an association at this stage rather than 
causation.  
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An association between TNF-α and a lower BMI in subjects with COPD has also been described, 
since TNF-α can trigger a decreased energy intake, and adversely influence protein and lipid 
metabolism [260]. Interestingly, it was also shown that subjects with a low BMI also had a lower 
KCO (indicating a more severe emphysematous process) compared to those with a normal BMI, 
although the association with emphysema was not confirmed since the study pre-dated 
quantitative CT scanning. Also, causation has not been definitively proven, since starvation itself 
may lead to an elevated level of TNF-α [261]. Additionally, trials of anti-TNF-α therapy have had 
disappointing (and possibly even detrimental) results [212], however, the absence of a 
demonstrable therapeutic effect may partly reflect generally low levels of TNF-α. On the other 
hand, the presence of TNF polymorphisms (such as rs361525) is associated with chronic 
bronchitis, a lower BMI and faster disease progression, in addition to increased airways 
secretions of TNF-α [262]. The detection of such polymorphisms for TNF-α may therefore 
enable the use of more targeted therapy for COPD, with the efficacy measured using a marker of 
disease activity. 
 
7.3.6 Relationship of Aα-Val360 to other biochemical markers 
 
Although sputum biomarkers are impractical since (for example) not all patients produce sputum, 
they nevertheless relate to disease progression in COPD [21] and in the current study they related 
to Aα-Val360. Interestingly, there was a stronger relationship between Aα-Val360 and LTB4 than 
between Aα-Val360 and IL-8 which is the converse of findings in subjects with usual COPD 
(Chapter 5 and [217]). Both IL-8 and LTB4 promote transendothelial migration of neutrophils, 
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and are increased in subjects with COPD related to A1AT deficiency compared to those with 
usual COPD (with an associated increase in sputum chemotactic activity) [263]. However, in 
vitro studies demonstrate that the relative contributions of IL-8 and LTB4 towards chemotaxis in 
the airways are similar in both usual COPD and A1AT deficiency, with the greatest contribution 
provided by LTB4 in both groups [263]. The disparity suggested by the in vitro data and Aα-
Val
360 
data regarding the relative roles of LTB4 and IL-8 may be explained by differences in 
chemotaxis in vitro compared to the true in vivo contributions, particularly in the lung 
parenchyma rather than the airway. The plasma marker Aα-Val360 may be more influenced by 
neutrophilic activity within the lung parenchyma, while clearly sputum markers will be more 
influenced by changes within the airway. Alternatively, the better relationship between Aα-Val360 
and LTB4 in A1AT deficiency may reflect greater activation of neutrophils rather than stronger 
chemotaxis, since LTB4 can also stimulate both neutrophil degranulation and oxidative 
metabolism [264]. This neutrophil ‘activation’ would be associated with greater tissue damage 
(and higher Aα-Val360 concentrations) in the A1AT deficient subject compared to the non-
deficient individual because of the differences in quantum proteolytic events between these 
groups as explained previously. 
 
The Aα-Val360 also partly relates to the A1AT/NE complex which is a marker of total NE release. 
However, the complex does not relate to any measure of disease severity which suggests that it is 
important to measure the activity of NE prior to its inhibition rather than total release. 
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7.3.7 Longitudinal Relationships 
 
Over the 6 years of the study there was significant disease progression as measured by all 
physiological tests. Linear regression demonstrated index case status, increasing age, higher 
baseline KCO and use of inhaled steroids to be significant factors for progressive disease 
measured by gas transfer which again highlights the importance of index case status in 
determining prognosis. The correlation with age is perhaps unsurprising since COPD is more 
likely to develop in A1AT deficient subjects with time, and reflects duration of the patient’s 
exposure to risk factors. The relationship with a higher baseline KCO is important and may be 
explained by the presence of increased disease activity in subjects with earlier disease. The 
relationship of decline with inhaled steroids is of interest, although it should be interpreted with 
significant caution, since this was a weak association in a non-randomised trial. This may 
therefore represent confounding rather than a true association since, for example, subjects who 
were deteriorating more quickly may be more likely to be commenced on inhaled corticosteroid 
treatment. Additionally, inhaled steroids were more likely to be prescribed to subjects with an 
‘asthmatic’ component which makes further analysis more difficult, since there is controversy 
regarding the diagnosis of asthma in subjects with COPD, emphysema and/or A1AT deficiency. 
Although NICE guidelines [2] suggest asthma may be distinguished from COPD by symptoms 
(Table 33), many of these symptoms are shared and they are less helpful in the 35 years or older, 
ex or current smoker who is commonly referred to the ADAPT registry. Also, it is increasingly 
recognised that patients with COPD have diurnal variability [265] and quantification of 
‘significant variability’ may be arbitrary. Furthermore, while significant bronchodilator 
reversibility of over 400 ml may help to distinguish asthma and COPD [2],  lesser reversibility 
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commonly occurs in patients with asthma and may also be observed in patients with COPD [95]. 
Finally asthma and COPD probably co-exist in a number of patients [266].  
 
Clinical Feature COPD Asthma 
Smoker or ex-smoker Common Possibly 
Symptoms<35 yrs old Rare Often 
Chronic productive cough Common Uncommon 
Breathlessness Persistent and progressive Variable 
Night-time waking with breathlessness 
or wheeze 
Uncommon Common 
Significant diurnal or day-to-day 
variability 
Uncommon Common 
Table 33. Clinical features which have been suggested to distinguish between asthma and COPD [2] 
 
Linear regression analysis identified being male and a current smoker as independent risk factors 
for disease progression measured by spirometry. The Aα-Val360 was greater in subjects who 
continued to smoke, and these subjects therefore have both ongoing NE activity and greater 
spirometric decline. The association between a higher baseline FEV1 (% predicted) and greater 
rate of decline is again of importance since these are likely to be subjects in whom targeted 
intervention may be more effective.  
 
Although the Aα-Val360 related to disease progression measured by physiological markers of 
disease severity in subjects with an FEV1>80%, it did not appear to relate to disease progression 
in the overall cohort, however, the relationships between markers of disease activity and disease 
severity are likely to be complex. Firstly, the absence of a relationship may be at least partly 
explained by confounding factors within the heterogeneous nature of the cohort which included 
subjects with a wide range of disease severity and a mix of index and non-index cases and current 
197 
 
and never smokers. Secondly, it may also be explained by the inter-patient variability of Aα-
Val
360 
or the variability and relative insensitivity of physiological tests for detecting changes in 
disease severity, since the annual loss of FEV1 was only 0.52 (IQR 0.11 – 1.63) % predicted/year 
(which is close to normal) while the annual change in KCO (% predicted) was -1.30 (IQR 0.22 – 
2.29) % predicted. Therefore these physiological tests may not allow discrimination between 
rapid and slow decliners, even within the scope of this large study. Additionally, physiological 
decline may not be linear, which would further complicate the relationships. Thirdly, the 
discrepancy between index and non-index cases both in terms of Aα-Val360 concentrations and 
disease severity also suggests that there are further confounding factors (presumably genetic) that 
are not adequately accounted for by the multivariate model used within the current study. 
Fourthly, it is important to consider that a marker of disease activity may predict overall disease 
progression, which may not be adequately measured by a single physiological marker such as 
either FEV1 or KCO, since some patients may exhibit significant changes in FEV1 and yet have 
little change in KCO. Fifthly, it is possible that a marker of neutrophilic disease activity (such as 
Aα-Val360) is a more important predictor of disease progression only in subjects with mild 
spirometric changes who may have an early and more distinct disease process.  
 
Sixthly, disease activity in patients may be highly variable and in these circumstances there 
would be no relationship between a measure of disease activity at a single time point and 
subsequent disease progression. However, the data reported in the current thesis suggest that, at 
least over the short term, Aα-Val360 is stable and therefore a relationship between Aα-Val360 and 
disease progression over a 2 or 3 year period may be expected if it reflects the key underlying 
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disease activity. Further data is required however to confirm stability over a longer period of time 
and to clarify this relationship. 
 
Finally, Aα-Val360 may be a good marker of NE related disease activity in the stable state, 
however, this may provide insufficient data to allow predictions to be made about disease 
progression. For example, a model of disease progression based purely on stable state Aα-Val360 
data will not necessarily account for the number of exacerbations (since both disease activity and 
Aα-Val360 rise significantly during these periods).With this in mind it should be noted that 
subjects with symptoms of COPD who experienced a purulent exacerbation had a higher stable 
state Aα-Val360 (Chapter 5), indicating this biomarker (at least partly) reflects the nature of 
exacerbations even when measured in clinically stable subjects. Also, enzymes other than NE 
may also be important in the pathogenesis of COPD (including Pr3 and MMPs), which may not 
be adequately accounted for by the Aα-Val360 model. However, there were clear (and highly 
statistically significant) relationships between Aα-Val360 and current markers of disease severity 
in COPD, and furthermore there is a trend towards a relationship with disease progression in the 
population with symptoms of COPD (Chapter 5) and the A1AT population with an FEV1>80% 
indicating that Aα-Val360 may be a marker of early disease activity (and may particularly relate to 
emphysema progression), although greater prognostic accuracy may be achieved by combining 
the results with a number of other relevant activity markers.  
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7.3.8 Aα-Val360 as a Marker of Early Disease 
 
Support for the concept of Aα-Val360 as a marker of activity in early disease was provided by the 
highly significant relationships with physiological, radiological and symptomatic markers of 
COPD disease severity in subjects with an FEV1 within the normal range (>80%). Furthermore 
within this subgroup, there was a significant association between Aα-Val360 and disease 
progression measured by decline in gas transfer. These data suggest that there are patients with 
little physiological evidence of disease who have an ongoing disease process which can be 
detected by a sensitive marker of disease activity such as Aα-Val360. Also, it demonstrates the 
potential heterogeneous nature of the pathophysiological processes in this group of patients 
which includes those with both early and mild disease. This suggests that intervention in this 
group of patients with earlier disease and a higher Aα-Val360 would be of greatest benefit, 
however clearly large prospective studies are required to investigate this further. 
 
7.3.9 Summary 
 
In the current study, the Aα-Val360 relates to the prevailing A1AT concentration in vivo 
confirming previous in vitro and observational data. Also, data from this large cohort of subjects 
with PiZ A1AT deficiency demonstrate that Aα-Val360 relates cross-sectionally to physiological, 
radiological and symptomatic markers of disease severity. Importantly, these relationships are 
also present in subjects with mild or no physiological change, in whom the Aα-Val360 
concentration also relates to disease progression. Aα-Val360 may be of particular use in 
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identifying subjects with progressive early stage disease especially as a measure of the 
emphysematous component of COPD. This marker maybe of greatest relevance in clinical trials, 
to develop and identify treatment interventions which may be effective prior to significant 
physiological or symptomatic decline. However, further work is required to understand the 
complex relationships between this marker and disease activity, severity and progression in 
subjects with A1AT deficiency in general, potentially by exploring the activity of other important 
enzymes as well as the impact of exacerbations. However, this is beyond the scope of the current 
thesis.  
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CHAPTER 8. IDENTIFYING SPECIFIC PR3 
FIBRINOGEN CLEAVAGE PRODUCTS: RESULTS 
AND DISCUSSION 
 
8.1 RESULTS 
8.1.1 Low Molecular Weight Peptides 
 
MS analysis detected a number of peptides in the solutions of fibrinogen following incubation 
with NE or Pr3 at 37
o
C, and many of these peptides were successfully identified (Figure 28) 
using peptide mass fingerprinting (MASCOT database). The identified peptides were derived 
from fibrinogen (the beta, gamma and alpha chains), Pr3 (termed myeloblastin by MASCOT) as 
well as minor contaminants of the human fibrinogen preparation (transthyretin, complement, 
immunoglobulin and keratin). The peak list for all the peptides or fragments identified by 
MASCOT in the solutions with a mass:charge below 5000 is shown in Figure 29, although there 
were also a number of peptides that were detected by MS but not identified. Although the peak 
lists for the NE/fibrinogen and the Pr3/fibrinogen solutions were similar, there were also peaks 
which were unique to either NE or Pr3 (Figure 30) indicating that certain products formed by the 
cleavage of fibrinogen are enzyme specific. 
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Taxonomy        : Homo sapiens (human) (20266 sequences) 
Timestamp       : 7 Jan 2011 at 15:36:27 GMT 
Protein hits    : FIBA_HUMAN  Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 
   CO4B_HUMAN  Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=1 
   TTHY_HUMAN  Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 
   FIBG_HUMAN  Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 
   K2C6A_HUMAN Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 
   PRTN3_HUMAN Myeloblastin OS=Homo sapiens GN=PRTN3 PE=1 SV=3 
   ANT3_HUMAN  Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 
   FIBB_HUMAN  Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 
   IGHG1_HUMAN Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 
 
 
FIBA_HUMAN    Mass: 94914    Score: 195    Matches: 28(5)  Sequences: 28(5)  emPAI: 0.57 
Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 
   
    
Observed   Mr(expt)   Mr(calc)    ppm   Miss  
Score
  
Expect  Rank  
Unique
  
 Peptide 
  1067.5225   1066.5152   1066.5117   3.28  0   30   2.3  1   U    I.MEILRGDFS.S 
  1159.5593   1158.5521   1158.5710   -16.34  0   30   2.9  1   U    T.ASTGKTFPGFF.S 
  1341.6891   1340.6818   1340.6837   -1.42  0   40   0.31  1   U    V.SFRGADYSLRAV.R 
  1350.6152   1349.6079   1349.6212   -9.83  0   57   0.004  1   U    D.SGEGDFLAEGGGVR.G 
  1385.6126   1384.6053   1384.6106   -3.83  0   36   0.38  1   U    V.SETESRGSESGIF.T 
  1465.6632   1464.6559   1464.6481   5.30  0   55   0.006  1   U    A.DSGEGDFLAEGGGVR.G 
  1474.6894   1473.6822   1473.6963   -9.57  0   26   5.8  1   U    T.ASTGKTFPGFFSPM.L 
  1478.7182   1477.7109   1477.7062   3.17  0   44   0.11  1   U    S.SSHHPGIAEFPSRG.K 
  1536.6952   1535.6879   1535.6852   1.77  0   52   0.014  1   U    T.ADSGEGDFLAEGGGVR.G 
  1573.7984   1572.7911   1572.8082   -10.91  0   34   1.3  1   U    T.SLGGWLLIQQRMDG.S 
  1587.7549   1586.7476   1586.7803   -20.62  0   26   6.6  1   U    T.ASTGKTFPGFFSPML.G 
  1640.7170   1639.7097   1639.7114   -1.02  0   32   0.89  1   U    T.SYNRGDSTFESKSY.K 
  1644.7587   1643.7514   1643.8018   -30.65  0   29   3.1  2   U    T.ASTGKTFPGFFSPMLG.E 
  1773.7824   1772.7751   1772.7968   -12.20  0   32   0.91  1   U    F.PGFFSPMLGEFVSETE.S 
  1822.8862   1821.8789   1821.8758   1.73  0   42   0.19  1   U    T.KESSSHHPGIAEFPSRG.K 
  1846.8431   1845.8359   1845.8606   -13.39  0   61   0.0017  1   U    T.ADSGEGDFLAEGGGVRGPR.V 
  1899.8703   1898.8630   1898.8468   8.53  0   46   0.05  1   U    T.SYNRGDSTFESKSYKM.A 
  1915.8280   1914.8207   1914.8232   -1.27  0   26   2.8  1   U    T.SSTSYNRGDSTFESKSY.K 
  1920.9035   1919.8962   1919.9128   -8.66  0   33   1.4  1   U    T.ASTGKTFPGFFSPMLGEF.V 
  1958.8871   1957.8798   1957.8865   -3.42  0   46   0.046  1   U    V.SETESRGSESGIFTNTKE.S 
  1970.9065   1969.8992   1969.8840   7.73  0   34   0.89  1   U    T.SYNRGDSTFESKSYKMA.D 
  2037.9753   2036.9680   2036.9664   0.80  0   36   0.85  1   U    T.NTKESSSHHPGIAEFPSRG.K 
  2044.9705   2043.9632   2043.9974   -16.74  0   28   4.3  1   U    T.ADSGEGDFLAEGGGVRGPRVV.E 
  2045.9252   2044.9179   2044.9185   -0.31  0   43   0.098  1   U    V.SETESRGSESGIFTNTKES.S 
  2174.9913   2173.9841   2173.9586   11.7  0   26   4.9  1   U    T.SSTSYNRGDSTFESKSYKM.A 
  2553.2097   2552.2024   2552.1781   9.50  0   99   3.6e-007  1   U    T.ASTGKTFPGFFSPMLGEFVSETES.R 
  2648.1877   2647.1804   2647.1746   2.18  0   85   5.9e-006  1   U    V.SETESRGSESGIFTNTKESSSHHPG.I 
  2766.3100   2765.3028   2765.3007   0.74  0   43   0.14  1   U    T.ASTGKTFPGFFSPMLGEFVSETESRG.S 
 
 
CO4B_HUMAN    Mass: 192673   Score: 91     Matches: 4(2)  Sequences: 4(2)  emPAI: 0.05 
Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=1 
       Observed   Mr(expt)   Mr(calc)    ppm   Miss  Score  Expect  Rank  Unique  Peptide 
  1739.9273   1738.9200   1738.9227   -1.54  0   26   8.7  1   U    R.NGFKSHALQLNNRQI.R 
  1890.9627   1889.9554   1890.0098   -28.78  0   80   3.5e-005  1   U    R.GLEEELQFSLGSKINVK.V 
  1896.0054   1894.9981   1895.0238   -13.52  0   29   4.2  1   U    R.NGFKSHALQLNNRQIR.G 
  2751.2254   2750.2181   2750.2858   -24.61  0   57   0.0031  1   U    R.TLEIPGNSDPNMIPDGDFNSYVRVT.A 
 
  
       Proteins matching the same set of peptides: 
       CO4A_HUMAN    Mass: 192650   Score: 91     Matches: 4(2)  Sequences: 4(2) 
  Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1 
 
3.     TTHY_HUMAN    Mass: 15877    Score: 73     Matches: 5(2)  Sequences: 5(2)  emPAI: 0.69 
  Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 
       Observed   Mr(expt)   Mr(calc)    ppm   Miss  Score  Expect  Rank  Unique  Peptide 
  958.5001   957.4928   957.5131   -21.18  0   41   0.24  1   U    T.TAVVTNPKE.- 
  1063.5149   1062.5076   1062.5094   -1.73  0   68   0.0005  1   U    V.VFTANDSGPR.R 
  1250.5439   1249.5366   1249.5615   -19.94  0   33   0.81  1   U    R.KAADDTWEPFA.S 
  1969.9546   1968.9474   1969.0044   -28.97  0   43   0.17  1   U    A.LLSPYSYSTTAVVTNPKE.- 
  2225.0911   2224.0838   2224.1627   -35.47  0   55   0.011  1   U    T.IAALLSPYSYSTTAVVTNPKE.- 
 
 
 
 
 
4. 
    
2.     
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FIBG_HUMAN    Mass: 51479    Score: 66     Matches: 2(1)  Sequences: 2(1)  emPAI: 0.09 
  Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 
 
Observed   
Mr(expt)   Mr(calc)    ppm   Miss  Score  Expect  Rank  Unique  Peptide 
1117.6130   1116.6057   1116.6291   -20.96  0   38   0.51  1   U    T.QSAIPYALRV.E 
2690.2878   2689.2805   2689.2886   -3.03  0   66   0.00078  1   U    T.ADYAMFKVGPEADKYRLTYAYFA.G 
 
5.     K2C6A_HUMAN    Mass: 60008    Score: 52     Matches: 2(0)  Sequences: 2(0)  emPAI: 0.07 
  Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 
Observed   Mr(expt)   Mr(calc)    ppm   Miss  Score  Expect  Rank  Unique  Peptide 
1407.6915   1406.6842   1406.7041   -14.18  0   52   0.021  1   U    K.ADTLTDEINFLR.A 
1701.7731   1700.7658   1700.8006   -20.46  0   32   1.4  1   U    G.LGLGGGSSYSYGSGLGVGGG.F 
  
       Proteins matching the same set of peptides: 
       K2C6B_HUMAN    Mass: 60030    Score: 52     Matches: 2(0)  Sequences: 2(0) 
  Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 
 
6.     PRTN3_HUMAN    Mass: 27789    Score: 52     Matches: 1(0)  Sequences: 1(0)  emPAI: 0.16 
  Myeloblastin OS=Homo sapiens GN=PRTN3 PE=1 SV=3 
Observed   Mr(expt)   Mr(calc)    ppm   Miss  Score  Expect  Rank  Unique  Peptide 
1042.5196   1041.5123   1041.5284   -15.39  0   52   0.018  1   U    T.RLFPDFFT.R 
 
 
7.     ANT3_HUMAN    Mass: 52569    Score: 50     Matches: 1(0)  Sequences: 1(0)  emPAI: 0.08 
  Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 
Observed   Mr(expt)   Mr(calc)    ppm   Miss  Score  Expect  Rank  Unique  Peptide 
2291.1072   2290.0999   2290.1441   -19.28  0   50   0.032  1   U    K.AFLEVNEEGSEAAASTAVVIAGR.S 
 
 
8.     FIBB_HUMAN    Mass: 55892    Score: 45     Matches: 2(0)  Sequences: 2(0)  emPAI: 0.08 
  Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 
Observed   Mr(expt)   Mr(calc)    ppm   Miss  Score  Expect  Rank  Unique  Peptide 
1160.6520   1159.6448   1159.6502   -4.69  0   39   0.32  1   U    M.KIRPFFPQQ.- 
2551.1382   2550.1309   2550.2238   -36.40  0   45   0.057  1   U    V.KDNENVVNEYSSELEKHQLYI.D 
 
 
10.    IGHG1_HUMAN    Mass: 36083    Score: 43     Matches: 2(0)  Sequences: 1(0)  emPAI: 0.12 
  Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 
Observed   Mr(expt)   Mr(calc)    ppm   Miss  Score  Expect  Rank  Unique  Peptide 
2130.9800   2129.9727   2130.0534   -37.90  0   44   0.1  1   U    D.PEVKFNWYVDGVEVHNAK.T 
2130.9846   2129.9773   2130.0534   -35.73  0   (37)  0.54  1   U    D.PEVKFNWYVDGVEVHNAK.T 
 
Figure 28: Peptide mass fingerprinting: the figure includes the results of a MASCOT search using data 
generated by MS of the Pr3/fibrinogen solution (15 minute incubation at 37
o
C). The displayed data only 
include the results where peptide mass fingerprinting successfully identified the peptide and parent 
protein. Peptides derived from the fibrinogen beta, gamma and alpha chain as well as from Pr3 
(myeloblastin) were detected and identified. The detection of minor contaminants of the human fibrinogen 
(transthyretin, complement, immunoglobulin and keratin) demonstrates the sensitivity of MS. The data 
include the experimental mass:charge ratio (‘observed’); the experimental mass:charge transformed to a 
relative molecular mass (‘Mr (expt)’); the calculated relative molecular mass for the peptide sequence 
(‘Mr (calc)’); number of missed cleavage site (‘miss’); probability score expressed as -10 x log 
(probability) (‘Score’); the number of times the expected ‘score’ would be obtained purely by chance, 
where a lower score is more significant (‘expect’); rank of the ions match, where 1 is the best match 
(‘rank’); U=peptide is unique to the protein (‘unique’); the sequence of the peptide (‘peptide’).  
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Figure 29: Mass spectrometry of solutions of NE/fibrinogen or Pr3/fibrinogen (15 minute incubation at 
37
o
C, followed by inhibition with 0.1% TFA). Each peak represents the detection of a fragment or peptide 
at the specific mass:charge ratio, while the signal intensity gives an indication of the number of ions 
detected. Peaks with a higher intensity can be confidently interpreted as representing a true finding 
(rather than background interference). Since the intensity largely reflects the ease of ionisation of the 
peptide, this measure only partly relates to the concentration of the peptide. Peaks at the same masses 
were detected in both solutions, however there were also peaks specifically formed through cleavage by 
Pr3 (red line) or NE (blue line) (Figure 30). 
 
A peak with a mass of 2021.3 daltons was detected in the Pr3/fibrinogen but not the 
NE/fibrinogen solution (following incubation at 37
o
C for 15 minutes) [Figure 30]. MS analysis of 
plasma from subjects with A1AT deficiency detected a similar peak, indicating a peptide of the 
same mass is also present in vivo, suggesting a specific Pr3 degradation product may be 
detectable in vivo. However, it was not possible to identify this peak using peptide mass 
fingerprinting and the MS-MS analysis was also unsuccessful as the fragmentation of the target 
was poor and therefore this fragment cannot conclusively be related to either Pr3 or fibrinogen. 
There was also a specific peak in the NE/fibrinogen solution and while this could not be detected 
in vivo, this may be accounted for by further in vivo degradation. 
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Figure 30: The MS analysis of the solution of Pr3/fibrinogen detected a peak at a molecular weight of 
2021.3 Daltons. This peak was also present in plasma from subjects with alpha-1-antitrypsin deficiency 
but was not identified in the NE/fibrinogen solution. Similarly, an NE specific fibrinogen degradation 
product was also formed with a molecular weight of 2046 daltons, and while this fragment was not 
identified in plasma this may be explained by further in vivo degradation of the fragment. These data 
suggest that there may be a fragment (with a molecular weight of 2021.3 daltons) which is formed by the 
actions of Pr3 on fibrinogen (but not NE) which can be detected in vivo in patients with A1AT deficiency. 
However, in the absence of specific MS identification, this cannot be concluded categorically since it is 
also possible that an alternate substance (unrelated to fibrinogen or Pr3) with the same mass:charge ratio 
is present in the plasma of patients with A1AT deficiency.  
 
 
8.1.2 Isolation of Cleavage Products using Gel Electrophoresis 
 
In the current thesis, further analysis focussed on the identification of larger molecular weight 
cleavage products since there are more likely to have a greater circulating half-life in vivo and to 
be more enzyme specific (since they will be generated by the initial Pr3 cleavage of fibrinogen) 
[214].  
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The non-reducing gel electrophoresis did not demonstrate any bands below 160 kDa. However, 
the reducing gel electrophoresis demonstrated several bands in both the enzymatically cleaved 
and uncleaved fibrinogen which were labelled A to F (Figure 31). 
 
Importantly, bands A and B were present in the Pr3/fibrinogen solutions but were not in the 
NE/fibrinogen solution or the uncleaved fibrinogen. Band B persisted in the 120 and 180 minute 
samples of Pr3/fibrinogen, however band A became progressively fainter over the same time 
period and was barely visible even at 60 minutes. Band A was also present after incubation of Pr3 
with fibrinogen for only one minute. 
NE
30
Pr3 
15 (I)
Pr3 
15 
(II)
Pr3 
30
Pr3 
60
UF
A B
C
D
E
F
 
Figure 31: Reducing Polyacrylamide Gel Electrophoresis of enzymatically cleaved and uncleaved 
fibrinogen. From left to right, the columns are labelled NE 30 (NE/fibrinogen incubated for 30 minutes); 
Pr3 15 (I) (Pr3/fibrinogen incubated for 15 minutes (1
st
 sample)); Pr3 15 (II) (Pr3/fibrinogen incubated 
for 15 minutes (2
nd
 sample)); Pr3 30 (Pr3 and fibrinogen incubated for 30 minutes); Pr3 60 (Pr3 and 
fibrinogen incubated for 60 minutes); UF (uncleaved fibrinogen). The Pr3 and fibrinogen were incubated 
on a number of occasions to ensure repeatability and in this figure, samples from 2 different incubations 
(both taken at 15 minutes) are shown on the same electrophoresis gel (labelled as I and II).The bands of 
interest are labelled A to F. Similar bands were generated for NE/fibrinogen at 15 minutes and 30 
minutes. Electrophoresis demonstrated identical bands with repeat testing.  
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8.1.3 Peptide Mass Fingerprinting 
 
Peptide mass fingerprinting of the in-gel digests successfully identified the bands labelled A to F 
(Figure 30). Bands D and E both represent isoform 2 of the complete fibrinogen alpha chain, 
however sequences within E could only be definitively identified up to the lysine residue at 598 
which may be explained by an alternate or truncated terminal sequence of the alpha chain which 
is only expressed by some individuals (and identified by gel electrophoresis of this pooled human 
fibrinogen solution). Band C represents the complete fibrinogen beta chain while F represents the 
complete gamma chain. Gel electrophoresis demonstrated that bands A and B both have masses 
between that of C (the complete fibrinogen beta chain) and D (the complete fibrinogen alpha 
chain). Since the masses of the alpha and beta chain are 69,757 and 55,892 daltons respectively, 
the molecular weight of the bands A and B is likely to be between these 2 values.  
  
Following in-gel digestion with trypsin (repeated on several occasions), peptide mass 
fingerprinting of band A consistently identified peptides derived from G72 to K527 of the 
fibrinogen alpha chain (Figure 32), which are recognised trypsin cleavage sites of fibrinogen. In-
gel digestion was also performed using Asp-N which demonstrated peptides between D26 and 
F520, which again are both known Asp-N cleavage points of fibrinogen. These peptide mass 
fingerprinting data were confirmed using HPLC MS-MS. Band A must therefore be generated by 
cleavage of the fibrinogen alpha chain on the carboxyl side of K527 by Pr3. However, these data 
also show that the amino terminus of A is relatively intact (with the exception of the initial 19 
amino acids that form part of the signal peptide of fibrinogen).  
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Peptide mass fingerprinting identified band B as a fragment of the fibrinogen alpha chain, 
although on repeated testing, the results of the MS analysis were less consistent than for band A. 
The apparent carboxyl terminus of band B was between K480 and K527 following digestion with 
trypsin, however, the peptide fragments detected beyond K480 varied with repeated testing.  
 
8.1.4 Data Analysis  
 
Since the specific cleavage sites of trypsin and Asp-N and the full amino acid sequence of human 
fibrinogen are known, potential sites of Pr3 cleavage of the carboxyl terminus of the fibrinogen 
alpha chain were then considered using the accrued data, including the peptide mass 
fingerprinting data and the molecular weight range of band A (demonstrated by gel 
electrophoresis and MS) (Figure 33).  
     1 MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS  
    51 DWPFCSDEDW NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK  
   101 DSHSLTTNIM EILRGDFSSA NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ  
   151 HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC RGSCSRALAR EVDLKDYEDQ  
   201 QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ LQKVPPEWKA  
   251 LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS  
   301 GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS TGSWNSGSSG TGSTGNQNPG  
   351 SPRPGSTGTW NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS  
   401 GNARPNNPDW GTFEEVSGNV SPGTRREYHT EKLVTSKGDK ELRTGKEKVT  
   451 SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK EVVTSEDGSD CPEAMDLGTL  
   501 SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF VSETESRGSE  
   551 SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS  
   601 YKMADEAGSE ADHEGTHSTK RGHAKSRPVR DCDDVLQTHP SGTQS 
Figure 32: Peptide mass fingerprinting of a trypsin digest of Band A demonstrated this band is 
generated from the fibrinogen alpha chain. The peptide sequences which were both detected and 
identified are highlighted in red and there is good sequence coverage between G72 and K527 (both 
known cleavage sites for trypsin), suggesting the Pr3 cleavage point is on the carboxyl side of 
K527. Asp-N cleavage demonstrated peptide sequences from D26 to F520. 
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        10         20         30         40         50         60  
MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS DWPFCSDEDW  
 
        70         80         90        100        110        120  
NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK DSHSLTTNIM EILRGDFSSA  
 
       130        140        150        160        170        180  
NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC  
 
       190        200        210        220        230        240  
RGSCSRALAR EVDLKDYEDQ QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ  
 
       250        260        270        280        290        300  
LQKVPPEWKA LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS  
 
       310        320        330        340        350        360  
GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS TGSWNSGSSG TGSTGNQNPG SPRPGSTGTW  
 
       370        380        390        400        410        420  
NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS GNARPNNPDW GTFEEVSGNV  
 
       430        440        450        460        470        480  
SPGTRREYHT EKLVTSKGDK ELRTGKEKVT SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK  
 
       490        500        510        520        530        540  
EVVTSEDGSD CPEAMDLGTL SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF  
 
       550        560        570        580        590        600  
VSETESRGSE SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS  
 
       610        620        630        640         
YKMADEAGSE ADHEGTHSTK RGHAKSRPVR DCDDVLQTHP SGTQS 
Figure 33: The diagram shows the sequence of the fibrinogen alpha chain with the signal peptide (which 
is removed following translocation across the endoplasmic reticulum [267]) in green text. The potential 
sites of trypsin and Asp-N cleavage around the likely carboxyl terminus of band A, are highlighted in 
yellow and blue respectively. The sites of trypsin and Asp-N cleavage identified by peptide mass 
fingerprinting which were closest to the likely carboxyl terminus are highlighted and in bold. Gel 
electrophoresis and MS analysis demonstrated that the molecular weight of band A is between 55,928 and 
69,757 daltons which suggests the carboxyl terminus of band A lies between M536 and G548 (underlined) 
since the amino terminus of the fibrinogen alpha chain remains relatively intact when A is generated. The 
carboxyl terminus is also unlikely to be beyond R547 since this represents a further potential trypsin 
cleavage site, and therefore in-gel digestion would generate a further fragment (T528 to R547). 
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8.1.5 Identification of the Carboxyl Terminus Peptide Fragment 
 
The data suggest that there is a high probability that the true carboxyl terminus of A (and 
therefore the point of Pr3 cleavage) lies in the amino acid sequence between the 2 trypsin specific 
cleavage sites K527 and G548. Therefore following in-gel digestion, a cleavage fragment must be 
generated which would not be identified by peptide mass fingerprinting (since the carboxyl 
terminus of the peptide fragment will be Pr3 specific and Pr3 cleavage data are not included in 
the online sequencing database). As demonstrated by peptide mass fingerprinting, the amino 
terminus of this fragment would either be D521 (when Asp-N is used for in-gel digestion) or 
T528 (trypsin) while the carboxyl terminus must lie between M536 and G548 (Pr3) 
 
The predicted cleavage points indicated the Asp-N digest was the most likely to produce the 
carboxyl fragment at a detectable molecular weight. The potential terminal fragments in the Asp 
N digest are likely to lie between D521 (after the final detectable amino acid in the Asp N 
digestion) and the subsequent trypsin cleavage site (R547) (Figure 33), since if the Pr3 cleavage 
site were on the carboxyl side of R547, a further complete trypsin-trypsin fragment would have 
been detected by peptide mass fingerprinting. The potential molecular weights of the fragment 
were calculated, assuming that following Asp-N digestion, its amino terminus lies at F520 
(Figure 34).  
 
No identifiable fragment was detected in the trypsin digest. 
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MS analysis of the Asp-N digest of band A detected a number of peaks of varying molecular 
weights [Figure 35], and many of these peaks were identified by peptide mass fingerprinting. 
However, a peak with a molecular weight 2236.08 (which would be consistent with a peptide 
fragment between D521 and V541 of the fibrinogen alpha chain) was detected by MS [Figure 
35], but not identified by peptide mass fingerprinting as would be anticipated if it were formed 
following cleavage by Pr3 because the peptide database does not include data on peptide 
fragments formed by Pr3. Furthermore, this peak at 2236.08 was the only peak of significant 
intensity that was detected, but not matched to a predicted Asp-N peptide fragment (using peptide 
Peptide Fragment   Molecular Weight (daltons) 
D      134.04  
DT     235.09    
DTA     306.13  
DTAS     393.16  
DTAST     494.21  
DTASTG    551.23  
DTASTGK    679.33  
DTASTGKT    780.37  
DTASTGKTF    927.44  
DTASTGKTFP    1024.49  
DTASTGKTFP G    1081.52  
DTASTGKTFP GF   1228.58  
DTASTGKTFP GFF   1375.65  
DTASTGKTFP GFFS   1462.68  
DTASTGKTFP GFFSP   1559.74  
DTASTGKTFP GFFSPM   1690.78  
DTASTGKTFP GFFSPML   1803.86  
DTASTGKTFP GFFSPMLG   1860.88  
DTASTGKTFP GFFSPMLGE  1989.93  
DTASTGKTFP GFFSPMLGEF  2136.99  
DTASTGKTFP GFFSPMLGEFV  2236.06  
DTASTGKTFP GFFSPMLGEFVS  2323.09  
DTASTGKTFP GFFSPMLGEFVSE  2452.14  
DTASTGKTFP GFFSPMLGEFVSET  2553.19  
DTASTGKTFP GFFSPMLGEFVSETE 2682.23  
DTASTGKTFP GFFSPMLGEFVSETV* 2652.25 
DTASTGKTFP GFFSPMLGEFVSETES 2769.26 
DTASTGKTFP GFFSPMLGEFVSETESR 2925.36 
 
 
 
 
 
 
 
 
Figure 34: he masses and amino acid sequences of peptide fragments that could potentially represent the 
carboxyl terminal fragment of band A (following cleavage with Asp-N). The molecular weight will be 
specific to the fragment generated by Asp-N cleavage at the amino terminus (at D521) and Pr3 cleavage 
at the carboxyl terminus. *is the molecular weight of a polymorphism with a valine substitution. These 
data were generated using http://expasy.org/cgi-bin/peptide-mass.pl 
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mass fingerprinting), and additionally was of a mass consistent with a potential carboxyl terminal 
fragment of band A (DTASTGKTFP GFFSPMLGEFV).  
 
 
Figure 35: MS analysis of the Asp-N digest of band A detected a number of peaks representing distinct 
peptides. The peak at 2236.08 (arrowed) would be consistent with the predicted molecular weight of a 
peptide fragment between D521 and V541, and also was not identified using peptide mass fingerprinting. 
Peptide mass fingerprinting identifies peptides by searching databases that include the likely fragments 
that would be formed following digestion using a known enzyme. However, a fragment produced by Pr3 
cannot be identified since the database does not include data relating to digestion with Pr3. 
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8.1.6 MALDI MS-MS Analysis 
 
 
Figure 36: MALDI MS-MS analysis of the 2236.08 Molecular Weight Peptide 
 
 
MS-MS analysis was also performed and, although this did not produce a comprehensive 
fragmentation (Figure 36), fragment ion analysis identified 10 of the expected 21 amino acids 
(DTASTGKTFP GFFSPMLGEFV) within the peptide with a mass of 2236.08.  
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8.2 DISCUSSION 
 
The central role of protease-antiprotease imbalance in the development of COPD has been 
increasingly recognized and although there may be a number of underlying mechanisms or 
pathways it is acknowledged that the proteases probably represent a final common 
pathophysiological pathway. Although NE has long been considered important in this process 
[68], the more recently discovered and often overlooked enzyme Pr3 may be of greater relevance 
since it is also capable of cleaving a number of extracellular matrix proteins in vitro [81]; 
producing emphysematous change [70] and mucus hypersecretion [268] in animal models; and 
apoptosis [269] and cytolysis [270] of human cells in vitro. Also, Pr3 is released at a greater 
concentration than NE [83], yet is less readily inhibited [81, 85], and therefore Pr3 may be more 
important than NE in the tissue destructive process. Nevertheless, both free NE and Pr3 are 
inhibited within the neutrophil microenvironment especially in plasma [54, 85] and this currently 
precludes the direct measure of their activity, which hinders the evaluation of their potential roles 
in vivo.  
 
The current thesis reports the validation of Aα-Val360, which is a fibrinogen cleavage product and 
a specific marker of pre-inhibition NE activity in vivo. Aα-Val360 is influenced by exacerbations 
and treatment, and also relates to current markers of COPD disease severity, with a possible 
relationship to disease progression (as described in earlier chapters and [214, 217]). In contrast to 
other human proteases which fail to generate Aα-Val360 Pr3 will produce some Aα-Val360, 
although only
 
at 15% of the rate of NE [214], demonstrating that this enzyme is also capable of 
215 
 
cleaving fibrinogen. It was therefore hypothesised that there would be a Pr3 specific fibrinogen 
cleavage product that could be a marker of Pr3 activity in vivo. 
 
8.2.1 Identification of Low Molecular Weight Peptides 
 
MS analysis of the solutions of NE/fibrinogen and Pr3/fibrinogen (formed in vitro) detected a 
number of peaks demonstrating that cleavage of fibrinogen by these enzymes produces several 
similar peptide products. This would be expected since human Pr3 and NE share a similar 
structure and functionality, and until recently there was no specific substrate available that was 
preferentially cleaved by Pr3 but not NE [271]. These same characteristics also partly account for 
the lack of progress in exploring the role of Pr3 in many disease processes (including COPD).  
 
Importantly, there were peaks detected by MS which were enzyme specific, including a peak at a 
mass of 2021.3 daltons which was detected in the Pr3/fibrinogen but not NE/fibrinogen solutions. 
A peptide with the same mass was also detected in the plasma of subjects with A1AT deficiency 
demonstrating that this cleavage product may also be present in vivo. Although the peptide with a 
mass of 2021.3 daltons could not be specifically identified using peptide mass fingerprinting, this 
would be expected for a peptide with a carboxyl or amino terminus which is generated by 
cleavage of fibrinogen by Pr3, since the SWISS PROT database include data on the peptides 
formed through cleavage of known peptides by specific enzymes (but not Pr3). The data provide 
further support for the hypothesis that this fragment was a Pr3 specific peptide. Unfortunately, 
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MS-MS analysis of the 2021.3 peptide also did not identify this fragment, which was largely due 
to poor fragmentation of the target.  
 
Since a larger peptide fragment would represent a more enzyme specific biomarker (it is more 
likely to be formed in the initial Pr3 cleavage of fibrinogen) and will also have a longer 
circulating half life [214], further study in the current thesis, focussed on the larger peptide 
cleavage products. 
 
8.2.2 Identification of Larger Molecular Weight Peptides 
 
8.2.2.1 Gel Electrophoresis 
 
In the absence of a reducing agent, no fragments below 160 kDa were detected using gel 
electrophoresis. However, the reducing gel demonstrated a number of bands in the 
NE/fibrinogen, Pr3/fibrinogen and uncleaved fibrinogen solutions, and furthermore, 2 of these 
bands (termed band A and band B) were only demonstrated in the Pr3/fibrinogen solution. The 
contrasting results of the non-reducing and reducing gels suggest that the peptide chains 
(including the cleavage products termed bands A and B) remain bound to other chains of 
fibrinogen by disulphide bonds in a stable large molecular weight structure, which is consistent 
with the known structure of fibrinogen [272]. The stability which these bonds afford to bands A 
and B are advantageous for a plasma biomarker since animal studies demonstrated the long 
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circulating half life of Aα-Val360 (which remains similarly bound to the beta chain by disulphide 
bonds), a characteristic associated with reduced longitudinal variability [214].  
 
The fibrinogen and NE or Pr3 were incubated for 15 minutes at physiological temperatures as this 
length of time produces the optimal yield of the NE/fibrinogen products [214], and the aim of the 
current study was to generate a Pr3 cleavage product under similar conditions. Band A was 
present from one minute and although it was still present at 30 minutes (demonstrating the 
relative stability of this product even in the presence of active enzyme), the appearance of the 
band was consistently more faint suggesting ongoing proteolytic destruction of band A, and again 
supported a 15 minute incubation as the optimum period for the generation and detection of Pr3 
specific fragments.  
 
It should be recognised that the in vitro digestion of fibrinogen by Pr3 cannot precisely reflect the 
in vivo conditions in which Pr3 is released at a very high concentration from the neutrophil, but 
may also be membrane bound. In vivo, as diffusion occurs, free Pr3 is rapidly inhibited by A1AT 
within the neutrophil microenvironment in a similar manner to NE [54], however membrane 
bound Pr3 is resistant to inhibition by A1AT [271] leading to ongoing digestion of surrounding 
peptides. Although in the absence of an effective marker of Pr3 activity, it is difficult to assess 
the exact contribution to tissue destruction of membrane-bound Pr3 compared to the free enzyme, 
a comparable methodology resulted in the development of a good marker of pre-inhibition NE 
activity (despite similar pitfalls). Also, the persistence of a large peptide fragment (band A) at 
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both one minute and 15 minutes suggest that this is a relatively stable cleavage product of 
fibrinogen, and therefore a potential biomarker of Pr3 activity.  
 
8.2.2.2 Peptide Identification: Fibrinogen Chains 
 
Edman degradation has been the traditional method of choice for protein sequencing, however 
over the last decade this has been surpassed by rapid advances in MS technology [233]. Although 
a number of factors, including the sensitivity and resolution of the MS machines, generally 
preclude the sequencing of whole proteins using MS, this is relatively easily overcome by the use 
of enzymes that generate a number of small peptides at known and specific cleavage points. 
These smaller peptides may then be identified by peptide mass fingerprinting which couples the 
highly precise MS mass measurements with data from sequence databases that allow ‘virtual’ 
cleavage of almost the whole proteome by certain specific enzymes [232, 233].  
 
In the current study, MS-MS and peptide mass fingerprinting following in-gel digestion 
identified the protein bands in the uncleaved fibrinogen solution to be the alpha, beta and gamma 
chains of fibrinogen. Although the complete beta and gamma chains were identified in all the 
solutions, the complete alpha chain was only present in the uncleaved fibrinogen. Also, following 
in-gel digestion of band E (only detected in the uncleaved fibrinogen solution), peptide mass 
fingerprinting identified the cleavage products to be derived from the fibrinogen alpha chain, 
however minimal coverage of the sequence of the carboxyl terminus of the alpha chain was 
detected in this band. It is possible that this band represents a polymorphism of the fibrinogen 
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alpha chain (since it was detected in pooled human fibrinogen) which is either a truncated form 
of the more common alpha chain variant or has an alternate carboxyl sequence. Although 
sequence databases include data on a number of alternate sequences, not all polymorphisms are 
included in the online databases (in this instance the SWISS PROT database), which is one 
drawback to peptide mass fingerprinting. 
 
8.2.2.3 Peptide Identification of Bands A and B 
 
Fragments of the fibrinogen alpha chain from D26 to K527 were identified by peptide mass 
fingerprinting (with good sequence coverage) from the in-gel digest of band A. Since the signal 
peptide of fibrinogen (from M1 to T19) is removed following translocation across the 
endoplasmic reticulum [267], these data suggest the amino end of band A lies at or within a few 
residues of the amino end of the intact parent chain.  Peptide mass fingerprinting also consistently 
identified F520 and K527 as the apparent carboxyl termini of band A, following Asp-N and 
trypsin cleavage respectively. The true carboxyl terminus (i.e. the site of Pr3 cleavage) would not 
be demonstrated by peptide mass fingerprinting since this method will only identify peptides 
cleaved at both the amino and carboxyl ends by specific enzymes which (unlike Pr3) are included 
in the sequencing database SWISS PROT. Nevertheless, the consistency of these data indicate 
that the true carboxyl terminus of band A lies between K527 and the subsequent trypsin cleavage 
point (R546), since if the Pr3 cleavage site lay on the carboxyl side of R546, a further trypsin-
trypsin cleavage fragment would be identified by peptide mass fingerprinting.  
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Gel electrophoresis separated bands A and B by similar distances, indicating that they have 
similar mass:charge ratios. Peptide mass fingerprinting also identified band B as a fragment of the 
fibrinogen alpha chain, although the data were less consistent compared to A and indicated an 
apparent carboxyl terminus between K480 and K527 following trypsin digest (which varied with 
repeated testing of different Pr3/fibrinogen digests even at the same time points). The variable 
results and incomplete identification suggest that band B is either a fragment of the alpha chain 
cleaved at a different site to A or a cleavage product of band E (the fibrinogen alpha chain 
polymorphism). It is also possible that B is a further Pr3 breakdown product of A, which may also 
explain the decreasing intensity of band A with increasing incubation time (Figure 31) however 
this is less likely since there was no corresponding increase in the intensity of band B. If band A 
results from the initial Pr3 cleavage of fibrinogen, this peptide would be more relevant as a target 
biomarker since initial degradation products are more likely to represent an in vivo degradation 
product formed prior to the rapid inhibition of Pr3. If bands A and B represent cleavage products 
of different polymorphisms of fibrinogen, the more consistent and complete peptide mass 
fingerprinting data for Band A and its derivation from the standard polymorphism suggest that A 
is the preferential target.  
 
8.2.2.4 Data Analysis 
 
Gel electrophoresis indicated bands A and B lie between the beta chain (molecular weight of 
55,892) and the alpha chain (molecular weight 69,757). The mass of a peptide fragment between 
A20 (the first amino acid of fibrinogen alpha chain following the signal peptide) and M536 is 
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56,050 which is just greater than the mass of the beta chain. Therefore, the true carboxyl terminus 
of band A post Pr3 cleavage is likely to lie on the carboxyl side of M536 (given the otherwise 
intact amino terminus demonstrated by trypsin and Asp-N cleavage). The peptide mass 
fingerprinting data detected peptides up to K527, but repeated testing failed to demonstrate any 
complete trypsin-trypsin or Asp-N–Asp-N cleaved peptides beyond this amino acid, suggesting 
the true carboxyl terminus lies on the amino side of R547 (the subsequent trypsin cleavage site). 
These data suggest the true (Pr3) carboxyl terminus of band A lies between M536 and R547. 
 
MS detected a peptide with a mass of 2236.08 which represents the exact mass of the peptide 
D521 to V541 (DTASTGKTFP GFFSPMLGEFV) which would be formed following Asp N 
cleavage of band A, if Pr3 cleaved at V541. MS-MS analysis demonstrated that this peptide is 
highly likely to represent the sequence with 10 positive hits. The MS analysis also provided 
further support for this hypothesis since no further peptide fragments consistent with other Pr3 
cleavage sites were detected. These data demonstrate that V541 represents the carboxyl terminus 
of band A and therefore the site of Pr3 cleavage data. This would also be consistent with previous 
data demonstrating that Pr3 preferentially cleaves peptide bonds where alanine, valine, leucine or 
serine are the amino acids are at the P1 and P1’ sites [81].  
 
8.2.2.5 Disadvantages of MS 
 
Peptide mass fingerprinting is a highly accurate technique but does have imperfections. 
Following, in-gel digestion, the concentration of fragments may be very low and at the limits of 
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detection for MS [233]. Also, not all polymorphic variants of protein sequences are included in 
the commonly used databases, which will prevent complete match identification, although this 
was only an issue in the current study for Band B and not Band A. Further problems with 
matching can occur because of non-specific modifications that are generated during protein 
extraction and processing, although these can partly be overcome by the use of compensatory 
computer algorithms or deliberate chemical effects that prevent to prevent this process [232, 
233]. For example, in the current study, iodoacetamide was used during the in-gel digestion to 
modify cysteine, which minimised other (non-specific) modifications and allowed the detection 
of the specific fibrinogen degradation products despite the difficulties presented by the use of 
MS. 
 
8.2.2.6 Summary 
 
These data (if correct) will allow the generation of a monoclonal antibody, necessary to develop a 
specific assay for Pr3 which would represent a new potential marker of protease related disease 
activity for use in patients with COPD and other diseases in which the neutrophil and its 
proteinases are implicated (including vasculitis). However, this assay would subsequently require 
extensive formal validation (as described for Aα-Val360 in earlier chapters) and this is therefore 
beyond the scope of the current thesis.  
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CHAPTER 9.  CONCLUSION AND FUTURE WORK 
 
9.1.1 Aα-Val360: Summary 
 
It is increasingly recognised that there is an urgent need for new markers of disease activity and 
severity in patients with COPD and emphysema [89] and the current thesis therefore describes 
the validation of Aα-Val360 which is a specific in vivo biomarker of pre-inhibition NE activity. 
Although other criteria for biomarkers have been described [209], an ideal biomarker of COPD 
disease activity that will serve all purposes should [207]: 
1. be central to the pathophysiological disease process 
2. be either a direct measure of that disease process (or a close surrogate) 
3. be stable and reproducible, but vary with events associated with disease progression  
4. relate to disease severity (assuming disease activity is relatively stable, or in a large cross-
sectional study that a biomarker would measure the predominant level of disease activity 
over the time course of the disease process) 
5. be responsive to therapies known to modify disease progression 
6. predict individuals who will progress more quickly 
 
There is increasing evidence that proteases are central to the pathophysiology of COPD and may 
represent a final common pathway leading to tissue destruction (see 1.2.4), and therefore as a 
marker of pre-inhibition NE activity, Aα-Val360 is a close surrogate of the disease process of 
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COPD fulfilling the second criterion. Importantly, the data reported in the current thesis 
demonstrate that the repeatability of the Aα-Val360 assay is consistent with other plasma 
biomarkers [211], and the Aα-Val360  concentration is constant within individuals over time, when 
in the clinically stable state. However, Aα-Val360 also rises significantly during an exacerbation 
(which are events known to relate to disease progression [118]) yet returns rapidly to baseline (or 
close to baseline) as recovery occurs, fulfilling the 3
rd
 criterion. Also, Aα-Val360 relates to 
physiological and radiological measures of disease severity and patient reported outcomes both in 
those with symptoms of COPD (Chapter 5) and in those with A1AT deficiency demonstrating its 
relationship with markers of COPD/emphysema disease severity (the 4
th
 criterion). There was a 
significant decrease in the Aα-Val360 in PiZ A1AT deficient subjects who received A1AT 
augmentation therapy which did not occur in controls, indicating that it may be a biomarker of an 
effective intervention (the fifth criterion). Finally, there was a possible relationship between Aα-
Val
360 
and disease progression measured by gas transfer in patients with symptoms of COPD and 
in subjects with A1AT deficiency with early disease (with mild spirometric changes) indicating 
that Aα-Val360 may be a marker of the disease activity driving the emphysematous process in 
early stage disease. Although there was no relationship with progression in the overall cohort of 
patients with A1AT deficiency, this may be explained by a number of factors (see 7.3.7) and 
prognostication may be enhanced by assessing activity with a number of different biomarkers 
(perhaps including Pr3) to ensure a comprehensive evaluation of the overall pathophysiology.  
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9.1.2 Aα-Val360: Further Work 
 
Although this thesis and other published work [214, 217] provide evidence to support the use of 
Aα-Val360 as a biomarker of neutrophilic disease activity in chronic bronchitis, COPD and 
emphysema. Although there appears to be a relationship with disease progression measured by 
gas transfer in patients with symptoms of usual COPD and patients with early stage COPD and 
A1AT deficiency, the absence of more clear relationships indicates that further work is required 
to enable a better understanding of the underlying pathophysiology of COPD and to establish the 
populations in which this marker of disease activity would be most useful.  
 
Firstly, the relationships between disease activity and severity are complex, and further 
investigation is hindered by the current absence of gold standard markers. Nevertheless, it is 
increasingly clear that disease progression (i.e. increasing disease severity measured by 
physiological or radiological tests) is not linear, and displays marked heterogeneity between 
individuals with COPD [181]. Disease activity is almost certainly as heterogeneous as disease 
progression between individuals (as demonstrated by the range of Aα-Val360 values reported in 
the current thesis), however there are insufficient data at present to establish whether disease 
activity remains stable over the medium to long term, although at least in the short term (over a 
few years) neutrophilic disease activity (measured by Aα-Val360 and reported in the current 
thesis) appears to be stable unless patients are experiencing exacerbations. This is important since 
the linearity of the 2 measures will influence their relationship, and this may be determined in 
future studies by assessing the cross-sectional and longitudinal relationships of repeated measures 
of both disease severity, rate of decline of disease severity (gas transfer, CT densitometry and 
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spirometry) and biomarkers of disease activity such as Aα-Val360 at several time-points, in a 
number of patients over a prolonged period of time.  
 
Secondly, while the within and between batch variability of the current Aα-Val360 assay is  
acceptable (and within the range of variability of other plasma and serum biomarkers [211]), 
patients with COPD progress at a relatively slow rate and therefore even less assay variability and 
more stable markers of disease activity may be required. This may be at least partly achieved by 
the development of a simpler and more robust assay using a monoclonal Aα-Val360 antibody and 
an ELISA technique (usual inter and intra-assay variability of about 10%) rather than the current 
polyclonal assay (variability of about 24%), and this work is currently underway.   
 
Thirdly, although the current data (Chapter 7) suggest that there may be a subgroup of PiZ 
patients with early disease in whom Aα-Val360 is associated with disease progression, there is no 
relationship within the overall PiZ population. However, the progression in the overall group was 
low (close to that of normal healthy individuals) and therefore a larger study may be required to 
effectively investigate these relationships, which is now achievable since the ADAPT database 
has around 800 PiZ individuals. Also, a larger population would allow the identification of other 
specific subsets or phenotypes (if any) in whom neutrophilic disease activity measured by Aα-
Val
360 
is more relevant.  
 
Fourthly, further studies are required to investigate Aα-Val360 in patients with usual ‘COPD’ with 
little or no spirometric change which would include patients with symptoms of COPD (cough, 
dyspnoea and chronic bronchitis) with a significant risk factor (e.g. smoking). The natural history 
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of the disease process in this group of patients is particularly poorly understood, and therefore it 
is important to accurately establish disease progression within this population more accurately 
and to determine whether a marker of disease activity (such as Aα-Val360) will help to distinguish 
between the potential phenotypes and prognosis of early or mild disease. Such patients could be 
identified through population screening, and assessed using both biomarkers and physiological 
markers of disease severity. 
 
Fifthly, it will be important to explore the value of Aα-Val360 as a marker of therapeutic efficacy 
in other clinical trials. Although there are few effective therapies for COPD, it is interesting to 
speculate that novel NE inhibitors may be successfully used to modify this disease process. 
Although a recent trial of one NE inhibitor over a 3 month period demonstrated a good safety 
profile, predictably there was no change in the physiological markers of disease severity within 
this timeframe [273], which again indicates the need for early readout biomarkers for use in 
phase I to III clinical trials. 
 
Finally, further studies are required to demonstrate whether Aα-Val360 is also an effective marker 
of activity in other disease processes within which the neutrophil has been implicated including 
cystic fibrosis, vasculitis, bronchiectasis and acute lung injury. Again these studies are underway, 
however are beyond the scope of the current thesis.  
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9.1.3 Pr3: Summary 
 
Pr3 may be a key mediator of tissue damage, and is released at a higher concentration than NE, is 
less readily inhibited by A1AT (particularly when cell membrane bound) but (in contrast to NE) 
is not inhibited by the major airway serine protease inhibitor SLPI which indicates Pr3 may be of 
particular importance in the larger airways (see 1.2.4.4 and 8.2).  In addition to measuring pre-
inhibition NE activity, it is therefore also likely to be important to measure Pr3 activity in 
subjects with COPD since this will provide further information about potential tissue damage, 
particularly within the airway. The current thesis therefore describes the identification of a 
specific pre-inhibition Pr3 fibrinogen cleavage product using MS technology which will allow 
the generation of a specific assay of Pr3 activity.  
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9.1.4 Pr3: Future Work 
 
Ideally, prior to the development of a specific antibody, MS analysis would be used to confirm 
the presence of the neoepitope in human plasma, however, with current technology this would be 
difficult owing to the range of other peptides and proteins which are present in plasma and the 
difficulties of firmly identifying large molecular weight products using MS based techniques. 
Also, although the peptide is not formed by when fibrinogen is cleaved NE, it will also be 
important to demonstrate whether any peptide is also a product of other proteases including the 
cathepsins, plasmin and trypsin.  
 
Further work would then be focussed on generating a specific monoclonal antibody and 
following this, western blot analysis will be required to establish the presence of the neoepitope 
in human plasma. Also, it would be important to demonstrate the generation of the product in 
human plasma following the addition of a neutrophil activator, and to show whether this process 
is abrogated in the presence of a specific inhibitor of Pr3. 
 
Following the successful generation of a specific antibody, an ELISA could be created along 
conventional lines. A plate would be coated in Pr3 cleaved fibrinogen and then incubated with 
the sample premixed with the specific Pr3 antibody. Following washing the plate would be 
incubated with a secondary (labelled) antibody to determine the amount of the Pr3 specific 
antibody that had bound to the plate not the sample and the Pr3 fibrinogen cleavage product 
concentration of the sample determined by interpolation from results using a standard peptide. 
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Further work would then be required to validate the assay in the same manner described in the 
current thesis for Aα-Val360.  
  
9.1.5 Other Enzymes  
 
Similar techniques could be used to develop assays of the activity of other enzymes which are 
believed to play a role in the tissue damage in COPD, including the MMPs and cathepsins 
(1.2.4). A composite measure of the activity of a number of different enzymes may then provide 
more detailed information about the overall disease activity or their interactions in patients with 
COPD.  
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